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ABSTRACT 
Introduction: Obesity is an excessive fat accumulation in the body, known to be a significant 
precursor to insulin resistance and type 2 diabetes. Complications associated with obesity can 
contribute to the development of cardiovascular disease which, in turn, is associated with 
abnormal mitochondrial energetics. Rooibos (Aspalathus linearis) has known antidiabetic, 
anti-obesity and cardiovascular benefits. We investigated these properties with a focus on 
mitochondrial function, using an aspalathin-rich green rooibos extract, Afriplex GRT Extract. 
Aims: (i) To determine whether Afriplex GRT Extract ingestion can improve the insulin 
resistance state elicited by a high fat diet using a rat model. (ii) To determine whether Afriplex 
GRT Extract ingestion has any effects on myocardial mitochondrial oxidative phosphorylation 
potential and the process of mitophagy 
Methods: Male Wistar rats were fed either a control or a high fat diet (HFD) for 16 weeks. Half 
of each group was treated with Afriplex GRT Extract (60mg/kg/day) from weeks 11 to 16. Body 
weight, food and water intake were monitored, and liver- and intraperitoneal fat (IP) weighed 
at sacrifice. After sacrifice, myocardial mitochondria were isolated. Half of these were used to 
measure respiration on an oxygraph and the other half for Western Blot analysis of proteins 
involved in mitophagy. In addition, hearts were freeze clamped immediately after sacrifice and 
used to determine levels of insulin signalling proteins. 
Results: The HFD caused increased body weight-, liver- and IP fat gain, and elevated leptin 
levels while it decreased insulin signalling protein expression (GLUT4, tAkt/PKB and tAMPK). 
Ingestion of Afriplex GRT Extract diminished the weight gain, liver weight gain, IP fat weight 
gain and leptin in HFD animals. Moreover, it improved oral glucose tolerance in control animals 
and, according to a borderline significance in a HOMA-IR calculation, insulin resistance in the 
control animals. However, an increased basal glucose level was seen in HFD animals treated 
with Afriplex GRT Extract. Afriplex GRT Extract improved mitochondrial coupling efficiency in 
HFD animals and oxidative phosphorylation in control animals. Afriplex GRT Extract 
decreased mitochondrial p62 and cytosolic Beclin-1 levels and BNIP3 dimerization in the 
mitochondria of the control animals, while increasing autophagic flux (LC3-II expression) in 
hearts from HFD animals. A decrease in Sesn2 levels indicated possible anti-oxidant effects. 
Conclusion: We conclude that Afriplex GRT Extract resulted in less weight gain in HFD 
animals, improved whole-body insulin sensitivity and enhanced mitochondrial function. At the 
dose used, no detrimental effects were observed. 
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OPSOMMING 
Inleiding: Vetsug is ‘n oormatige vet akkumulasie in die liggaam en ‘n belangrike oorsaaklike 
faktor vir insulien-weerstandigheid en tipe 2 diabetes. Komplikasies geassosieer met vetsug 
kan bydra tot die ontwikkeling van kardiovaskulêre siektes, wat weer geassosieer word met 
abnormale mitochondriale funksie. Rooibos (Aspalathus linearis) is bekend vir anti-diabetiese, 
anti-vetsug en kardiovaskulêre voordele. Ons het hierdie eienskappe ondersoek met ‘n fokus 
op mitochondriale funksie, deur die gebruik van ‘n aspalatien-ryk groen rooibos ekstrak, 
Afriplex GRT Ekstrak. 
Doelstellings: (i) Om te bepaal of die inname van Afriplex GRT Ekstrak insulien-
weerstandigheid, geïnduseer deur ‘n hoë vet dieet in ‘n rotmodel, kan verbeter. (ii) Om te 
bepaal of die inname van Afriplex GRT Ekstrak enige effek het op miokardiale mitochondrale 
oksidatiewe fosforilasie potensiaal en die proses van mitofagie. 
Metodes: Manlike Wistar rotte is gevoer met óf ‘n normale kontrole dieët (standaard rotkos) óf 
‘n hoë vet dieët (HFD) vir 16 weke. Die helfte van elke groep is behandel met Afriplex GRT 
Ekstrak (60mg/kg/dag) vanaf weke 11 tot 16. Liggaamsgewig, kos- en water inname was 
gemonitor en die lewergewig en intra-peritoniele (IP) vet gemeet na terminasie. Miokardiale 
mitochondria is geisoleer: een helfte van die preparaat was gebruik om respirasie te meet in 
‘n oksigraaf, en die ander helfte vir Westerse klad analise van mitofagie geassosieerde 
proteïene. Harte is ook onder basale omstandighede gevriesklamp en gebruik om die vlakke 
van die insulien seintransduksiepad proteïene te bepaal. 
Resultate: Die HFD het ‘n verhoging veroorsaak in liggaamsgewig-, lewer- en IP vet toename, 
sowel as in leptien vlakke teweeggebring. Daar was ook ‘n afname in insulienseintransduksie 
proteïene (GLUT4, tAkt/PKB, en tAMPK). Die inname van Afriplex GRT Ekstrak het die gewig 
toename sowel as die lewer, IP vet toename en leptien vlakke in die HFD diere verlaag.  
Afriplex GRT Ekstrak het die orale glukose toleransie in kontrole diere en, volgens ‘n 
grensgeval beduidendheid van ‘n HOMA-IR berekening, insulien weerstandigheid in die 
kontrole diere verbeter. Daarteenoor is verhoogde basale glukose vlakke in die HFD diere wat 
behandel was met Afriplex GRT Ekstrak, waargeneem. Afriplex GRT Ekstrak behandeling het 
die mitochondriale koppeling in die HFD diere en oksidatiewe fosforilasie in die kontrole diere 
verbeter. Dit het ook ‘n afname veroorsaak in mitochondriale p62, sitosoliese Beclin-1 vlakke 
en BNIP3 dimerisering in die harte van kontrole diere, terwyl dit ‘n verhoogte autofagie-fluks 
(LC3-II uitdrukking) in die harte van die HFD groepe veroorsaak het. Verlaagde Sesn2 
uitdrukking dui moontlike anti-oksidatiewe effekte aan. 
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Gevolgtrekking: Afriplex GRT Ekstrak het gewigsverlies in HFD diere teweeggebring en 
insulien-weerstandigheid en mitochondriale funksie verbeter. Met die dosis gebruik was daar 
geen nadelige effekte waargeneem nie. 
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CHAPTER 1: Literature Review 
Rooibos, an indigenous plant to South Africa, is source to a famous and well-loved 
traditional tea. Afriplex GRT Extract is a spray dried, laboratory standardized extract 
made from green rooibos and has a high aspalathin content. Aspalathin is a potent 
anti-oxidant that is said to have positive effects on diabetic patients (Koza, 2013). With 
the increasing interest in natural products, the modern society always searches for 
more plant-based medicines and diets. In this thesis, it will be discussed how obesity 
can lead to cardiovascular diseases (CVDs), through insulin resistance and diabetes. 
With a focus on mitochondrial energetics, fat metabolism, glucose metabolism and 
insulin signalling, the effects of Afriplex GRT Extract will be investigated.  
1. From Obesity to Diabetes 
Obesity is an excessive accumulation of fat in the body (Hebebrand, et al., 2017).  It 
is currently so common in the human population that it is seen as the most significant 
contributor to ill health, more so than undernutrition and infectious diseases 
(Kopelman, 2000). Obesity has been recognized as an epidemic that causes a rise in 
diabetes; and the notion that obesity is a significant and very common precursor to 
diabetes has been proved and demonstrated by previous research (Morris, et al., 
1989). 
In an interview with Dr. Vash Mungal-Singh (CEO of the Heart and Stroke Foundation 
of South Africa), she explained why South Africa is facing this “obesity epidemic” (Pan 
American Health Organization, 2012).  She explains that South Africans “eat too much, 
drink too much alcohol, and don’t move enough.” Obesity does not only lead to 
diabetes, but it can cause a plethora of health problems such as insulin resistance, 
joint pain, hypertension, strokes, cardiovascular disease and some cancers 
(Kopelman, 2000; Formiguera & Cantón, 2004). 
According to The World Health Organization (2016), since 1980, obesity has more 
than doubled (The Heart and Stroke Foundation South Africa, 2016). Out of 1.9 billion 
overweight people, 600 million were classified as obese. In 2014, 39% of adults (18 
years and above) were overweight and 13% obese. More concerning is that 41 million 
children (under the age of 5) were already overweight/obese in 2014. South Africa has 
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the highest overweight and obesity rate across sub-Saharan Africa. A third of our men 
and 70% of our women are classified as overweight or obese (The Heart and Stroke 
Foundation South Africa, 2016). Amongst children between the ages of 2 and 14 
years, 1 in 4 girls and 1 in 5 boys are either overweight or obese.  
Obesity is driven by a change in eating habits and a decrease in physical activity of 
the human population. Dr. Mungal-Singh clarifies that, due to the increase in 
urbanisation and ‘faster paced lifestyles,’ people rely more and more on fast foods and 
Westernised diets (high in sugar, salt and unhealthy fats) (The Heart and Stroke 
Foundation South Africa, 2016). Obesity occurs when energy intake (mainly stored as 
triglycerides) is greater than energy output (Spiegelman & Flier, 2001). Due to this rise 
in energy intake, body-weight increases to an extent where there are substantial health 
consequences .  
Adipose tissue is the main storage site for triglycerides (Ashrafi, 2007). In mammals, 
this connective tissue comes in two types namely; white and brown adipose tissue 
(Eder, et al., 2009). For this thesis, focus will be shifted solely to white adipose tissue. 
Not only does white adipose tissue serve as a source of energy, but it has functions in 
both heat insulation and mechanical cushion. Adipose tissue can be found 
subcutaneously, where its function as heat insulator is utilized. By surrounding internal 
organs, adipose tissue can also prevent physical shock to these organs (such as the 
kidneys) (Ashrafi, 2007). 
White adipose tissue, especially visceral adipose tissue, is recognized as an endocrine 
organ and secretes many protein hormones such as; leptin (which is a cytokine-like 
hormone secreted in proportion to fat mass), adipokines (such as interleukin-6 (IL-6)) 
and adiponectin (Maffei, et al., 1995; Trayhurn & Bing, 2006; Eder, et al., 2009). The 
pancreas produces insulin, which is also secreted in proportion to fat mass (Friedman 
& Halaas, 1998).  Insulin is one of the regulators that sustain energy balance and, 
along with leptin, cause inhibitory effects on energy intake (Ashrafi, 2007).  
Adiponectin is the most profusely secreted protein by white adipose tissue (Brochu-
Gaudreau, et al., 2010). Adiponectin has anti-inflammatory, insulin-sensitizing and 
anti-atherosclerotic properties. The insulin-sensitizing properties of adiponectin is 
regulated by its activation of AMP-activated protein kinase (AMPK), p38 mitogen-
activated protein kinase (MAPK) and PPARα (peroxisome proliferator-activated 
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receptor aplha)  (Deepa & Dong, 2009). Adiponectin is also a direct regulator of IL-6, 
which is a pro-inflammatory factor and a key regulator in inflammation, haematopoiesis 
and immune responses (Akira, et al., 1993). Decreased serum levels of adiponectin 
can be seen in obesity and type 2 diabetes (T2D) (Li & Wu, 2012). Furthermore, 
adiponectin levels are inversely correlated with cardiovascular disease development 
(Shibata, et al., 2009).  
1.1. Assessing Obesity 
1.1.1. Body Mass Index (BMI) 
To calculate a person’s BMI, the patient’s weight (kg) is divided by the square of the 
height (m2) (Department of Health and Human Services USA, n.d.) (Kopelman, 2000).  
A body-mass index (BMI) of 30 kg m-2 or more indicates obesity in humans. However, 
when the BMI is between 25 kg m-2 and 29.9 kg m-2, the person is considered 
overweight (Hu, 2008). 
While BMI is an easy and inexpensive way of assessing obesity, many say that it is 
not the most accurate way of measuring obesity. In Medical News Today, an article 
was published by Christian Nordqvist stating that BMI does not take muscle mass, 
bone density, body composition, racial differences or gender differences into account 
(Nordqvist, 2013).  
1.1.2. Waist-to-height Ratio (WHtR) 
Waist-to-height ratio is a better measuring tool than BMI (Ashwell, et al., 2014). It is 
much simpler, because it uses the waist circumference and height. It is also a better 
method because, unlike BMI that does not consider lean body mass versus body fat, 
it includes the waist. The waist is a prime spot for abdominal fat to accumulate. 
The waist-to-height ratio stipulates that the waist circumference should be less than 
half the height. 
1.1.3. Waist Circumference (WC) 
To measure the WC is also easy and inexpensive. The WC is measured either at the 
waist, belly button, or the smallest point of the midsection (Hu, 2008). Using WC as an 
indicator of obesity is suitable because of its simplicity and the direct relationship 
between the WC and the abdominal fat mass (Pouliot, et al., 1994). Men with a WC of 
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120 cm (or more) and women with a WC of 88 cm (or more) are normally considered 
to be at risk for cardio-metabolic disease (Wang, et al., 2005).  
1.1.4. Waist-to-hip Ratio (WHR) 
The WHR is the ratio of the circumference of the waist to the circumference of the hip. 
The WHR measures the abdominal obesity, similarly to the WC. The WHR is 
calculated by measuring the waist- and hip circumference, followed by the dividing of 
the waist measurement by the hip measurement (Hu, 2008). A WHR of more than 0.8 
(in women) and 0.9 (in men) is considered excess abdominal fat distribution, according 
to a report from the WHO (World Health Organization, 2008). 
1.1.5. Skinfold Thickness 
To measure the skinfold thickness, a special calliper is used to pinch the skin and fat 
underneath it. This is done in certain areas of the body, such as the trunk, thighs and 
parts of the upper arm. Predictions of the body fat percentage is calculated with 
specific equations (Hu, 2008). To measure the skinfold thickness is convenient, safe, 
inexpensive and easy. It is, however, not very accurate or reproducible (Hu, 2008).  
1.2. Insulin Resistance 
Obesity is a leading risk factor for developing insulin resistance (National Institute of 
Diabetes and Digestive and Kidney Diseases, 2009). Insulin is secreted post-prandial 
and is the main hormone regulating high blood glucose levels. Insulin stimulates 
peripheral insulin sensitive tissue such as the liver, fat, heart and muscle to take up 
glucose from the circulation into the cells (see ‘2.3 Insulin Metabolism’) (Roland, 2016). 
When a person is insulin resistant, the peripheral tissue becomes resistant to the 
action of insulin to an extent that it cannot stimulate the cells effectively anymore. In 
other words, the body does produce insulin, but it is not used efficiently (Cefalu, 2001). 
Because the cells are not able to absorb the glucose efficiently, it causes a high 
glucose content in the blood.  
Insulin resistance can thus lead to damaged blood vessels, increasing the risk for heart 
diseases and strokes (National Institute of Diabetes and Digestive and Kidney 
Diseases, 2009). Endothelial cells of the blood vessels secrete vasoconstrictors and 
vasodilators that regulate the microvascular flow (Lewis, 1998). Hyperglycaemia 
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causes an inhibition of and decrease in the production of the vasodilator, nitric oxide 
(NO), in arterial endothelial cells (Williams, et al., 1998; Brownlee, 2001; Brochu-
Gaudreau, et al., 2010). High blood pressure and an eventual narrowing of the blood 
vessels are caused by this decrease (Vallance & Norman, 2001; Hoshiyama, et al., 
2003; Koh, et al., 2005).  
When there is a high blood glucose level for an extended period, the blood vessels 
are not able to relax or dilate properly (Koh, et al., 2005). The phosphorylation of nitric 
oxide synthase results in the production of NO. Excess glucose causes high levels in 
the glucose derived monosaccharide O-linked N-acetylglucosamine (O-G1cNAc) (Liu, 
et al., 2000). High O-G1cNAc levels inhibit this phosphorylation, thus decreasing nitric 
oxide production (Karunakaran & Jeoung, 2010). Without sufficient nitric oxide levels, 
the blood vessels are constantly contracted and would ultimately negatively influence 
the passage of blood through these vessels. This poor circulation will increase the risk 
of strokes and heart attacks (more under ‘2.6. Pathophysiology of Diabetes’). 
Developing T2D is another risk of insulin resistance (Balarini & Braga, 2016). The link 
between insulin resistance and prediabetes or T2D is evident. Since insulin resistance 
already places a high demand on the β-cells for insulin secretion, T2D can develop. 
When a person is prediabetic, the blood glucose levels are normal because the β-cells 
can still produce necessary insulin to overcome the insulin resistance (see Figure 1.1 
below) (Bell, 2003; Tabák, et al., 2012). Insulin levels are, however, higher than 
normal.  This stress on the pancreas leads to an unceasing loss of β-cell function, 
resulting in the development of T2D. This is the tipping point where the pancreas is 
unable to secrete enough insulin, therefore blood glucose levels rise above normal. It 
has been shown that prediabetic persons are prone to develop T2D within 10 years, if 
they do not change their lifestyle by losing weight and increasing physical activity 
(National Institute of Diabetes and Digestive and Kidney Diseases, 2009).  
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Figure 1.1 The progression of prediabetes to type 2 diabetes (T2D) (Bell, 2003; Tabák, et al., 2012). 
1.2.1. Assessing insulin resistance 
1.2.1.1. Oral Glucose Tolerance Test 
An Oral Glucose Tolerance Test (OGTT) is a procedure used to diagnose insulin 
resistance or prediabetes (Center for Young Women's Health, 2016). This test 
determines how efficiently the body metabolises sugar or carbohydrates. When doing 
an OGTT on a human, the patient is given a concentrated sugary drink when in a 
fasting state. The blood glucose level is tested at basal level (before ingestion of the 
drink) and at different intervals thereafter up to 120 min. Diabetic persons will have a 
blood glucose level of more than 10.0 mmol/L at 2 hours, whereas a non-diabetic 
person will have a blood glucose level of less than 7.8 mmol/L (American Diabetes 
Association, 2006). 
In rodents, sucrose, at a concentration of 1 g/kg, is given to the rats after an overnight 
fast by oral gavage.  Accordingly, the blood glucose levels are measured at basal level 
and at different intervals up to 120 min. 
1.2.1.2. The HOMA-IR Index 
Another way of assessing insulin resistance and β-cell function is the HOMA-IR 
(homeostatic model of insulin resistance) assessment. This is calculated from fasting 
glucose and insulin or C-peptide concentrations (Matthews, et al., 1985).  
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The equations to calculate the HOMA-IR and HOMA-β can be seen below: 
𝐻𝑂𝑀𝐴 − 𝐼𝑅 =
𝐺𝑙𝑢𝑐𝑜𝑠𝑒 (
𝑚𝑚𝑜𝑙
𝐿 ) × 𝐼𝑛𝑠𝑢𝑙𝑖𝑛(
𝑚𝑈
𝐿 )
22.5
⁄  
𝐻𝑂𝑀𝐴 − 𝛽 =
20 × 𝐼𝑛𝑠𝑢𝑙𝑖𝑛 (
𝑚𝑈
𝐿 )
𝐺𝑙𝑢𝑐𝑜𝑠𝑒 (
𝑚𝑚𝑜𝑙
𝐿 ) − 3.5
⁄  % 
The HOMA-β calculates the β-cell function, whereas HOMA-IR calculate insulin 
resistance. For the purpose of this thesis, we will only be calculating the HOMA-IR 
index, because insulin resistance is the point of interest in this case.  
1.3. Diabetes 
Obesity is a preventable disease and so is T2D. Koza (2013) states that, according to 
the Human Sciences Research Council's 2013 health and nutrition survey, one in 10 
South Africans live with diabetes; and a quarter of people (between ages 55 and 64) 
are on their way to developing diabetes because of their extremely high blood sugar 
levels. People that develop T2D later in life have very high sugar levels because their 
bodies cannot utilize the amount of sugar that they ingest fast enough. An 
approximation that the prevalence of diabetes will increase to 552 million by 2030 was 
made by The International Diabetes Federation. It is said that 95% of that 552 million 
is associated with T2D  (WHO Fact Sheet No: 311 , 2016). 
Of diabetic people above the age of 65, at least 68 % die from some form of a heart 
disease. Another statistic stated by the American Heart Association (2015) declares 
that diabetic adults are more likely to develop heart disease than non-diabetic people. 
Thus, it is said that diabetes is one of the seven major controllable risk factors for CVD.  
Diabetes is a condition of hyperglycaemia (Rother, 2007).  There are currently 3 types 
of diabetes; recognized by either pancreatic β-cells that are not able to maintain 
sufficient insulin secretion, or because the insulin is no longer used efficiently by the 
body.  (i) Type 1 diabetes (T1D) is a T-cell mediated autoimmune response against 
the β-cells that can be influenced by environmental factors and genetics. This causes 
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destruction of the β-cells, thus producing insufficient insulin for the body to use. T1D 
is an incurable disease that needs insulin treatment.   
(ii) In T2D, either insulin resistance or decreased β-cell function can be the cause 
(Rother, 2007). The insulin sensitivity is decreased in liver, adipose and muscle tissue, 
resulting in over secretion of insulin in the body. It prevents the body from clearing the 
blood glucose efficaciously. Refer to Figure 1.2 for the effects of T2D on the insulin 
signalling pathway (more discussed in ‘2.3.1. Insulin Signalling’). As previously 
mentioned under ‘1.2. Insulin Resistance,’ we know T2D patients have high levels of 
blood glucose that can eventually lead to heart disease, stroke, kidney failure and 
many more complications (National Institute of Diabetes and Digestive and Kidney 
Diseases, 2009). 
(iii) In pregnant women, gestational diabetes occurs when the woman suddenly 
becomes glucose intolerant (National Institute of Diabetes and Digestive and Kidney 
Diseases, 2009). This condition normally reverses after pregnancy. 
Healthy eating, exercise, blood sugar monitoring and pharmacotherapy are involved 
in the management of T2D. The goal for treating diabetes is to maintain the blood 
sugar levels within the normal range (between 3.9 and 5.5 mmol/L) (Defronzo, 2009; 
Chatterjee & Davies, 2015; Spero, 2016). A high-fiber, low-fat diet is recommended 
for diabetes, as well as regular aerobic exercise. If diet and exercise do not improve 
blood sugar levels, diabetes medications or insulin therapy can be used. Possible 
treatments for T2D include metformin, meglitinides, sulfonylureas (SU), 
thiazolidinediones, DPP-4 inhibitors, glucagon-like peptide-1 (GLP-1) receptor 
agonists, SGLT2 inhibitors and insulin therapy. Metformin is, however, the most 
recommended treatment for T2D (National Institute of Diabetes and Digestive and 
Kidney Diseases, 2009).  
Metformin (an AMPK activator) acts by reducing the glucose levels in plasma (Zhou, 
et al., 2001; Madiraju, et al., 2014). Metformin also reduces gluconeogenesis, glucose 
secretion in the liver and endogenous glucose production. Moreover, metformin helps 
the body to utilize insulin more efficiently (similarly to thiazolidinediones). 
Thiazolidinediones improves insulin sensitivity and reduces β-cell failure by causing a 
decrease of free fatty acid accumulation and inflammatory cytokines; as well as an 
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increase in adiponectin levels and β-cell structure and function preservation (Consoli 
& Formoso, 2013). Metformin and thiazolidinediones are insulin sensitizers.  
Meglitinides and SU are insulin secretagogues that help the body to secrete more 
insulin (Johnson, 2015). GLP-1 receptor agonists activate GLP-1 receptors in the 
small intestine to slow down digestion and pancreatic receptors to induce insulin 
secretion (Deacon, et al., 2012). Normally, GLP-1 is secreted by the L-cells of the gut 
on ingestion of a meal. It acts as an incretin hormone to decrease glucagon secretion 
and induce glucose-dependent insulin secretion from the pancreas even before the 
rise in plasma glucose or fatty acid levels (Lim & Brubaker, 2006; Marathe, et al., 
2011). It has been shown that T2D patients have low levels of GLP-1 (Lastya, et al., 
2014). GLP-1 is a protein therefore needs to be injected by the patient.   
DPP-4 inhibitors inactivate the DPP-4 enzyme that usually breaks down GLP-1. DPP-
4 inhibitors can be taken orally.  DPP-4 inhibitors function and improve insulin 
secretion similarly to GLP-1 receptor agonists.  SGLT2 inhibitors prevent the kidneys 
from reabsorbing glucose into the blood (Tahrani, et al., 2013). SGLT2 is found on the 
nephron and is responsible for more than 90 % of glucose reabsorption from the 
urinary filtrate. When SGLT2 is inhibited, this reabsorption is decreased and leads to 
increased glucose excretion in urine. As a last option, insulin therapy is sometimes 
needed in patients with T2D. Insulin cannot be taken orally, because insulin is a protein 
and will be broken down by the digestion system. Therefore, insulin is taken by 
injection.  
To control blood glucose levels is a big challenge; and the use of plant derived 
nutraceuticals (along with current therapies that improve metabolic disturbances) can 
be helpful and promising (Rother, 2007; Dludla, et al., 2014).  In Canada, for example, 
the increase in diabetes leads to the search for ways to manage T2D by plant-based 
diets. These are diets that discourage meat, eggs, diary and processed foods (Rinaldi, 
et al., 2016). Rinaldi et al., (2016) concludes that plant-based diets manage and 
prevent T2D by weight-loss properties and the ability to decrease cholesterol levels.   
Medicinal plants have anti-hyperglycaemic effects because of their capability to 
restore pancreatic tissue function by either increasing insulin production, reducing 
glucose absorption in the intestines or facilitating metabolites in the insulin processes 
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(Malviya, et al., 2010). Researchers argue that plant derived medicines are low cost, 
less toxic and free from the side effects that come with synthetic drugs (Parikh, et al., 
2014). Although this is not entirely true, the vast majority of indigenous people prefer 
natural products, and to a large portion of the South African population, it is all that is 
available to them. These are some of the reasons why the modern consumer prefers 
more natural products. 
 
Figure 1.2 A diagram showing the effects of T2D on insulin signalling (adapted from Aulston, et al., (2013)). The 
dotted lines indicate inhibition of the Akt pathway by increased FFA levels and hyperglycaemia. The solid lines 
indicate that the respective pathways are unaffected. 
1.4. Cardiovascular Disease 
People with diabetes may suffer from certain conditions or complications that 
contribute to the development of CVD (Muhlestein, et al., 2003). These conditions 
include hypertension, abnormal cholesterol levels, high levels of triglycerides, obesity, 
absence of physical activity, and smoking (Dokken, 2008; American Heart Association, 
2015). 
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Because of the high energy requirements of the heart, it can use fatty acids, 
carbohydrates, amino acids and ketone bodies as sources of energy (Lopaschuk, et 
al., 2010; Boundless, 2016). Under normal conditions, it will utilize fatty acids as the 
energy substrate of choice. Beta-oxidation of long-chain fatty acids provides energy to 
maintain the constant contractile activity of the heart (Lopaschuk, et al., 2010) (see 
‘2.1. Cardiac Metabolism’ for a detailed discussion). This oxidation is a complex 
metabolic process and ensures that the energy demands of the heart are met. Fatty 
acid metabolism is affected by alterations in contractile work, changes in hormone 
levels, limited oxygen supply and the presence of substrates such as glucose 
(Lopaschuk, et al., 2010). Alterations in the metabolism and excessive uptake and β-
oxidation of fatty acids (as in obesity and diabetes) may negatively affect cardiac 
function (Lopaschuk, et al., 2010) (discussed in ‘2.6.6. Heart Failure’). 
2. The Human, the Heart and its systems 
 
2.1. Cardiac Metabolism  
The heart is a vital organ that pumps not only blood, but nutrients and oxygen to the 
cells in our bodies (Stefan, 2015). With the cardiovascular system, the heart also has 
a waste removal function via the blood and vessels. The heart’s wellbeing and health 
is of high importance and dysfunction in this organ can lead to major complications 
such as fatigue, an irregular heartbeat and much more. Lifestyle choices, genetics and 
age are only three of many factors that may compromise cardiac health.   
Cardiomyocytes are terminally differentiated muscle cells (Woodcock & Matkovich, 
2005). Cardiomyocytes are striated and contain actin and myosin filaments which are 
essential for the contractile activity of the heart. When these filaments slide over each 
other, the heart contracts. For this to happen, biochemical processes that require 
adenosine tri-phosphate (ATP) are necessary. ATP is the high-energy molecule 
ultimately responsible for contraction of the cardiomyocytes.  
First, the ATP is bound to myosin allowing the myosin to move to a high-energy state. 
ATPase then converts ATP to ADP (adenosine diphosphate) and inorganic phosphate 
(Pi) (Figure 1.3) (Duke, 1999; Boundless, 2016). This energy release allows the 
myosin head to change position, rendering it ready to bind actin. ADP and P i are still 
attached and myosin is still in a high energy state configuration. When calcium ions 
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attach to troponin (a protein complex), muscle contraction cycle is triggered. 
Consequently, active-binding sites on the actin is exposed. The myosin bridges the 
gap by attaching to the exposed actin-binding site. When the myosin binds to the actin, 
Pi is released, causing myosin to undergo a confirmation change to a lower energy 
state. As the energy is used by myosin, it pulls the actin-filament towards the M-line. 
The sarcomere will eventually shorten and cause the muscle to contract. This 
conformational change in myosin and pulling of the actin-filament is called the power 
stroke. The myosin is in a low-energy state after this power stroke.  
Even though ADP is released after the power stroke, the bridge between myosin and 
actin is still in position. ATP moves the myosin to another high-energy state when it 
binds to it again, releasing the myosin head from the actin-filament (Lymn & Taylor, 
1971). This muscle contraction cycle can then be repeated as soon as ATP is attached 
to myosin again. Without ATP, muscles would constantly be in their contracted state 
(hypercontracture). 
 
Figure 1.3 The cross-bridge muscle contraction cycle (Boundless, 2016). 
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It is well established that cells use ATP as a direct source of energy to accomplish 
different cellular tasks. These tasks include cellular division and substance 
transportation across the membrane. The latter statement makes it evident that ATP 
and its availability influences the survival or death of a cell. Unlike other organs, the 
heart does not have a large energy reserve and relies on external substrates to enter 
the heart and source ATP. Even though the mitochondrial ATP synthase enzyme 
(F1F0-ATPase) is the main synthesizer of ATP, it is also produced from the metabolism 
of substrates such as glucose, free fatty acids and lactate (Depre, et al., 1999). The 
heart is a constantly contracting organ, thus demanding continuous supply of ATP 
(Nagoshi, et al., 2011).  
In the fed state, the heart preferentially uses carbohydrates as source of ATP because 
insulin levels are high. Contrastingly, in the fasted state, free fatty acids are the major 
ATP source of choice (Opie, 2004). As mentioned earlier, when ketone bodies and 
amino acids are abundant, the heart can also utilize these as sources of ATP. In the 
heart, more than 95% of ATP formation comes from the oxidative phosphorylation 
process in the mitochondria. The remaining ATP is generated by glycolysis and GTP 
formation in the citric acid cycle (also called Krebs cycle or TCA cycle).  
(1) Glucose transporters (GLUT1 and GLUT4) transfer glucose into a cell (see ‘2.2.3.2 
Glycolysis’ for a detailed description) (Bonen, et al., 1990; Van Den Brom, et al., 2013). 
Glucose is converted to pyruvate through the glycolytic pathway in the cell cytoplasm 
(Nelson & Cox, 2004). The pyruvate dehydrogenase (PDH) complex, spanning the 
mitochondrial inner and outer membrane, is involved in the transformation of pyruvate 
to acetyl-CoA that will enter the citric acid cycle and electron transport chain (ETC) to 
produce ATP (Figures 1.4 and 1.5). PDPs (PDH phosphatases) and PDKs (PDH 
kinases) regulate PDH activity, and PDH is dephosphorylated in its active state.  
(2) As mentioned earlier, free fatty acids are abundant in the blood when the body is 
in a fasted state, causing high free fatty acid intake into the heart (Bonen, et al., 2004; 
Opie, 2004). These free fatty acids are then used for oxidative metabolism. Passive 
diffusion or protein channels (cluster of differentiation 36 (CD36)) can transport the 
long chain fatty acids from the plasma into the cardiomyocytes (see ‘2.2.2. Fatty Acid 
Metabolism’). The free fatty acids (that have entered the cell) will then bind to the 
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intracellular fatty acid binding protein and be activated by coenzyme A (CoA) to form 
fatty Acyl-CoA derivatives.  
Extra fatty Acyl-CoA can be stored as triglycerides. The CPT (carnitine palmitoyl 
transferase) system consist of CPT-1 and CPT-2 (McGarry & Brown, 1997). CPT-1 is 
an integral protein that converts long-chain fatty acids to acylcarnitine and shuttles it 
across the membrane to undergo β-oxidation and eventually produce acetyl-CoA. 
NADH (nicotinamide adenine dinucleotide) and acetyl-CoA are both coenzymes and 
by-products of β-oxidation (Stanley, et al., 2005). Acetyl-CoA is metabolised in the 
mitochondrial matrix through the citric acid cycle. NADH fuels the ETC and plays a 
role in ATP synthesis (more under ‘2.2.1.1. Oxidative Phosphorylation’) (Stanley, et 
al., 2005).  
Citrate synthase is one of the citric acid cycle enzymes and produces citrate by 
condensing acetyl-CoA and oxaloacetate (Stanley, et al., 2005; Van Den Brom, et al., 
2013). Isomerization of citrate then takes place, followed by different conversion 
reactions that will eventually produce malate. These conversion reactions are the 
source of the by-products of the citric acid cycle, NADH and FADH2. Oxaloacetate and 
NADH are produced when malate is dehydrogenated. The cycle repeats itself when 
oxaloacetate reacts with acetyl-CoA. A schematic representation of fatty acid and 
glucose metabolism in the cardiomyocyte can be seen in Figure 1.4 (Lopaschuck, et 
al., 2010; Van Den Brom, et al., 2013).  
 
Figure 1.4 A schematic of glucose and fatty acid metabolism in a cardiomyocyte (adapted from Van Den Brom, 
et al., (2013)). 
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2.2. Energy metabolism 
A key regulator in energy metabolism is PGC-1α (Liang & Ward, 2006). PGC-1α 
(PPARγ coactivator-1α) interacts with the transcription factors that are pivotal in 
glucose- and fat metabolism, thermogenesis, heart development, fiber type switching 
in skeletal muscle and mitochondrial biogenesis (Puigserver & Spiegelman, 2003; 
Gambino, et al., 2011).  
These transcription factors are known as PPARs (peroxisome proliferator-activated 
receptors) and are lipid sensors that act in response to dietary lipid intake (Michalik, 
et al., 2006). They regulate lipid metabolism and storage. More specifically, PPARγ 
(peroxisome proliferator-activated receptor gamma) is a ligand-activated 
transcriptional factor that control genes regulating glucose- and lipid metabolism 
(Desvergne & Wahli, 1999). PPARγ is mainly involved in lipid metabolism, 
carbohydrate metabolism and adipocyte differentiation. The activation of PPARγ is 
linked to decreased blood glucose levels. 
PGC-1α promotes cardiac mitochondrial biogenesis and is thus essential for the heart 
and its unceasingly high demand for ATP (Lehman, et al., 2000). Increased PGC-1α 
expression stimulates hepatic gluconeogenesis and fatty acid oxidative metabolism, 
and is therefore increased in fasting states (Yoon, et al., 2001; Kim, et al., 2005).  
PGC-1α is also known to increase glucose uptake by upregulating GLUT4 expression 
in skeletal muscle and cultured muscle cells (Michael, et al., 2001; Evans, et al., 2004). 
In the muscles of T2D, reduced and compromised PGC-1α levels have been observed 
(Liang & Ward, 2006). It has been shown that T2D patients have downregulated PGC-
1α levels in the muscles or a polymorphism on the PGC-1α gene (Gly482Ser) (Hara, 
et al., 2002; Mootha, et al., 2003).  
2.2.1. Mitochondria  
2.2.1.1. Oxidative Phosphorylation 
During aerobic respiration, oxidative phosphorylation is the final step that occurs in the 
inner membrane of the mitochondria to produce ATP (Figure 1.5) (Alberts, et al., 2002; 
Stanley, et al., 2005; Vos, et al., 2015). Electrons from NADH and FADH2 (which are 
by-products formed in the citric acid cycle from glycolysis and fatty acid oxidation) pass 
along mobile electron carrier molecules (see ‘2.1. Cardiac Metabolism’). Two carrier 
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molecules (coenzyme-Q (CoQ) and cytochrome c) are embedded in the inner 
mitochondrial membrane (IMM), along with four enzyme complexes (I, II, III, IV) that 
are involved in oxidative phosphorylation (Lesnefsky, et al., 2001; Berg, et al., 2002). 
The complexes include NADH dehydrogenase (complex I), succinate dehydrogenase 
(complex II), cytochrome c oxidoreductase (complex III), and cytochrome c oxidase 
(complex IV). The transfer of these electrons through a series of oxidation/reduction 
reactions from one complex to the next, is referred to as the ETC (as mentioned 
previously).  
The reduction of NAD+ provides two electrons to complex I. This reduction is fuelled 
by the substrates pyruvate, glutamate and malate. Malate is converted to 
oxaloacetate, that will, in turn, condense with acetyl-CoA to form citrate. Citrate is then 
metabolised in the citric acid cycle.  The translocation of protons via complexes I, II 
and IV takes place from the mitochondrial matrix to the inner-membrane space (Chan, 
2006).  
Complex II, located in the IMM, is also involved in the citric acid cycle (Tzagoloff, 
1982). The conversion of succinate to fumarate transfers electrons to the non-haem 
group on complex II. Hereafter the substrate is transferred to CoQ. Complex III is 
involved in the electron transfer between reduced CoQ to oxidized cytochrome c. 
Complex IV (IMM) transfers the electrons to oxygen to form water. 
 
 
 
 
 
Figure 1.5 A schematic of oxidative phosphorylation, with the focus on the electron transport chain (adapted from 
Vos et al., (2015), Alberts et al., (2002) and Nelson & Cox (2004). 
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As mentioned earlier, oxidative phosphorylation is the main pathway that synthesizes 
ATP (Okuno, et al., 2011). The final reaction, where ADP and inorganic phosphate (Pi) 
form ATP, is catalysed by F1F0-ATPase. F1F0-ATPase does this by utilizing the protons 
that create an electrochemical potential across the inner membrane (Rines & Ardehali, 
2014). The oxidative phosphorylation rate is influenced by the rate of myocyte energy 
demand and ATP utilisation (Stanley, et al., 2005).  
ATP formed from oxidative phosphorylation is transferred to the cytoplasm from the 
mitochondrial matrix (Berg, et al., 2002; Klingenberg, 2008; Vos, et al., 2015). The 
transporter proteins responsible for facilitating this are known as ADP/ATP 
translocases of ADP-ATP carrier (AAC) (Adrian, et al., 1986; Klingenberg, 2008). 
Normally, some ATP molecules will re-enter the mitochondria (as ADP) to be 
recharged and thus maintain the ATP concentration in the cell to be higher than the 
ADP concentration. The rest of the ATP is used to drive other cellular processes 
(Alberts, et al., 2002). 
To experimentally determine the bioenergetics in oxidative phosphorylation, the 
oxygen consumption of mitochondria must be determined. This can be done with a 
classic standard Clark-type oxygen electrode devised by Chance and Williams 
(Chance & Williams, 1955). Generally, State 1 respiration is the rate at which 
mitochondria consume oxygen in the presence of Pi (Brand & Nicholls, 2011). State 2 
measures ADP independent respiration but in the presence of substrates (glutamate-
malate or palmitoyl-malate). This is a measure of mitochondrial oxygen leak or 
uncoupled mitochondria. As soon as ADP is added (state 3), F1F0-ATPase function is 
activated, and mitochondria rapidly consumes oxygen to form ATP from ADP. This 
increase in ADP and energy demand enhance phosphorylation, thus increasing 
formation of ATP. State 4 respiration is when all the ADP is converted to ATP and 
phosphorylation is decreased. Respiration then reaches an equilibrium and respiration 
rate is decreased. This allows the mitochondria to respire as if they were in the resting 
state (or state 2). Again, a high respiration rate in the absence of ADP, is indicative of 
uncoupled mitochondria or an oxygen leak.  
ATP turnover and substrate oxidation controls state 3 (Brand & Nicholls, 2011). Thus, 
a decrease in the state 3 respiration means that there is an inhibition in either the 
substrate metabolism, processing enzymes or enzymes involved in the ETC. Proton 
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leaks and agents that can cause F1F0-ATPase to recycle ATP to ADP, affect the state 
4 respiration.  
Conventionally, functional mitochondria should be able to make ATP as needed to 
meet energy demands (Brand & Nicholls, 2011). As measure of mitochondrial function, 
the RCI (respiratory control index) is used. The RCI is calculated by dividing the state 
3 respiration by state 4 respiration. A high RCI value shows that the mitochondria 
display a high capacity for substrate oxidation and formation of ATP. A low RCI value 
because of high state 4 respiration indicates uncoupling of the mitochondria. This is 
usually because of leakage of H+ from the inner membrane space into the matrix, 
thereby dispersing the electrochemical gradient without producing ATP. A high 
expression of uncoupling proteins will result in such a H+ leak.  RCI values can vary 
and be influenced by how the substrates have been utilized and from which tissues 
the mitochondria were isolated from. Despite the latter, the RCI is still a dependable 
parameter to measure mitochondrial function, because it is influenced by any change 
in the oxidative phosphorylation process. 
The ADP/O ratio is the number of ATP molecules produced by the ETC, where two 
electrons move through the ETC (Brand & Nicholls, 2011). When there is an 
uncoupling (or disconnection) of the mitochondria proton translocation for ATP 
synthesis, the ADP/O ratio will be affected; indicating reduced coupling efficiency of 
the mitochondria. The function and mitochondrial oxidative capacity can thus be easily 
and reliably calculated by experimentally investigating the respiratory rates and ADP/O 
ratio. 
The oxidative phosphorylation rate is another index to be used for evaluation of 
mitochondrial function and can be calculated for state 3 to determine the number of 
moles ATP produced per milligram mitochondria protein per minute. This is done by 
multiplying state 3 with the ADP/O ratio.  
2.2.1.2. Autophagy and Mitophagy 
Not only are mitochondria vital for cell metabolism, but they also regulate cell death. 
Stressors that can induce cell death include DNA damage, nutrient deficiency, growth 
factor loss, hypoxia, ischaemia/reperfusion, caloric restriction and oxidative stress 
(Høyer-Hansen, et al., 2007; Fulda, et al., 2010; Mihaylova & Shaw, 2012).  
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Cell death can occur by necrosis, apoptosis or autophagy (Fulda, et al., 2010). 
Necrosis is a non-apoptotic, passive and accidental cell death and results from 
environmental distress with uncontrolled release of inflammatory contents (Fink & 
Cookson, 2005).  
In contrast, apoptosis is defined as an active and programmed process of cellular 
death to avoid inflammation (Fink & Cookson, 2005). Apoptosis can be introduced by 
either intrinsic (mediated by mitochondrial factors) or extrinsic factors (mediated by 
death receptor ligation). Both these pathways lead to the activation of apoptosis via 
caspase-3 and caspase-7 (Ichim & Tait, 2016). Either (1) B-cell lymphoma 2 (Bcl-2) 
family proteins (located on outer mitochondrial membrane (OMM)) or (2) mPTP 
(mitochondrial permeability transition pore) opening can mediate intrinsic apoptosis 
(Hengartner, 2000; Fulda & Debatin, 2006).  
(1) There are two types of proteins in the Bcl-2 family, namely; pro-apoptotic and anti-
apoptotic. Bcl-2/adenovirus E1B 19-kDa protein-interacting protein 3 (BNIP3), from 
the BH3 proteins family, is a pro-apoptotic protein (Burton & Gibson, 2009).  Stress 
indicators from the cytosol ‘activate’ these pro-apoptotic proteins that will, in turn, 
transduce the stress signals to the mitochondria to initiate cell-death. The pro-
apoptotic proteins (e.g. Bax) bind to the anti-apoptotic proteins (Bcl-2) to neutralize 
them (Chipuk, 2008). Cytochrome C and second mitochondria-derived activator of 
caspase (SMAC/Diablo) are then released into the cytosol to form an apoptosome that 
will allow the cell to undergo the programmed cell death (Cory & Adams, 2002).  
(2) As mentioned previously, the electrochemical gradient is essential for the normal 
formation of ATP. Therefore, the IMM must be well maintained. Two essential factors 
for this maintenance include the mPTP and mitochondrial Ca2+ uniporter (MCU). The 
MCU is a selective ion channel that regulates Ca2+ uptake through the IMM (Tsai, et 
al., 2016). Different signals cause change in the IMM that can lead to the opening (or 
formation) of the mPTP (Halestrap, 2009). Inhibitors of the mPTP include adenine 
nucleotides, whereas increased matrix Ca2+ and ROS induce opening of the mPTP 
(Murphy & Steenbergen, 2008). When the pore opens, cytochrome C can leak out of 
the mitochondria to induce apoptosis. Furthermore, a loss in the electrochemical 
gradient occurs, leading to the destruction of the ETC causing inhibition in ATP 
synthesis and reversal of F1F0-ATPase occur because of this destruction of the ETC, 
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thus causing ATP depletion and cell death (Halestrap & Richardson, 2015). The 
mitochondria can also swell and burst due to the constant influx of solutes through the 
open pore (Newmeyer & Ferguson-Miller, 2003). Oxidative stress, phosphate levels, 
membrane potential and alteration in the mPTP’s Ca2+ sensitivity can control the 
opening of the pore. Thus, an increase in Ca2+ uptake in the mitochondria can be 
pathological and initiate cell death. The immunosuppressant drug cyclosporine A 
(CsA) can limit mPTP opening (Crompton, et al., 1988). 
According to Halestrap. et al., (2004), the mPTP consists of adenine nucleotide 
translocator (ANT), Cyclophilin-D (Cyp-D), F1F0-ATPase and mitochondrial proteins 
that are utilized as pore modulators (Halestrap, et al., 2004). According to other 
studies, other proteins have been identified as part of the mPTP, such as voltage-
dependent anion channels (VDACs), hexokinase II (HK), the inorganic phosphate 
carrier (PiC), peptidyl prolyl isomerase F (PPIF), the peripheral benzodiazepine 
receptor (TSPO) and several members of the Bcl-2 family (Szabó, De Pinto, & Zoratti, 
1993; Beutner, Rück, Riede, & Brdiczka, 1998; Vander Heiden, et al., 2001; Basso, et 
al., 2005; Chiara, et al., 2008; Sileikyte, et al., 2011; Varanyuwatana & Halestrap, 
2012). Cyp-D is believed to help regulate and increase Ca2+ permeability, thus opening 
the pore. CsA inhibits mPTP opening by inhibiting binding of Cyp-D to the ANT (Clarke, 
et al., 2002; Liu, et al., 2011). Inorganic phosphates also have an important role in the 
pore’s opening (Leung, et al., 2008). GNX-4975 is a novel inhibitor of the mPTP that 
has recently been identified (Richardson & Halestrap, 2016). 
When harmful substances and malformed proteins need to be eliminated, or when 
compensation is needed for a loss of nutrients, autophagy is the intracellular process 
of degradation to maintain a positive energy balance (Yorimitsu & Klionsky, 2005). In 
healthy cells, autophagy is also used to help them survive (Lamb, et al., 2013). 
Autophagy removes cytoplasmic components such as pathogens and dysfunctional 
mitochondria. Autophagy can be (1) chaperone-mediated, which has limited 
degradation capacity because only cytosolic proteins with a certain peptide sequence 
motif are degraded (Majeski & Dice, 2004). Two other processes include (2) 
microautophagy (by means of direct lysosomal engulfment of the cytosolic cargo) and 
(3) macroautophagy which can also for example remove damaged mitochondria by 
means of the formation of an autophagosome (Reggiori & Klionsky, 2002).  
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Autophagy involves autophagy receptors that are classified according to their cargo 
binding domains (Behrends & Fulda, 2012). In vesicle biosynthesis, ubiquitin-like 
(UBL) systems are vital. They are activated by AMPK (a cellular energy sensor) and 
mTORc1 (mTOR complex 1, a nutrient sensor) (Lamb, et al., 2013). Ubiquitin binding 
domains utilize protein specific interactions. In the formation of the autophagosome, 
an isolated membrane (in the cytosol) is elongated around the cargo destined for 
elimination (see Figure 1.6) (Eskelinen, 2005; Hamacher-Brady, 2012; Kruppa, et al., 
2016). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6 A representation of the autophagic process (adapted from Hamacher-Brady (2012)). 
The membrane elongates and matures until the cargo is fully engulfed and enclosed 
(Lamb, et al., 2013). Ubiquitination reactions allow for this elongation and protein 1-
light chain protein 3 (LC3-I) is essential for this process (Tanida, et al., 2008). LC3-II 
(formed when LC3-I conjugates with phosphatidylethanolamine in the membrane) 
plays a role in the elongation of the outer membrane of the autophagosome. LC3-II 
remains on the autophagosome until it is removed by deconjugation and the 
autophagosome becomes an autophagolysosome. The LC3-II present inside the inner 
vesicle, however, stays associated with the complete autophagosome allowing 
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investigators to associate LC3-II levels to autophagosome number (Klionsky, et al., 
2012). Fusion of the autophagosome to the endosomes and lysosomes take place to 
form the autophagolysosome that will finally degrade the cargo (Shen & Mizushima, 
2014; Kruppa, et al., 2016).  
There are several proteins involved in the regulation of autophagy. More specifically, 
ATG (autophagy related) proteins that regulate the autophagosome formation 
(Mizushima, et al., 2003). Three ATG groups are involved. There is the (1) Atg9 system 
that is essential for expansion of the phagophore (Feng & Klionsky, 2017). The (2) 
PI3K (phosphoinositide 3-kinase) complex that consists of Beclin-1 and Vps (vacuolar 
protein sorting) 34 and 15 (Itakura, et al., 2008). Lastly is the (3) UbI (ubiquitin-like) 
protein system with Atg8 (LC-3), Atg12, enzymes and proteases (Nakatogawa, 2013). 
Autophagy is regulated by class I PI3Ks and class III PI3Ks (Katayama, et al., 2007). 
The former negatively regulates autophagy, whereas class III PI3K positively regulates 
autophagy. Not only does mTOR (mammalian target of rapamycin, a downstream 
target of class I PI3K/Akt) regulate cell growth and proliferation, but it can sense 
changes in energy and stress levels too (Cuyàs, et al., 2014). Growth can be promoted 
by mTOR by inhibiting autophagy and activating RNA translation (Kim, et al., 2011). 
In contrast, when nutrient levels are low, mTOR is inhibited and autophagy is 
continued.  
Dephosphorylation of mTOR allows its detachment from the Atg13 complex and 
initiates autophagosome formation and cell death by autophagy (Jung, et al., 2009). 
When class III PI3K associates with Beclin-1 (which is involved in autophagosome 
formation) the PI3P (phosphatidylinositol 3-phosphate) complex is formed to allow for 
autophagy to be initiated (Komatsu, et al., 2007; McKnight & Zhenyu, 2013).  
Autophagy can be quantified by many techniques, including Western blotting (more 
explained under ‘8. Western Blots’). Western blotting that aims to quantify autophagy 
focusses on the levels of LC3-II (Sharifi, et al., 2015). The conversion of LC3-I to LC3-
II is taken as a good measure of autophagic flux, therefore the amount of autophagy 
that has occurred in a certain time span. The focus on LC3-II is because it is 
permanently associated with the autophagosome at its inner membrane, until it is 
degraded.  The protein p62 (p62/SQSTM1 also known as sequestosome) is a ubiquitin 
scaffold protein and functions by enabling autophagic degradation of aggregated 
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ubiquitinated protein.  It is also used as an indicator of autophagy progression because 
of its role as an adaptor protein and ubiquitin binding cargo receptor (Sharifi, et al., 
2015). To summarise, autophagy can be identified by certain indicators namely; 
increased LC3-II, Beclin-1 and decreased p62 levels (Komatsu, et al., 2007; Meyer, et 
al., 2013).  
As mentioned earlier, autophagy can be selective by targeting a specific organelle. 
This selective autophagy is mediated by membrane embedding and an example 
thereof is mitophagy (autophagy of the mitochondria) (Behrends & Fulda, 2012). The 
quality of a cell’s mitochondria is vital for its viability and this mechanism is maintained 
by mitochondrial autophagy. Mitochondrial autophagy (or mitophagy) recognizes a 
damaged mitochondrion, thus allowing it to be engulfed by autophagosomes (Saito & 
Sadoshima, 2015).  
Mitophagy is most commonly mediated by PINK1 (PTEN-induced putative kinase 
protein 1) that contains a mitochondria-targeting signal and Parkin (cytosolic E3 
ubiquitin ligase) (Lazarou, 2015). In normal, polarized mitochondria, PINK1 is 
translocated into the mitochondria via TOM (translocase of outer membrane) and TIM 
(translocase of inner membrane). PINK1 is then attached to the IMM (Lazarou, et al., 
2012). PINK1 is degraded by the N-end rule pathway, where the proteasome is 
degraded by N-terminal processing (Yamano & Youle, 2013). The N-end rule pathway 
degrades proteins by identifying the stability of a protein by its N-terminal residue 
(Varshavsky, 1996).  
This import of PINK1 to the IMM is repressed in depolarized mitochondria, thus 
resulting in accumulation of PINK1 at the OMM (Jin, et al., 2010). This then causes 
the formation of a complex between TOM and PINK1 (700 kDa) that 
autophosphorylates at Ser 228 and Ser 402. Increased unfolded protein in the 
mitochondria also leads to PINK1 accumulation on the OMM.  
Subsequently, PINK1 will then phosphorylate S65 on Ubiquitin and the ubiquitin-like 
domain of Parkin. As a result, Parkin ubiquitinates mitochondrial substrates on the 
OMM to recruit p62 which can associate with LC3 (refer to Figure 1.7) (Shires & 
Gustaffson, 2015).  
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Figure 1.7 A representation of mitophagy (adapted from Shires & Gustaffson (2015)). 
Mfn2 (mitofusin 2) is a substrate found on the OMM that is phosphorylated by the 
PINK1 accumulating on the OMM (Chen & Dorn, 2013). PINK1 accumulation also 
ameliorates the recruitment of Parkin to the phosphorylated Mfn2 on the damaged 
mitochondria surface (in cardiomyocytes, Mfn2 serves as a mitochondrial receptor for 
Parkin) (Saito & Sadoshima, 2015). Other proteins that also recruit Parkin to damaged 
mitochondria include VDACs (voltage-dependent anion channels) (Su, et al., 2012). 
LC3 proteins are bound to phagophores and recruited to the OMM via autophagy 
adaptors such as p62 and NBR1 (neighbour of BRCA1 gene 1) (Kirkin, et al., 2009). 
Kirkin, et al., (2009) states that NBR1 and p62 promotes autophagic degradation. 
These phagophores then expand and engulf the mitochondrion, forming an 
autophagosome (as discussed previously). 
Beclin-1 not only plays a pivotal role in autophagy, but in tumor-suppression as well 
(Kang, et al., 2011). Beclin-1 is a component of the class III PI3K complex that 
mediates vesicle-trafficking processes and autophagosome formation in 
macroautophagy. On the other hand, it can also associate with Bcl-2 (an anti-apoptotic 
protein) to inhibit autophagy (Marquez & Xu, 2012; Galluzzi & Kroemer, 2013).  
As mentioned earlier, BNIP3 is another pro-apoptotic protein that can be found on the 
mitochondrial membrane. BNIP3 can activate the downstream effectors of Bax/Bak by 
associating with Bcl-2 (Walls, et al., 2009; Marquez & Xu, 2012). This protein is a weak 
inducer of cell death, compared to that of other family members. BNIP3 can cause cell 
death in three different ways including apoptosis, necrosis and autophagy. BNIP3 
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(inserted into the mitochondrial membrane) transcription is activated by HIF-1 (a 
hypoxia-inducible factor-1 responsive element) under hypoxic conditions. In a study 
by Quinsay et al. (2010), they proved that, in cardiomyocytes, extensive autophagy is 
associated with an overexpression of BNIP3. Moreover, they also demonstrated that 
BNIP3 prompts and induces autophagy irrespective and independent of ROS 
generation, Ca2+ and mPTP opening (Quinsay, et al., 2010). 
A third process whereby mitophagy can be regulated is by ULK1 (Unc-51 Like 
autophagy activating Kinase 1) (Wu, et al., 2014). When phosphorylated by AMPK, 
ULK1 connects cellular sensing to mitophagy (Egan, et al., 2011; Jeon, 2016). It has 
been reported that FUNDC1 (FUN14 Domain Containing 1) is a mitophagy receptor 
and that ULK1 translocates to damaged mitochondria and phosphorylates FUNDC1 
at Ser17 (Liu, et al., 2012; Wu, et al., 2014). This phosphorylation at Ser17 enhances 
FUNDC1 binding to LC3 whereas ULK1-binding-deficient mutant of FUNDC1 prevents 
this translocation of ULK1 to mitochondria, thus inhibiting autophagy. A 
phosphorylation-mimetic mutant of FUNDC1 (S17D) and kinase-active ULK1 
enhances LC3 interaction to form the autophagosome in cells without ULK1, thus 
enhancing mitophagy (Wu, et al., 2014). 
2.2.2. Fatty acid metabolism 
It is evident that energy supplies need to be managed sufficiently in all living 
organisms. The regulation of the uptake of fatty acid (FA) across the plasma 
membrane from the heart and skeletal muscles, is maintained by fatty acid translocase 
FAT/CD36 (see Figure 1.4) (Bonen, et al., 2004). The uptake of FA into the myocyte 
can be regulated in two ways, according Bonen et al. (2004). Regulation can be by 
either increasing the FAT/CD36 plasmalemmal content or by relocation of FAT/CD36 
to the plasma membrane. The FA transport rate is reduced when FAT/CD36 is 
repressed. On the other hand, as soon as exposure to insulin or muscle contraction 
takes place, FAT/CD36 translocation to the cell surface is induced and FA transport 
increases (Bonen, et al., 2004).  
FAT/CD36 is also located on the mitochondrial membrane and is said to be involved 
in mitochondrial FA oxidation (Bonen, et al., 2004). Parkin can stabilize CD36 by 
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ubiquitination in hepatocytes, thus regulating CD36 stability and maintaining FA 
uptake (refer to ‘2.2.1.2 Autophagy and mitophagy’) (Saito & Sadoshima, 2015). 
2.2.3. Glucose metabolism 
In mammals, most tissues depend solely on glucose for metabolic energy, but the 
heart and skeletal muscle prefer fatty acids (Holloway, et al., 2010). Glucose 
homeostasis and metabolism is maintained and controlled by the interaction of insulin, 
glucagon, amylin and incretin hormones (refer to Figure 1.8) (Moore & Cooper, 1991; 
Näslund, et al., 1999; Ward, 2016). Insulin is a hormonal regulator of glucose in the 
circulation, where it controls both the release and utilization of glucose. In a 
hyperglycaemic state, insulin is released by the β-cells of the pancreas to decrease 
the blood glucose concentration by stimulating glucose uptake by peripheral insulin 
sensitive tissue  (Aronoff, et al., 2004). Initially, insulin has been thought of being the 
only regulator of diabetes and insulin deficiency, but there has been an expansion in 
the understanding of glucoregulation where additional hormones have been 
discovered (Aronoff, et al., 2004; Nelson & Cox, 2004).  
Also in the pancreas, are α-cells that release glucagon when blood glucose 
concentration drops below certain threshold values (hypoglycaemia) (Aronoff, et al., 
2004). This discovery was made in the 1950s and it led to a better understanding of 
the associations between insulin and glucagon. In diabetes, the inappropriate increase 
in α-cell function leads to hyperglucagonaemia. Accordingly, hyperglucagonaemia can 
also contribute to the hyperglycaemic state (by stimulation of hepatic glucose 
production) seen in diabetic patients (Unger, et al., 1970). 
Amylin is thought to be associated with insulin and, just like insulin, is also deficient in 
diabetic persons (Moore & Cooper, 1991; Aronoff, et al., 2004). Glucagon-like peptide-
1 (GLP-1) is an incretin hormone, released by the L-cells of the gut, that stimulates the 
secretion of insulin after a meal. GLP-1 is also an important contributor to glucose 
homeostasis maintenance (Aronoff, et al., 2004). 
Blood glucose levels are increased after a meal, especially a carbohydrate-rich meal 
(Radziuk, et al., 1978; Bacha, et al., 2010). This excess glucose can be stored in either 
cardiac myocytes and skeletal muscle, or adipocytes (Berg, et al., 2002). In cardiac 
myocytes, skeletal muscle and liver, glucose is stored in the form of glycogen. In 
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adipocytes, the glucose is converted to triacylglycerols (Berg, et al., 2002; Nelson & 
Cox, 2004).  
Excess glucose can be converted into different forms: glycogen or fatty acids 
(Acheson, et al., 1988; Nelson & Cox, 2004). The (1) glycogenesis pathway converts 
glucose to glycogen (which is the glucose storage polymer). (2) Glycolysis converts 
glucose 6-phosphate to pyruvate.  Pyruvate can then be converted to fatty acids or it 
can be metabolized to produce more ATP (by entering the citric acid cycle) (Näslund, 
et al., 1999; Ward, 2016).  
When acetyl-CoA enters the pathway of lipid metabolism (instead of the citric acid 
cycle), glucose is converted to fatty acids. When energy is needed (hypoglycaemia), 
acetyl-CoA enters the citric acid cycle to release the stored energy derived from 
carbohydrates, fats and proteins (Näslund, et al., 1999; Berg, et al., 2002).  
 
Figure 1.8 A representation of glucose metabolism (adapted from Ward (2016)). 
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2.2.3.1. Glucose Transport 
Glucose transporters (GLUTs), are the proteins involved in mediating and controlling 
glucose transport into cells (Thorens & Mueckler, 2009). Of the 14 GLUT genes in the 
human genome, the protein production of only 2 will be further discussed in this review. 
GLUT1 is the basal glucose transporter that is present in most cells (Scheepers, et al., 
2004). GLUT1 allows most tissues to be able to take up glucose at basal levels 
(Mueckler, 1990). GLUT4 is the insulin-responsive transporter that is present in 
muscle, cardiac- and fat cells. Insulin regulates the level of GLUT4 on the surface of 
muscle and fat cells.  
In myocytes and adipocytes, glucose uptake is facilitated by GLUT4. GLUT4 is mostly 
retained in small intracellular vesicle membranes between meals, but some of the 
GLUT4 molecules can be found in the plasma membrane (Nelson & Cox, 2004). High 
levels of blood glucose activate the release of insulin from the pancreas (Leto & Saltiel, 
2012). The insulin then prompts the intracellular vesicles to move to the plasma 
membrane. It is here where the vesicles fuse with the plasma membrane and expose 
the GLUT4 molecules on the outer surface of the cell. This movement and exposure 
of the GLUT4 molecules increase the rate of glucose uptake. As soon as the blood 
glucose levels are normalized, the release of insulin slows down and most of the 
GLUT4 molecules are internalized from the plasma membrane and stored in vesicles 
(Nelson & Cox, 2004). The signalling processes involved in this, will be discussed in 
Figure 1.9 below. 
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Figure 1.9 How insulin regulates glucose transport by GLUT4 into a myocyte (adapted from Nelson & Cox (2004). 
2.2.3.2. Glycolysis  
Through glycolysis, glucose molecules are broken down to form pyruvate by means 
of enzyme-catalyzed reactions (Nelson & Cox, 2004; Gargani, et al., 2012). Figure 
1.10 shows the enzymes involved in the metabolism of glucose to pyruvate. The first 
part of the glycolysis pathway breaks the glucose down. Step 1 in the glycolysis 
pathway is catalyzed by hexokinase. This pathway starts with a glucose molecule that 
is phosphorylated to produce glucose-6-phosphate. Phosphorylation adds a 
phosphate group to a molecule, thus using one ATP molecule at this step. In the 
second step, phosphoglucose isomerase (PI) converts glucose-6-phosphate to 
fructose-6-phosphate (F6P). At the third step, another ATP molecule is used to provide 
a phosphate group to the F6P; producing fructose-1,6-bisphosphate (FBP). 
Phosphofructokinase catalyzes this conversion. Aldolase then converts FBP to 
produce glyceraldehyde-3-phosphate (GAP) and dihydroxyacetone phosphate 
(DHAP). GAP continues to the glycolytic pathway, but DHAP is reacted on by 
triphosphate isomerase to produce GAP at a later stage.  
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GAP is now phosphorylated and oxidized by NAD+ (Nelson & Cox, 2004; Gargani, et 
al., 2012). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is responsible for 
this reaction. A NAD+ molecule is converted to NADH when it ‘pulls’ a hydrogen atom 
from the GAP. In this reaction, the GAP molecule then yields 1,3 biphosphoglycerate. 
NADH and hydrogen. Phosphoglycerate kinase (PGK) comes in to play next. PGK 
converts 1,3 biphosphoglycerate to 3-phosphoglycerate, and causes the loss of a 
phosphate group. This phosphate group is transferred to an ADP molecule to yield an 
ATP molecule.  
At this stage, the position of the phosphate group on the 3-phosphoglycerate is 
rearranged (Nelson & Cox, 2004). This is made possible by phosphoglycerate mutase 
(PGM) that converts 3-phosphoglycerate to 2-phosphoglycerate. Enolase will 
subsequently convert 2-phosphoglycerate to phosphoenolpyruvate (PEP) by 
dehydrating the 2-phosphoglycerate. The final step entails the conversion of 
phosphoenolpyruvate to pyruvate. This is made possible by pyruvate kinase. A 
phosphate group from the PEP is transferred to an ADP molecule to produce an ATP 
molecule. Note that there are two PEP molecules, thus yielding two ATP molecules. 
This pathway consumes two ATP molecules and generates three ATP molecules. 
The metabolic conditions and oxygen levels influence what happens next to the 
pyruvate molecules next (Nelson & Cox, 2004). In aerobic conditions, the PDH 
complex converts the pyruvate to acetyl-CoA in the mitochondria. Acetyl-CoA will then 
enter the citric acid cycle to aid in ATP synthesis (refer to ‘2.2.1.1. Oxidative 
Phosphorylation’) (Hashimoto, et al., 2006). In contrast, in anaerobic conditions, the 
electron transport slows down and pyruvate is transformed into lactate (Nelson & Cox, 
2004; Rogatzki, et al., 2015). This inhibits the glycolytic pathway because of an 
increase in the NADH concentration and decrease in NAD⁺ (Stryer, 1995). Glycolysis 
is essential because it is a major source of ATP that can still to a certain extent, take 
place in anaerobic conditions. The reduction of pyruvate to lactate re-oxidizes NADH 
and allows the glycolysis pathway to continue.  
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Figure 1.10 The glycolytic pathway (modified from Gargani et al. (2012)). 
2.2.3.3. Gluconeogenesis 
The opposite of glycolysis is gluconeogenesis (“the formation of a new sugar) (Nelson 
& Cox, 2004). This metabolic pathway converts pyruvate and carbon compounds to 
glucose, thus generating/synthesizing glucose from non-carbohydrate substrates 
(lactate, citric acid, amino acids and glycerol) (Nordlie, et al., 1999). Gluconeogenesis 
comes in to play when the supply of glucose is depleted; such as in periods of intense 
exercise, fasting, starvation and low-carbohydrate diets. The liver, and sometimes the 
cortex of the kidneys, serves as the sites at which gluconeogenesis occurs, but this 
does not play an important role in heart muscle metabolism (Exton & Park, 1968; 
Nelson & Cox, 2004). 
2.2.3.4. Glycogenolysis 
Gluconeogenesis is not the only mechanism by which humans and some animals 
prevent hypoglycaemia. Glycogenolysis degrades glycogen to glucose, as opposed to 
gluconeogenesis (Hers, 1976; Nelson & Cox, 2004). Glycogen functions as energy 
storage in the muscle and liver. When glucose is suddenly in need, glycogen can 
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quickly be metabolized to produce it. Glycogenolysis is stimulated when an adrenaline-
induced fight-or-flight response is needed (McCorry, 2007).  
2.2.3.5. Glycogenesis 
When glucose and ATP levels are too high, glycogenesis converts glucose to glycogen 
(Bonen & McDermott, 1990; Nordlie, et al., 1999). This process also occurs in the liver 
and muscle cells. One ATP molecule per glucose unit (in the glycogen structure) is 
required for this synthesis of glycogen (Nelson & Cox, 2004). 
2.3. Insulin Metabolism 
The hormone insulin, that was briefly discussed earlier, is produced in the pancreas 
and secreted into the blood (Brownlee, 2001; Bevan, 2009). It tightly regulates the 
human metabolism. After food intake, the digestive tract will break down the 
carbohydrates into glucose, leading to insulin secretion by the pancreas (Saltiel & 
Kahn, 2001). Insulin then controls and stimulates the cells in the body to absorb the 
glucose and use it for energy (National Institute of Diabetes and Digestive and Kidney 
Diseases, 2009).  
2.3.1. Insulin Signalling 
Insulin in the circulation binds to the α-subunits of the insulin receptor (IR) on insulin 
sensitive peripheral tissues (Lizcano & Alessi, 2002). A schematic of the IR can be 
seen in Figure 1.11 (Voet, et al., 2006). The IR comprises of two α-subunits and two 
β-subunits (Voet, et al., 2006). Each α-subunit is linked to a β-subunit and the two α-
subunits are in turn linked to each other by disulfide bonds. The α-subunits contain 
insulin binding sites and are located on the outside of the cell. The intracellular β-
subunit contains the insulin-regulated tyrosine protein kinase (Cell Signaling 
Technology, 2016). Insulin binding activates the intrinsic tyrosine kinase activity of the 
β-subunits and will phosphorylate the insulin receptor substrate (IRS) proteins. IRS-1 
and IRS-2 are the main substrate proteins in the heart. Proteins that have the Src 
Homology 2 (SH-2) domains in their structure can recognize the phosphotyrosine 
binding (PTB) domains on IRS1 (White, 1997). 
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The insulin signalling pathways control many processes such as glucose uptake 
(GLUT4 vesicle translocation), enzyme activation/inactivation, mitogenic responses, 
lipid synthesis and protein synthesis (White, 1997; Nelson & Cox, 2004). Insulin 
promotes protein synthesis by stimulating amino acid uptake into cells. Moreover, 
insulin also inhibits protein degradation, thus enhancing protein synthesis. The 
synthesis of lipids, inhibition of lipolysis and uptake of fatty acids can also be enhanced 
by insulin (Saltiel & Kahn, 2001).  
 
Figure 1.11 A schematic diagram of the IR (adapted from Voet et al. (2006)). 
2.3.1.1. The PI3K-dependent pathway 
The activation of PI3K is fundamental for insulin stimulated glucose uptake (Zhu, et 
al., 2013). The PI3K/PKB pathway mediates the metabolic effects caused by insulin. 
The serine/threonine kinase Akt is also known as protein kinase B or PKB (from here 
on will be referred to as Akt/PKB) (Cong, et al., 1997). In the PI3K-dependent pathway, 
the IRS-1 protein is the main link between the IR and PI3K (with SH-2 domains in the 
p85 regulatory subunit) (Rondinone, et al., 1997). 
IRS-1 proteins have functions in glucose uptake in cardiac, skeletal muscle and 
adipose tissue; whereas IRS-2 is involved in glucose and insulin production in the liver 
and pancreatic β-cells respectively (Hers, et al., 2011; Hardin, et al., 2015). However, 
when IRS-1 levels are low (for example in non-insulin dependent diabetes mellitus or 
insulin resistance), IRS-2 takes over the role as main docking site for PI3K. For IRS-2 
to bind to PI3K (in a similar way that IRS-1 does), a higher insulin concentration is 
required (Rondinone, et al., 1997). 
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To initiate the Ras/MAPK pathway, IRS-1 activates it by forming a complex with GRB2 
(refer to Figure 1.12 (Hemmings & Restuccia, 2012)) (discussed under ‘2.3.1.2.1. 
Ras/MAPK pathway’).  
 
Figure 1.12 A representation of the PI3K-dependent pathway (adapted from Hemmings & Restuccia (2012), 
Jeon (2016) and Sakamoto & Holman (2008)). 
The activation of PI3K by IRS-1 converts PIP2 (phosphatidylinositol 4,5-bisphosphate) 
to PIP3 (phosphatidylinositol (3,4,5) triphosphate) by phosphorylating the membrane 
lipid bound PIP2 (Hemmings & Restuccia, 2012). The level of PIP3 is regulated by 
PTEN (a protein tyrosine phosphatase that preferentially dephosphorylates 
phosphoinositide substrates, such as PIP3). PTEN downregulates intracellular levels 
of PIP3, thus down-regulating Akt/PKB signalling pathways (Hers, et al., 2011). 
These polyphosphoinositides perform like “docking sites” on the plasma membrane 
(Hers, et al., 2011). Proteins containing pleckstrin homology (PH) domains can bind 
to these docking sites. This includes mTORc2 (mTOR complex 2), Akt/PKB and PDK1 
(3-phosphoinositide-dependent protein kinase 1). The latter explains that Akt/PKB is 
not directly activated by PIP3 but rather recruited by it to the plasma membrane and 
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brought in close proximity to the enzymes that will phosphorylate it to be activated 
(Cell Signaling Technology, 2016).  
In the PI3K/PKB pathway, PIP3 binds to Akt/PKB; aiding in the phosphorylation of key 
proteins (which can then be activated by other kinases) (Bevan, 2009; Hemmings & 
Restuccia, 2012). PIP3 changes the Akt/PKB conformation to allow for subsequent 
phosphorylation by PDK1 or mTORc2 (Song, et al., 2005). 
PDK1 phosphorylates Akt/PKB at Thr308 (partial activation of Akt/PKB). When 
Akt/PKB is phosphorylated by mTORc2 at Ser473, full enzymatic activity is stimulated 
(full activation of Akt/PKB) (Bevan, 2009; Hemmings & Restuccia, 2012). Members of 
the PI3K-related kinase family are also able to phosphorylate Akt/PKB at Ser473 
(Calleja, et al., 2007) (Hers, et al., 2011). When Akt/PKB is active, it can follow different 
signalling paths (see schematic Figure 1.12). Golding, et al. (2009) suggests that ATM 
(ataxia-telangiectasia (A-T) mutated) can also act on and regulate Akt/PKB 
phosphorylation (Halaby, et al., 2008; Golding, et al., 2009). ATM plays an important 
role in DNA repair and cell cycle checkpoints (Lavin & Shiloh, 1997). 
Activation of Akt/PKB at the PH domain results in the initiation of at least two pathways. 
Firstly, Akt/PKB enters the cytoplasm where GSK-3β (glycogen synthase kinase-3β) 
can be phosphorylated and inactivated. This phosphorylation can lead to an increase 
in glycogen synthase activity, thus upregulating glycogen synthesis (Cross, et al., 
1995). Secondly, Akt/PKB can phosphorylate AS160 (Akt substrate of 160kDa) and 
therefore recruit GLUT4 (glucose transporter 4) to the membrane, increasing glucose 
uptake (Cong, et al., 1997; Sakamoto & Holman, 2008).  
Furthermore, activation of Akt/PKB at the catalytic (Cat) domain leads to activation of 
two more pathways (Manning & Cantley, 2007). Firstly, Akt/PKB can activate mTOR 
to induce protein synthesis. This happens when Akt/PKB inactivates the RHEB (Ras 
homolog enriched in brain) protein via TSC1 (tuberous sclerosis 1).  Secondly, 
Akt/PKB can monitor cell survival by inhibiting the pro-apoptotic agent, FoxO1 
(Forkhead box protein O1) (Tran, et al., 2003; Accili & Arden, 2004). When Akt/PKB 
phosphorylates FoxO1, gluconeogenesis is decreased. The latter occurs when insulin 
activates Akt/PKB in the liver and translocates to the nucleus, where FoxO1 is located. 
It is here where FoxO1 is phosphorylated at Ser256, Ser319 and Thr24. This results 
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in the relocation and degradation of FoxO1, thus decreasing G6Pase transcription; 
leading to the reduced gluconeogenesis mentioned earlier  (Cell Signaling 
Technology, 2016). 
AMPK, on the other hand, controls cellular and organismal metabolism in eukaryotic 
organisms (Nelson & Cox, 2004; Jeon, 2016). AMPK has a plethora of metabolic 
functions. It is a fuel-sensing enzyme that is stimulated by low intracellular ATP levels; 
and can also inhibit cellular growth (as a metabolic checkpoint) when nutrients are low 
(Ruderman, et al., 2013). AMPK can enhance glucose uptake (by phosphorylating 
TBC1D1, also known as AS160) and autophagy (via inhibition of mTORC1) (Jeon, 
2016). As mentioned previously, AMPK can also stimulate autophagy by activating 
ULK (see ‘2.2.1.2. Autophagy and Mitophagy). This enzyme additionally plays a role 
in activating both glycolysis and fatty acid oxidation and uptake (via CD36 
translocation and CPT-1 activation) (Mihaylova & Shaw, 2012; Jeon, 2016). In 
addition, FoxO and PGC1α can be activated by AMPK, thus mediating many other 
metabolic processes (Jeon, 2016). 
 
The growth and mitogenic effects of insulin signalling is mediated by both the Akt/PKB 
and Ras/MAPK pathways. In the CAP/Cbl pathway, IR activation causes the 
phosphorylation of Cbl (more will be explained under ‘2.3.1.2.2. CAP/Cbl pathway’) 
(Lizcano & Alessi, 2002; Hers, et al., 2011). Diabetes, cancer and cardiovascular 
diseases result from a dysregulation of the PI3K/PKB pathway (Hers, et al., 2011). 
Abnormal gain or loss in Akt/PKB activation can cause many of the pathophysiological 
properties of type-2 diabetes and cancer.  
2.3.1.2. The PI3K-independent pathway  
When insulin activates IRS1 by binding to the IR, it can activate more pathways than 
just the PI3K-dependent pathway. When IRS1 and GRB2 (an adaptor protein) interact, 
the Ras/MAPK pathway is activated (Bevan, 2009; Boucher, et al., 2014). The 
translocation of the CAP/Cbl complex to the lipid rafts in the plasma membrane, 
activates the CAP/Cbl pathway; resulting in increased glucose uptake (refer to Figure 
1.13) (Molina & Adjei, 2006; Watson & Pessin, 2006). The Ras/MAPK and CAP/Cbl 
pathways are both activated by PI3K-independent signalling. 
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Figure 1.13 A representation of the PI3K-independent pathways (adapted from Molina & Adjei (2006) and 
Watson & Pessin (2006)). 
2.3.1.2.1. Ras/MAPK pathway 
The Ras/MAPK pathway is a cascade that activates mitogen-activated protein kinases 
(MAPK’s); along with mitogenic responses by means of gene transcription (Bevan, 
2009). This pathway is activated when IRS-1 associates with GRB2, thus directing the 
growth, proliferation, differentiation and survival of cell types. MAPK’s include three 
groups of serine/threonine kinases namely; extracellular signal-regulated kinases 
(ERK1, ERK2 and ERK3), c-Jun amino-terminal kinase (JNK), and p38 MAPK’s. The 
Ras/MAPK pathways can also be activated without IRS-1 (Orton, et al., 2005; Hardin, 
et al., 2015). This happens by the association between SHC and GRB2; but for the 
purpose of this literature review we will not be focusing on the latter.  
Ras (which is a small GTPase) is activated at the proximal part of the Ras/MAPK 
pathway (Kolch, 2000). Receptor tyrosine kinases, G-protein-coupled receptors and/or 
integrins can bind to their respective receptors to activate Ras. These membrane 
proteins form large signalling complexes that convert Ras into its activated form 
(Orton, et al., 2005). This is accomplished by inducing the exchange of Ras-bound 
GDP with GTP.  The interaction between Ras and SOS (son of sevenless homolog 1), 
a GDP/GTP-exchange factor, controls this process. GAPs (GTPase-activating 
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proteins) de-activate Ras and significantly enhance very low GTPase activity of Ras. 
Thus, it effectively optimizes the hydrolysis of GTP to GDP  (Orton, et al., 2005). 
GRB2 associates and binds to SOS, thus activating Ras. When Ras is activated, the 
small G-proteins recruit c-Raf to the plasma membrane (Bevan, 2009). This is where 
Raf is activated, in turn activating MEK1 by phosphorylating two serine residues of the 
protein. MEK1 phosphorylates ERK1/2 (serine/threonine kinase) at threonine and 
tyrosine residues. By directly phosphorylating transcription factors or indirectly 
targeting substrates such as p90-RSK family kinases (which has the ability to modify 
histones and transcription factors), activated ERK can regulate gene expression 
(Kolch, 2000; Orton, et al., 2005). 
2.3.1.2.2. CAP/Cbl pathway 
For the purpose of the current thesis, this pathway will only be discussed briefly. 
Glucose uptake is also mediated by this pathway by means of the recruitment of 
GLUT4 translocation to the plasma membrane (Bevan, 2009). Cbl is recruited to the 
IR by CAP (Baumann, et al., 2000). The CAP-Cbl complex dissociates from the IR and 
moves to lipid rafts in the plasma membrane. CAP-Cbl and Crk, which is associated 
with C3G (the Rho-family guanine nucleotide exchange factor) will then interact, 
activating TC10 (a GTP-binding protein). The CAP-Cbl pathway is involved in the 
movement of the GLUT4 vesicles on the actin cytoskeleton to the cell membrane.  
2.4. Cellular Stress 
Stress is a reaction to a threat or demand the body is faced with. Stress of the human 
body can lead to many unhealthy conditions, such as high blood pressure and heart 
disease (WebMD, 2016).  
Chronic stress induces an increased and consistent heart rate, elevated stress 
hormones, high blood pressure, and an increased risk for heart attack and stroke 
(Torpy, et al., 2007). Stress hormones, such as catecholamines like adrenaline, can 
cause damage to the heart if exposed to elevated levels of these hormones for an 
extended period.  The increased blood pressure and heart rate causes the heart to 
work harder to keep up with the blood flow demand.  
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The physiological effect of stress can be counteracted by sestrins (Sesns) (Budanov, 
et al., 2010). Sesns are stress-responsive proteins that are transcriptionally regulated 
by p53 (a tumor suppressor) and FoxO. Sesn2 (the cardiac isoform of sestrin) is mainly 
regulated by p53 (Budanov, et al., 2010; Dong, et al., 2017).  Sesn2 is also known as 
hypoxia-inducible gene 95 (Hi95), indicating that it is stress-responsive and induced 
by oxidative stress, hypoxia or DNA damage (Lee, et al., 2013; Rhee & Bae, 2015). 
These regulators have functions such as oxidative stress inhibition, insulin resistance 
regulation, age attenuation and tumour suppression (Lee, et al., 2013). 
Sesn2 can suppress oxidative stress by (1) operating as an alkylhydroperoxide 
reductase to rescue the peroxidase activity of overoxidized peroxiredoxins, or (2) by 
activating Nrf2 to upregulate anti-oxidant enzymes (Budanov, et al., 2004; Bae, et al., 
2013; Yang, et al., 2014). Sesn2 also inhibits mTOR signalling by interacting with 
GATOR2 and phosphorylating TSC2 (Parmigiani, et al., 2014) (Budanov & Karin, 
2008). In a study by Dong, et al. (2017), the effects of Sesn2 on cardiomyocyte 
hypertrophy was investigated. They concluded that Sesn2 can protect cardiomyocytes 
from hypertrophy induced by phenylephrine. Sesn2 does this by inhibiting ERK1/2 
signalling. 
Normally Sestrins inhibit mTORc1 by activating AMPK, thus preventing autophagy 
(Budanov, et al., 2010). This process is valuable and advantageous for the prevention 
of aging and age-associated pathologies. Consequently, when Sestrins are inhibited 
and mTOR activity increased, autophagy can be promoted  (Wullschleger, et al., 
2006).    
2.5. The Physiological difference between Humans and Rodents  
 
As previously discussed, T2D develops because of glucose homeostasis 
dysregulation. As a worldwide diabetic epidemic is rising, research needs to be 
performed to investigate and try to understand the pathophysiology of T2D 
(Chandrasekera & Pippin, 2013). The pathophysiology seen in obesity in humans can 
be mimicked by a popular animal model (Sumiyoshi, et al., 2006). This is the diet-
induced obesity model that entails the intake of fat that comprises the diet to be of high 
caloric value. This model can lead to an increase in fat and insulin resistance in the 
animal. 
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Short lifespans and breeding periods, low maintenance and cost, ease of handling and 
easy genetic manipulation are all factors contributing to the preference of rodent 
species in T2D research. The development of hypothesis formation to data acquisition 
is managed with relative ease and in a short timeframe (Chandrasekera & Pippin, 
2013). These animal models all elicit different phenotypic manifestations of T2D in 
humans; ranging from variations in severity, penetrance and duration (Chatzigeorgiou, 
et al., 2009).  
Rodent models do have similarities with the human diabetic condition because the 
phenotype in these animals are also dependent on genetics, sex and age (Neubauer 
& Kulkarni, 2006). Furthermore, rodent models allow researchers to study the 
molecular mechanisms behind diabetes and to follow all the stages of the disease 
(Cefalu, 2006). Genetic manipulation is easy in rodents, and they have a relatively 
short breeding span. Rodents also allow researchers to gain access to physiological 
and invasive testing. 
There are, however, limitations to the use of rodent models (Cefalu, 2006). Most 
rodent models cannot fully represent the natural pathophysiological mechanisms 
involved in the complex T2D state in the human. In rodents, the inability to increase β 
cells mass in response to obesity-induced insulin resistance causes diabetes. Rodents 
usually develop diabetes without showcasing the same islet pathology that 
researchers see in humans (islet amyloidosis) (Kaplan & Wagner, 2006). Questions 
surrounding the relevance of animal models to the human diabetic condition remain 
unanswered.  
Of main concern is the difference between the specific physiological or 
pathophysiological mechanisms in humans and rodents. Examples that Kaplan & 
Wagner (2006) give are the differences between the percentage energy of the resting 
metabolic rate needed by the brain (20 % in humans and 3 % in rodents), the role of 
gender in human diabetes, and factors such as insulin resistance and T2D 
development from psychosocial stress in humans (Franconi, et al., 2008). These 
variables could possibly influence the physiology, onset and development of diabetes 
in rodents and humans. 
Considering all of this, there is no model of T2D that will encompass all of the 
characteristics of the disease in humans (Chatzigeorgiou, et al., 2009). These animal 
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models do, however, represent many of the pathophysiological conditions that we see 
in diabetic humans and are thus used in T2D research. 
2.6. Pathophysiology of Diabetes 
Some pathophysiological mechanisms in diabetes include weakened insulin secretion 
from the pancreatic β cells, increased secretion of glucagon from pancreatic α cells, 
amplified production of hepatic glucose and inhibited glucose uptake in peripheral 
tissues (Defronzo, 2009). As previously mentioned, diabetes is also a major risk factor 
for CVD. The pathophysiological effects of diabetes have harmful effects on the 
macro- and microvasculature (Muhlestein, et al., 2003). Diabetes also cause chronic 
inflammation and an increase in oxidative stress. The over-activation of the 
inflammatory response causes an accumulation of leukocytes while endothelium 
abnormalities cause hypercoagubility (Dokken, 2008). These factors and their 
pathophysiological significance will be explained in detail. 
2.6.1. Macrovasculature 
The following factors contribute to the atherogenicity and macrovascular disease seen 
in diabetic patients. Dyslipidemia, increased triglycerides and decreased HDL 
cholesterol are associated with atherosclerosis (Fagot-Campagna, et al., 2000). 
These are all conditions that can arise in diabetic patients, along with an abnormal 
structure of the lipoprotein particle. The LDL cholesterol in diabetic patients is very 
susceptible to atherosclerosis because of their small and dense form (Rosenson, 
2004). Because these small LDL particles can penetrate and attach to the arterial wall, 
they are more atherogenic and prone to oxidation (Chan, 1998). This is due to the 
addition of new properties to the LDL particle that the immune system does not 
recognize and classifies as ‘foreign.’ This induces a variety of biological responses 
that attracts leukocytes to the blood vessel which allows the leukocytes to ingest lipids 
and stimulate the proliferation of leukocytes, endothelial cells and smooth muscle 
cells. These factors all contribute to the formation of atherosclerotic plaque.  
LDL particles in diabetic patients also become easily glycated, which allows them to 
promote atherogenesis (this is because glycation lengthens the LDL particle’s half-life) 
(Napoli, et al., 1997). Hypertriglyceridaemia is also present in diabetic blood and can 
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cause increased production of small LDL particles and decreased HDL cholesterol 
transport to the liver (Duell, et al., 1991; Shen, 2007).  
Endothelial dysfunction can promote atherosclerosis (Celermejer, 1997). Normally, 
healthy endothelium displays vasodilatory, anti-atherogenic and anti-inflammatory 
properties (Dokken, 2008). As soon as these properties are affected and 
compromised, atherosclerosis is promoted. This leads to the conclusion that insulin 
deficiency and insulin resistance promotes dyslipidaemia (Dokken, 2008).  
2.6.2. Microvasculature 
Microvascular disease in diabetes come in the following forms: retinopathy, 
nephropathy, neuropathy and damage to the vasculature of the brain, heart and 
peripherals (Dokken, 2008). Usually damages to the microvasculature are not related 
to lipid levels or atherosclerosis, but to cellular and molecular mechanisms. (1) Central 
and (2) local regulatory mechanisms control the micro-circulation (Lewis, 1998). The 
(1) central regulation involves the autonomic sympathetic and parasympathetic 
nerves; and are the central regulators of vascular smooth muscle function (McCorry, 
2007).  Local products of metabolism and substances produced by endothelial cells 
(such as vasodilators and vasoconstrictors) are, on the other hand, part of the (2) local 
regulatory mechanism. The vascular smooth muscle unceasingly receives signals 
(from the regulatory system), nitric oxide (from the endothelium) and metabolic 
products. These factors all contribute to the microvascular flow and help the 
adjustment to the metabolic needs of the tissue (Lewis, 1998).  
Defects in the endothelium, local metabolism and autonomic nervous system arise in 
diabetes (Smith, et al., 1981). Diabetic autonomic neuropathy (DAN) is a condition 
accompanied by the diminished autoregulation of blood flow in vascular beds, resulting 
in the high cardiovascular mortality (Ewing, et al., 1980; Taskiran, et al., 2002; Dokken, 
2008). Diabetic patients also have decreased NO levels (as mentioned in ‘1.2. Insulin 
Resistance’) and increased endothelin-1 (ET-1, a vasoconstrictor), causing a hyper-
constricted state (Brownlee, 2001; Koh, et al., 2005). Hypertension and limited blood 
flow to the tissues are results of this.  
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The thickening of the basement membrane of the capillary is another sign of diabetic 
microvascular disease, weakening the selectivity and amount of the transport of the 
different metabolic products and nutrients between tissue and blood (Hayden, et al., 
2005).  Exercise-stimulated delivery and transport of oxygen from the capillaries, in 
the skeletal muscle, are delayed in diabetic patients. Therefore, T2D patients normally 
have poor exercise tolerance (Bauer, et al., 2007).  
Interdependent mechanisms (such as pressure, flow, size and charge specificity) 
regulate the transport of substances and hormones from the circulation to the tissue 
interstitium (through the micro vessel walls) (Tooke, 1989; Hayden, et al., 2005). 
Thickening of the basement membrane, however, increases the permeability of the 
microvasculature. This is because of the physical changes in the normal electrical 
charge around the pores between endothelial cells. These alterations allow large 
molecules to pass through the microvasculature. In diabetic patients, microvascular 
disease (and microalbuminuria) can be picked up by a transcapillary leak of albumin 
in the kidney (Weir, 2007). 
2.6.3. Inflammation 
Tissue injury and pathogen exposure initiate an inflammatory response in the body 
(Pickup, et al., 1997). This is how the body heals and fights off infection. The activation 
of leukocytes and a family of chemokines and cytokines all regulate this response. 
Inflammation is beneficial and healthy, but a chronic activation can be harmful. It has 
been said that diabetes is a low-level and chronic state of inflammation (Wellen & 
Hotamisligil, 2005). This constant immune activation may lead to the insulin resistance 
in prediabetic and diabetic persons, as well as the increased cardiovascular risk 
(Festa, et al., 2000). 
The reduced NO and increased ET-1 levels in diabetic patients (as discussed under 
‘2.6.2. Microvasculature’) can lead to the release of pro-inflammatory cytokines and 
enhancement of vascular permeability, apoptosis, leukocyte recruitment and ROS 
production. This can, therefore, intensify and aggravate the injury (Chung & Barnes, 
1999; Woods, et al., 1999). 
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Obesity is related to increased adipokine levels (IL-6, IL-1β, TNF-α and plasminogen 
activator inhibitor 1 (PAI-1)) that are also associated with the inflammatory response 
(Trayhurn & Wood, 2005). As fat mass increases, so do these pro-inflammatory 
cytokines; apart from adiponectin that is decreased in obesity (Arita, et al., 1999). 
Adiponectin levels have an inverse relationship with cardiovascular disease. 
2.6.4. Oxidative Stress 
Reactive oxidative species (ROS) and its production are stimulated by pro-
inflammatory cytokines (‘2.6.3 Inflammation’) (Watts & Koller, 2004). ROS molecules 
are molecules that have an unpaired electron in the outer orbital, making it highly 
reactive to other molecules (Panth, et al., 2016). The ROS molecule must obtain a 
stable state and electron pair, causing it to either donate an electron or take up a 
proton from these other compounds. When ROS binds to other compounds, the 
function and structure of the tissue changes. This bonding between compounds can 
be damaging and because ROS molecules are reactive, they can directly impair cell 
components such as plasma membranes, lipids, proteins and organelles (Watts & 
Koller, 2004).  
ROS production is a normal process of the immune system (Nourooz-Zadeh, et al., 
1997). ROS becomes dangerous when oxidative stress persists. This is a state where 
the production of ROS exceeds the anti-oxidant properties of the cells. In diabetic 
patients, the chronic oxidative stress is allegedly associated with: the excess fatty 
acids and glucose seen in the hyperglycaemic state, and the mitochondrial dysfunction 
seen in insulin resistance (Nourooz-Zadeh, et al., 1997; Petersen, et al., 2004).  
Complications seen in insulin resistance and diabetes are related to mitochondrial 
dysfunction (Sohal & Sohal, 1991; Nishikawa & Araki, 2007). ATP is produced by the 
mitochondria via oxidative phosphorylation (refer to ‘2.2.1.1. Oxidative 
Phosphorylation’) and the ETC has two sites that generate ROS. It has been said that 
the increase in blood glucose levels in diabetes increases ROS production (Nishikawa 
& Araki, 2007).  
Chronic hyperglycaemia induces diabetic complications by four mechanisms; (1) 
polyol pathway activation, (2) increased advanced glycosylation end products, (3) 
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protein kinase C activation and (4) hexosamine pathway activation (Brownlee, 2005). 
Hyperglycaemia-induced mitochondrial ROS production activates these four 
hyperglycaemic damage pathways, confirming the important role of oxidative stress in 
the pathophysiology of the cardiovascular consequences linked to diabetes 
(Brownlee, 2005; Dokken, 2008). 
It has been previously mentioned that insulin resistance in diabetes over-activates the 
inflammatory response (Dokken, 2008). Leukocytes, or white blood cells, are part of 
the inflammatory response and immune system. Even though mitochondria are the 
major source of ROS, activated leukocytes can also produce ROS. Leukocytes can 
thus also contribute to the diabetic related oxidative stress. 
2.6.5. Hypercoagulability  
Hypercoagulability is another pathophysiological effect seen in diabetes (Dokken, 
2008). Thrombotic deaths occur mostly when an atherosclerotic plaque ruptures and 
occlude a major artery by a thrombus (blood clot) (Gu, et al., 1998). The vascular 
endothelium is the first defense against any thrombotic event and because diabetes 
contributes to extensive endothelial dysfunction, this defense is weakened (Weyrich, 
et al., 2002).  
Platelet hyperactivity is seen in a diabetic patient’s blood by the (1) increased 
circulating platelet aggregates, (2) increased platelet aggregation, (3) increased 
platelet coagulation products in the plasma (products such as β-thromboglobulin, 
platelet factor IV, thromboxane B2), and (4) increased coagulation activation markers 
(prothrombin I and II and thrombin-anti-thrombin complexes) (Carr, 2001). There are 
also increased levels of clotting factors such as fibrinogen, factors VII, VIII, XI, XII, 
kallikrein and von Willebrand factor (vWF).  The anticoagulant mechanisms (the 
fibrinolytic systems) are seen to be weakened in diabetic persons because of the 
irregular clot structures that are resistant to fibrinolysis. The increased PAI-1 levels are 
also a factor contributing to these inhibited anticoagulant mechanisms (Carr, 2001). 
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2.6.6. Heart Failure 
Chronic heart failure can result from any structural or functional defect in the heart that 
prevents the ventricle to fill and eject blood properly (Hunt, et al., 2001).  Systolic heart 
failure is dysfunction in the contractility of the heart (left ventricular ejection fraction of 
less than 45 %) and diastolic heart failure is classified as dysfunction in the ability of 
the heart to relax and fill up with blood (Dokken, 2008; Gutierrez & Blanchard, 2004).  
Diabetic patients may suffer from heart failure due to the myocardial damage that 
occurs after an ischaemic or thrombotic event. Endothelial dysfunction and 
hypercoagulable blood are factors that can cause heart failure in a diabetic patient 
(Gutierrez & Blanchard, 2004; Dokken, 2008).  
There have, however, been cases where heart failure was not due to thrombotic 
events, but other pathophysiological factors (for example diabetic cardiomyopathy 
(DCM)) (Dokken, 2008). DCM is a myocardial disease in diabetic patients that cannot 
be attributed to any CVD (Marwick, 2006; Dokken, 2008). Myocardial damage, in 
DCM, is without macrovascular damage but with microvascular dysfunction 
(Kawaguchi, et al., 1997). The myocardial injuries, fibrosis and hypertrophy in DCM 
may be caused by the microvascular damages seen in a diabetic patient’s heart.   
It has been repeatedly shown, by observational studies, that diets with a high intake 
of plant-based foods and beverages have a lower risk of chronic diseases (such as 
CVDs and some cancers) (McKay & Blumberg, 2006). These studies suggest that this 
correlation may be connected to the phytochemical constituents and the macro- and/or 
micronutrient content of the foods. Evidence that an aqueous fermented rooibos (FRE) 
extract can protect cardiomyocytes from diabetic rats against oxidative stress and 
ischaemia is presented by Dludla et al. (2013). They performed an ex vivo study where 
they investigated the effect of the chronic exposure to FRE on cardiomyocytes isolated 
from streptozotocin (STZ) induced diabetic rat hearts (Dludla, et al., 2014). 
DCM is a heart disorder in diabetic people where the heart muscles are affected. The 
pathogenesis of DCM includes an excessive generation of free radicals. The reduction 
of these excessive free radicals, by the consumption of anti-oxidants, is becoming a 
very popular way to battle DCM. Therefore, utilizing the antidiabetic, anti-inflammatory 
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and free radical scavenging effects of rooibos for DCM treatment, is very appealing 
(Dludla, et al., 2014). 
In their study, when the cardiomyocytes were exposed to an ischaemic solution, the 
cardiomyocytes presented with a decrease in ATP levels, metabolic activity and 
intracellular GSH (glutathione). A related increase in apoptosis and intracellular ROS 
molecules were also seen.  When pre-treated with FRE, these effects were decreased 
and proved better than that of vitamin E (an anti-oxidant). These results affirmed that, 
even under stressful conditions, FRE pretreatment of cardiomyocytes reduced 
intracellular ROS, apoptosis and improved ATP and GSH levels. Therefore, the 
authors of this study stated that it makes sense to use rooibos/FRE as a supplement 
of plant-derived anti-oxidants to protect against increased oxidative stress (Dludla, et 
al., 2014). 
3. Rooibos: South Africa’s favourite tea 
The increasing interest in the use of plant-based extracts in commercially available 
products is evident. Pantsi et al. (2011) noted that, according to the World Health 
Organization, about 80% of the world population relies on indigenous/traditional 
medicines for primary health needs. Many studies have revealed that the complexity 
and variety of compounds in medicinal plants contribute to their uses in treatment of 
diseases such as diabetes and cancer (Gurib-Fakim, et al., 2010; Street & Prinsloo, 
2013).  
Wild growing plants are under extreme pressure because of the increased demand for 
local and export markets (Cunningham, 1993). This creates a need for an alternative 
supply of plant material for medicinal purposes. The cultivation of these plants on a 
large scale can contribute to a growing economy and job opportunities in South Africa. 
Aspalathus linearis is regarded to be one of the 10 most prominently used plants for 
medicinal purposes (Street & Prinsloo, 2013).  
Polyphenols have strong anti-oxidant properties and the potential to improve diabetic 
complications (Zang, et al., 2006). Tea is one of the population’s major sources of 
polyphenolic dietary intake and there is a strong relationship between drinking tea and 
the decreased risk of CVD. Rooibos, an herbal tea unique to South Africa, produced 
Stellenbosch University  https://scholar.sun.ac.za
48 
 
from Aspalathus linearis, has a high phenolic content and possesses anti-oxidant, anti-
inflammatory and antidiabetic properties, making it a perfect potential candidate for 
treatment (and possibly prevention) of diabetes or CVD (Street & Prinsloo, 2013).    
Not only are job opportunities for about 8000 farm labourers in South Africa provided 
for by rooibos, it also provides income for employees involved in upstream activities 
(processing, packaging and retailing) (South African Rooibos Council, 2016). Rooibos 
consumption around the world has reached 15 000 tons in 2015, increasing exports 
up to 7 000 tons per year. More than 30 countries import rooibos from South Africa; 
including Germany, the Netherlands, Japan, UK and USA.  
3.1. Rooibos 
Rooibos, produced from Aspalathus linearis, is an herbal tea that has many health-
promoting properties with no reported harmful stimulants (Joubert & De Beer, 2007). 
Just like traditional rooibos, green rooibos tea also comes from Aspalathus linearis, but 
the production process, however, differs for the two teas (Bezuidenhout, 2007; Street & 
Prinsloo, 2013). 
Normally, after harvesting, the tea is bruised and exposed to oxygen on dry-beds  
(Joubert & Schulz, 2006). The traditional taste and red colour comes from the oxidation 
of the tea leaves. Although this process provides the pleasant taste, it also causes a loss 
of valuable nutrients (Bezuidenhout, 2007).  
3.1.1. Aspalathin 
Aspalathin, a dihydrochalcone glucoside found in Aspalathus linearis, is a potent anti-
oxidant that, when oxidized, changes to flavanones and polymeric brown products 
(Schulz, et al., 2003). This traditional processing decreases the anti-oxidant activity of 
rooibos aqueous infusions. This is assessed by evaluating rooibos’ ability to scavenge 
superoxide anion and DPPH (2,2-diphenyl-1-picrylhydrazyl) radicals. In a study by 
Schulz, et al. (2003), it was reported that the amounts of aspalathin and nothofagin 
decreased in fermentation. They concluded that there is generally a good linear 
relationship between the total anti-oxidant activity and aspalathin content in 
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commercial unfermented rooibos tea.  They also stated that green rooibos has a 
higher anti-oxidant capacity and ability to scavenge biologically relevant ROS.  
 
This gives rise to an increasing interest in the development of green rooibos. Green 
rooibos is an unfermented product that maximises aspalathin content and anti-oxidant 
potential (Schulz, et al., 2003). It is well-established that foods which enhance the 
functioning of the body and supply protection against diseases spark great interest in 
consumers. Interestingly, Dr. Christo Muller of the SA-MRC stated that green rooibos 
increases the breakdown of sugar into energy and improves cellular metabolism 
(Koza, 2013). The anti-oxidants in the Afriplex GRT Extract increase insulin sensitivity 
and break down blood glucose levels. 
 
As discussed in detail in the first part of this dissertation, diabetes is a very serious 
disease. More knowledge and insight are required on green rooibos tea’s glucose 
control properties. This might potentially lead to improved drugs that can control this 
disease. Aspalathin and nothofagin (along with their structural flavonoid analogues) 
show moderate anti-mutagenic properties. Street and Prinsloo (2013) states that 
rooibos has hepato-protective properties.  
Marnewick et al. (2010) performed a study on adults at risk of cardiovascular disease 
to investigate the effect rooibos has on biochemical and oxidative stress parameters. 
Their study concluded that the consumption of fermented rooibos does indeed improve 
the lipid profile and the redox status. Both of these factors are associated with heart 
disease. Tannin is commonly found in tea but is infamous for inhibiting protein and 
mineral absorption; as well as slowing down metabolism. Rooibos has a low tannin 
content and modulates the serum lipid profile by increasing HDL-cholesterol levels and 
decreasing the triacylglycerol and LDL-cholesterol levels (Joubert & Schulz, 2006).  
McKay and Blumberg (2006) presented studies that demonstrated a significant 
difference in the number of polyphenols present between green and red rooibos. 
These studies show that green rooibos has a higher percentage of total polyphenols, 
flavonoids and non-flavonoids than fermented rooibos. These differences are because 
of the enzymatic and chemical modification caused by processing and fermentation. 
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Up to date, the only known natural source of aspalathin is rooibos. Rooibos is also one 
of two known sources of nothofagin.  
Since 2007, ‘green’ rooibos tea has been receiving attention from many health-
conscious consumers, locally and internationally (Bezuidenhout, 2007). This makes 
Afriplex GRT Extract a potential solution for a number of health problems. 
3.1.2. Aspalathin Function and Anti-Oxidant Capacity 
Aspalathin is a very powerful anti-oxidant that protects body tissues (Koza, 2013). He 
states that aspalathin improves lipid metabolism and has the potential to be used to 
protect against the development of diabetes (Koza, 2013).  
According to Koza (2013), the development of new drugs for T2D should focus on 
treatments to improve insulin resistance with fewer side effects. He says that, with 
aspalathin, the onset of diabetes could possibly be delayed. Rooibos also helps 
prevent blood clots by reducing the amount of fat molecules (cholesterol) in the blood 
and this, in turn, protects the heart.  
According to research supported by the Cancer Association of South Africa, six 200 
ml cups of strong rooibos tea a day increases GSH (a natural anti-oxidant) by almost 
100%. GSH binds and removes toxins from the body, helping to eliminate harmful 
substances in our systems, says Carl Albrecht (head of research at the cancer 
association) (Koza, 2013). Rooibos stimulates the body to produce more GSH.  
4. Afriplex Green Rooibos Extract 
Afriplex is a company focussing on plant extracts and natural additives. Afriplex, founded 
in 2000, is the acronym for African Plant Extracts and it has been their aim to add value 
to South African flora and local markets. Afriplex started producing a green rooibos tea 
in 2003. GRE serves as an improved product, better than normal rooibos tea. Danie Nel 
(Afriplex MD) says that green rooibos not only is a better source of nutrients than normal 
rooibos but contains less tannins as well (Table 1.1). Tannins are commonly found in tea 
and allegedly slows down the body’s metabolism and ability to absorb minerals and 
proteins (Bezuidenhout, 2007).  
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Afriplex developed a process to keep the anti-oxidants intact. Instead of exposing the 
leaves to oxygen, an inert gas was used. This inert gas slows down the oxidation process 
during the drying-out stage, which produces a high-quality green rooibos tea 
(Bezuidenhout, 2007).  
Afriplex states that health-conscious clients understand the health benefits of the green 
tea variant and will therefore easily make the transition from normal rooibos tea. Nel 
explains that South Africans are traditional rooibos tea drinkers and will therefore need 
to get accustomed to the green rooibos tea taste (Bezuidenhout, 2007).  
Afriplex GRT Extract is a laboratory standardized extract of unfermented Aspalathus 
linearis (Burm.f.) R. Dahlgren rich in aspalathin and nothofagin, making it a potential 
powerful anti-oxidant. It is a red coloured powder and might have potential beneficial 
effects on diabetes. This aspalathin-rich product is currently being investigated for 
possible commercialization. 
Aspalathin comprises about 14% of the Afriplex GRT Extract and gives this product, 
along with nothofagin, its anti-oxidative properties (Beelders, et al., 2012; Ku, et al., 
2015). Another flavonoid is PPAG (phenylpropenoic acid glucoside) that has positive 
effects on both pancreatic β-cells and hyperglycaemia (Himpe, et al., 2016), whereas 
quercetin is known to improve obesity (Kuppusamy & Das, 1992; Ahn, et al., 2008; 
Rivera, et al., 2008). PPAG is also said to improve oxidative stress (Dludla, et al., 
2014; Dludla, et al., 2017). Table 1.1 summarizes the concentrations of the different 
components in the Afriplex GRT Extract (Beelders, et al., 2012) (refer to Appendix B for 
the HPLC analysis of Afriplex GRT Extract). 
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Table 1.1 Concentration of flavonoids, flavonols and polyphenols in 
Afriplex GRT Extract (g compound/100 g soluble solids) 
PPAG 0,423265 
Aspalathin 12,78348 
Nothofagin 1,974419 
Orientin 1,255839 
Isoorientin 1,427281 
Vitexin 0,338513 
Isovitexin 0,298022 
      Q-3- ROB 
 
1,040565 
Rutin 0,496034 
Hyperoside 0,398773 
Isoquercitrin 0,572251852 
The current study aimed to investigate the following in view of (i) the recognized high 
incidence of obesity, T2D and CVD, as well as (ii) the possibility that an aspalathin-
rich substance may ameliorate these conditions: 
• To characterize the effects of the high fat diet on the basal metabolism and 
signalling in the animals. 
• Whether Afriplex GRT Extract ingestion has any effect on the high fat diet and 
control diet. 
• Whether Afriplex GRT Extract ingestion can improve the insulin resistance state 
elicited by a high fat diet using a rat model. 
• Whether Afriplex GRT Extract ingestion has any effects on myocardial 
mitochondrial oxidative phosphorylation potential and the process of 
mitophagy. 
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To answer these questions, a Wistar rat model of diet-induced obesity was used and 
compared to chow-fed control animals. Both groups were treated with Afriplex GRT 
Extract for a period of 6 weeks. Animals were grouped as follows:  
 
Figure 1.14 A flow chart showing the animals distribution of cohort 1. Note that the 10 IU insulin was 
injected in the animal 10 minutes prior to sacrifice. WB = Western Blot. 
Please note that the discrepancies between the n-values from Figure 1.14 and the 
Western Blots (Figures 3.23 to 3.35) are because there were very few freeze-clamped 
hearts available for Western Blot analysis. 
The 2DG uptake experiments were done on the cardiomyocytes from the first cohort. 
The cardiomyocytes were treated with insulin ex vivo, but no effect was seen. We thus 
proceeded to cohort 2 where some of the animals were injected with insulin in vitro, 
10 minutes before sacrifice. Some of the rats were injected with insulin in order to 
activate the insulin signalling pathway and to decrease glucose levels. This was 
performed to see if the treatment with Afriplex GRT Extract affected the insulin 
signalling pathway in the heart.  
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Figure 1.15 A flow chart showing the animals distribution of cohort 2.     
In the second cohort, a group of HFD animals were treated with metformin, because 
it is known that metformin decreases glucose levels to treat diabetes. The control 
animals were not treated with metformin, because the treatment would have 
decreased the glucose levels and caused hypoglycaemia in the control animals. 
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CHAPTER 2: Materials and Methods 
The following experiments were performed at the Faculty of Medicine and Health 
Sciences, Tygerberg Campus, Stellenbosch University. 
1. Animal Treatment, Biometric Measurements and Sacrifice of Animals 
Ethical clearance was obtained from the Committee for the use of animal in research 
of the University of Stellenbosch (SU-ACUD15/00102 (2016) and SU-ACUD16/00179 
(2017)). The study was conducted under the revised South African National Standard 
for the Care and Use of Animals for Scientific Purposes (South African Bureau of 
Standards, SANS 10386, 2008). 
Male Wistar rats (initial body weights of 190 ± 10 g) were fed a high fat diet (HFD) and 
compared to age matched controls (fed normal rat chow). The animals received 
separate diets for a total of 16 weeks, with free access to food and water. Body weights 
were measured weekly and food- and water intake daily, throughout the 16-week 
period. They were kept on a 12-hour day/night cycle in the Central Research Facility 
of the Faculty of Health Sciences of the University of Stellenbosch. 
From week 11 to 16, half of each group was treated with Afriplex GRT Extract (60 
mg/kg/day) in the form of jelly cubes. The jelly cubes were made from a mix containing 
4 g commercially available jelly, 4 g gelatin, 25 ml boiling H2O and the calculated 
amount of Afriplex GRT Extract powder (calculated according to the body weight of 
the animals). After the jelly and gelatin granules were dissolved, a repetitive pipette 
(Gilson™ Distriman™ Positive-Displacement Repetitive Pipette) was used to 
dispense 1 ml of the mixture into each cube on an ice-tray. The tray was placed in a 
fridge to set, where after one cube was given to every rat per day. The Afriplex GRT 
Extract jelly-cubes were prepared weekly and given to the animals daily. 
The Afriplex GRT Extract dosage administered was deduced from available literature 
on similar extracts, since no information was available regarding the exact dosage of 
this specific product. A similarly prepared green rooibos extract was demonstrated to 
lower plasma glucose levels in rats at a dosage of 30 mg/kg (Muller, et al., 2012). In a 
different mouse study, this exact extract was administered at doses of 0.3 % and 0.6% 
of the diet (Kamakura, et al., 2015). If this is calculated according to a rat weighing 
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250 g, and consuming approximately 20 g food per day, the dosage would be about 
250 mg/kg/day, which is very high indeed. In a personal communication between Prof. 
Barbara Huisamen and Dr. Christo Muller it was said that a 90 mg/kg/day dosage was 
used in non-human primates. When this is calculated according to the equations of 
Freireich EJ, et al. (1966), the dosage for a rat will be 180 mg/kg/day. Therefore, it 
was decided on a slightly higher dose than the initial 30 mg/kg/day (Muller, et al., 
2012), but lower than the dosage used in mice or non-human primates. 
In cohort 2, as a positive control, a group of HFD rats were treated with the antidiabetic 
substance, metformin, at 50 mg/kg/day. Body weights were monitored throughout the 
16-week period. After 16 weeks, animals were sacrificed by means of an overdose of 
Eutha-naze (at 160mg/kg sodium pentobarbital). The body weight, fasting glucose and 
insulin levels were determined at sacrifice. To assure that the animals showed no 
response, a foot-pinch test (pedal reflex) was done before opening the chest cavity. 
As soon as the animal showed no pedal reflex, the chest cavity was opened and the 
heart was removed for further experimentation. The intraperitoneal fat (IP fat) was 
weighed and stored hereafter. 
2. Composition of Diet 
Two different diets, namely the high fat diet (HFD) and control diet, were fed to the 
animals for the period of 16 weeks. The high fat diet was prepared from 200 ml boiling 
water, 390 g normal rat chow, 100 g fructose (Sigma-Aldrich), 100 g casein (Sigma-
Aldrich), 10 g cholesterol (Sigma-Aldrich), 750 g Holsum cooking fat and 790 g Nestle 
sweetened condensed milk. The pellets were soaked in boiling water and crushed to 
a smooth consistency. The other ingredients were mixed in and the food was stored 
in a fridge. The food was made up weekly. 
3. Oral Glucose Tolerance Test and Glucose Measurement 
An Oral Glucose Tolerance Test (OGTT) monitors the blood glucose level at different 
intervals. This procedure determines how efficiently the body metabolises sugar or 
carbohydrates and is thus a central marker for determining insulin sensitivity. Animals 
were fasted overnight. For the duration of the procedure, the animals were 
anaesthetized by intraperitoneal injection of 0.1 ml Eutha-naze (50 mg/kg sodium 
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pentobarbital). The basal glucose level of each animal was determined by pricking the 
tail, collecting a drop of blood and measuring with a commercially available handheld 
glucometer. Hereafter, 1 mg/kg of 50 % sucrose solution was gavaged to each animal. 
Thereafter, using the same tail prick, the blood glucose level was monitored and 
measured at different intervals (3 minutes, 5 minutes, 10 minutes, 15 minutes, 20 
minutes, 25 minutes, 30 minutes, 45 minutes, 60 minutes, 90 minutes and 120 minutes 
respectively). After this metabolic insult, the animals were left to recover for a week 
before further experiments were conducted. 
4. Biochemical Analysis: Assays 
4.1. Blood Collection 
After fasting the animals overnight, 1 ml blood was drawn directly from the carotid 
artery while the animal was under anesthesia. Blood was collected from all the groups 
at week 15. The blood was then centrifuged for 10 minutes at 3000 rpm (revolutions 
per minute) on the Damon/IEC Division Clini-Cool Centrifuge. The serum was 
removed and stored at -80 °C. This blood was used to determine fasting insulin levels. 
4.2. Leptin Assay 
For determining leptin levels, Abcam® Leptin Rat ELISA (Enzyme-Linked 
Immunosorbent Assay) kit was used. This kit contained a 96-well plate and all the 
reagents needed. The reagents and standards were prepared (according to the 
manufacturer’s instructions) and equilibrated to room temperature before use. All the 
samples were analyzed in duplicate.  
The 96-well plate supplied was ready to use and rinsing of the plate was not 
necessary. Samples were diluted 3-fold by using 1X Assay Diluent D. 100 µl of the 
standards, along with the samples, were pipetted into their respective wells. The wells 
were covered and incubated for 2 and a half hours at room temperature, while shaking 
gently on a shaker. During this incubation, the leptin in the samples bound to the 
immobilized antibody in the wells. The wells were then washed 4 times with 300 µl 1X 
Wash Solution, using a multi-channel pipette. After the last wash, the plate was 
inverted on a paper towel to decant all the remaining Wash Buffer. 
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After this, 100 µl of Biotinylated Leptin Antibody was added to each well and allowed 
to incubate for 1 hour at room temperature while gently shaking. The unbound 
Biotinylated Antibody was then washed away (as previously done) before adding 100 
µl HRP (horse radish peroxidase)-conjugated streptavidin to each well. This was 
allowed to incubate for 45 minutes at room temperature while gently shaking. After 
washing again, 100 µl TMB (3,3’,5,5’-Tetramethylbenzidine substrate) One-Step 
Substrate Reagent was then added and allowed to incubate for 30 minutes at room 
temperature while gently shaking in the dark. This reaction turned the samples a blue 
colour. The colour developed in proportion to the leptin levels. The colour changed to 
yellow as soon as 50 µl of the Stop Solution was added to each well. By using the 
microplate reader, the colour intensity was immediately measured at 450 nm. 
The mean absorbance of each set of the duplicates of the samples and standards was 
calculated. For a 4-parameter logistic equation curve, the standard concentration was 
stipulated on the x-axis and absorbance on the y-axis. An increase in the absorbance 
was directly proportional to the levels of leptin in the serum samples. The standard 
curve was used as a reference for the determination of the samples. To set up the 
curve and calculate the insulin levels, an online ELISA analysis program 
(http://elisaanalysis.com) was used. Refer to Figure 2.1 for a summary of the protocol. 
Figure 2.1 A schematic of the Abcam Leptin Rat ELISA (adapted from the ab100773 ELISA protocol). 
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4.3. Adiponectin Assay 
For determining adiponectin levels, Abcam’s® Adiponectin Rat ELISA kit was used. 
This kit contained a 96-well plate and all the reagents needed. The reagents and 
standards were prepared (according to the manufacturer’s instructions) and 
equilibrated to room temperature before use. All the samples were analyzed in 
duplicate.  
The 96-well plate supplied was ready to use and rinsing of the plate was not 
necessary. Samples were diluted 1:400 by using 1X Diluent N. 50 µl of the standards, 
along with the samples, were pipetted into their respective wells. The wells were 
covered and incubated for 1 hour at room temperature, while shaking gently on a 
shaker. During this incubation, the adiponectin in the samples bound to the 
immobilized antibody in the wells. The wells were then washed 5 times with 200 µl 1X 
Wash Buffer, using a multi-channel pipette. After the last wash, the plate was inverted 
on a paper towel to decant all the remaining Wash Buffer. 
After this, 50 µl of Biotinylated Adiponectin Antibody was added to each well and 
allowed to incubate for 1 hour at room temperature while gently shaking. The unbound 
Biotinylated Antibody was then washed away (as previously done) before adding 50 
µl 1X Streptavidin-Peroxidase Conjugate to each well. This was allowed to incubate 
for 30 minutes at room temperature while gently shaking. After washing again, 50 µl 
Chromogen Substrate was then added and allowed to incubate for 10 minutes at room 
temperature while gently shaking in the dark. This turned the samples a blue colour. 
The colour develops in proportion to the adiponectin levels. The colour changed to 
yellow as soon as 50 µl of the Stop Solution was added to each well. By using the 
microplate reader, the colour intensity was immediately measured at 450 nm and 570 
nm. 
The average absorbance of each set of the duplicates of the samples and standards 
was calculated. For a 4-parameter logistic equation curve, the standard concentration 
was stipulated on the x-axis and absorbance on the y-axis. An increase in the 
absorbance is directly proportional to the levels of adiponectin in the serum samples. 
The standard curve was used as a reference for the determination of the samples. To 
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set up the curve and calculate the insulin levels, an online ELISA analysis program 
(http://elisaanalysis.com) was used. Refer to Figure 2.2 for a summary of the protocol. 
Figure 2.2 A schematic of the Abcam Adiponectin Rat ELISA (adapted from the ab108784 ELISA 
protocol). 
4.4. Insulin Assay 
To determine insulin levels, the RayBio® Rat Insulin ELISA kit was used. This kit 
contained a 96-well plate and all the reagents needed. The reagents and standards 
were prepared (according to the manufacturer’s instructions) and equilibrated to room 
temperature before use. All the samples were analyzed in duplicate.  
The 96-well plate supplied was ready to use and rinsing of the plate was not 
necessary. Of the standards and samples,100 µl was pipetted into the ready to go 96-
well plates. The insulin present in the serum samples bound to the immobilized 
antibody. This incubation was allowed for 2 and a half hours while gently shaking. The 
wells were then washed 4 times with 300 µl 1X Wash Solution. After the last wash, the 
plate was inverted onto a paper towel to decant the remaining 1X Wash Solution.  
100 µl of the prepared biotinylated anti-Rat Insulin antibody was added and incubated 
for 1 hour while gently shaking. Unbound biotinylated antibody was washed away as 
previously mentioned, before adding 100 µl of the prepared HRP-conjugated 
Streptavidin. Incubation for 45 minutes while gently shaking was allowed to take place 
before washing the wells again. 100 µl of the TMB One-Step Substrate Reagent was 
added and incubated for 30 minutes in the dark room while gently shaking, allowing 
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the samples to develop a blue colour. To stop the reaction and change the colour to 
yellow, 50 µl of the Stop Solution was pipetted into each well. The absorbance was 
then immediately measured at 450 nm.  
The mean absorbance of each set of the duplicates of the samples and standards was 
calculated. For a 4-parameter logistic equation curve, the standard concentration was 
stipulated on the x-axis and absorbance on the y-axis. An increase in the absorbance 
was directly proportional to the levels of insulin in the serum samples. The standard 
curve was used as a reference for the determination of the samples. To set up the 
curve and calculate the insulin levels, an online ELISA analysis program 
(http://elisaanalysis.com) was used. Refer to Figure 2.3 for a summary of the protocol. 
Figure 2.3 A schematic of the RayBio Insulin Rat ELISA (adapted from the ELR-Insulin ELISA 
protocol). 
5. Isolation of Ventricular Cardiomyocytes 
After the removal of the heart from the chest cavity, the heart was placed in ice-cold 
Krebs-Henseleit buffer (119 mM NaCl, 24.9 mM NaHCO3, 4.75 mM KCl, 1.19 mM 
KH2PO4, 0.6 mM MgSO4·7H2O, 0.59 mM Na2SO4, 1.25 mM CaCl2·12H2O and 10 mM 
glucose), after which the heart was cannulated via the aorta onto the perfusion system. 
The heart was retrogradely perfused with a calcium (Ca2+) free Hepes buffer (‘Solution 
A’ containing: 6 mM KCl, 1 mM Na2HPO4, 0.2 mM NaH2PO4, 1.4 mM MgSO4, 128 mM 
NaCl, 10 mm 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (Hepes), 5.5 mM D-
glucose and 2 mM pyruvate; pH 7.4) at 37 °C for 5 minutes.   
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Throughout the perfusion procedure, the heart was continuously gassed with 100 % 
oxygen (O2). After the first 5 minutes, the hearts were perfused with Hepes digestion 
buffer (‘Solution B’ containing: ‘Solution A’, 0.7 % fatty acid free BSA, 1 mg/ml 
Worthington Collagenase Type II and 18 mM BDM (2,3-butanedione monoxime) (an 
ATPase inhibitor to prevent the activation of the myosin protein and contraction) for 15 
minutes in a re-circulating manner.  
Hepes, BDM, D-glucose and the Na-pyruvate were all purchased from Sigma-Aldrich 
(St Louis MO). Worthington Collagenase Type II was purchased from Worthington 
Biochemical Corporation (Lakewood, NJ). BSA and fatty acid free BSA was obtained 
from Roche (Cape Town).  
50 µl of 100 µM CaCl2 addition was started after 20 minutes and 25 minutes. The 
reason for the slow addition of CaCl2, was to prevent Ca2+ overload. The indication of 
when the heart was fully digested was when the perfusate changed from a dripping to 
a free-flowing state. The heart was detached from the cannula; where after the 
connective tissues were removed, as well as the ventricles from the atria. The 
ventricular tissue was then torn apart and incubated for 15 minutes under 100 % O2 in 
50 ml post-digestion buffer (‘Solution C’ containing: 50 % of ‘Solution A,’ 50 % of 
‘Solution B,’ 1 % BSA, 1 % fatty acid free BSA and 0.2 mM CaCl2) in the IncuShaker 
at 37 °C and 30 rpm. After the 15 minutes of incubation, 100 mM CaCl2 was added at 
16, 17, 18, 19 and 20 minutes respectively. These additions were done to reach a final 
concentration of 1.25 mM (4 x 100 µl 100 mM CaCl2 and 1 x 125 µl 100 mM CaCl2). 
The tissue was then filtered through a 200 x 200 µm nylon net and gently spun down 
at 300 rpm for 3 minutes. The supernatant was aspirated and the pellet suspended in 
35 ml Solution D for 5 minutes (‘Solution D’ containing: ‘Solution A,’ 2 % fatty acid free 
BSA and 1.25 mM CaCl2). This suspension step in 2 % BSA solution was to ensure 
that the live cells form a loose pellet and settle under gravity.  Only viable 
cardiomyocytes will settle into a pellet and the non-viable cells will ‘float’ around in the 
supernatant, thus the removal of the supernatant will also remove the non-viable cells. 
The loose pellet was resuspended in the 15 ml fresh Solution D under 100 % O2 for 1 
hour, slowly rotating in the IncuShaker at 30 rpm. 
The cells were removed and left to settle under gravity for about 5 to 8 minutes. The 
supernatant was gently removed and the pellet resuspended in 6 ml Solution E 
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(‘Solution E’ containing: ‘Solution A’ minus D-glucose and pyruvate, plus 2.0 % fatty 
acid free BSA and 1.25 mM CaCl2). The cells were spun down gently at 100 rpm for 3 
minutes. This washing step was repeated 3 times in fresh Solution E and the 
supernatant discarded after each wash. After the third wash, the cells were finally 
suspended in 5.5 ml fresh Solution E. 
5.1. 2DG Uptake Induced By Insulin Concentrations 
2DG is a glucose molecule that can be taken up but not metabolized by the 
cardiomyocytes, because of the hydrogen molecule it contains (instead of a 2-hydroxyl 
group) at position C2. The uptake of 2DG by cardiomyocytes was measured at 
different insulin concentrations. 
The first step for this assay was to prepare the dilutions of Phloretin (Phl), insulin and 
2DG. Insulin, deoxy-glucose and phloretin were obtained from Sigma-Aldrich (St 
Louis, MO). The radiolabelled 2DG was purchased from PerkinElmer South Africa 
(Pty) Ltd. 
The phloretin was prepared from 100 µl Phl stock (64 mM stock solution in DMSO) 
and 900 µl Solution E. 2DG was made up from 580 µl deoxy-glucose (45.6 mM stock 
solution) and 20 µl radioactive (tritiated) deoxy-glucose. Insulin was made up in a 
concentration of 100 nM in Solution E.  
The cells were incubated at 37°C in Solution E in a total volume of 750 uL in a 24-well 
plate in a bench top incubator (IncuShaker). Phloretin, at a concentration of 400 uM, 
was initially only added to the designated phloretin samples to act as a control for 
carrier-mediated glucose uptake.  Each dilution was made up in duplicate. After 20 
minutes, 75 µl of the different insulin concentrations (100 nM, 10 nM, 1 nM) were 
added to their respective samples. At 35 minutes, glucose uptake was initiated by 
adding 25 µl of the 2DG to all the samples. After a further 30 min of incubation, to 
terminate glucose uptake, Phloretin was added to all the samples (except the Phloretin 
marked samples).  
Plastic pasteur pipettes were used to transfer the contents from each of the flat-
bottomed tubes over to Eppendorf tubes. The Eppendorf tubes were spun down at 
14500 rpm for 90 seconds in a mini-centrifuge (Eppendorf® Minispin®). The 
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supernatant was aspirated and the pellet washed with ~250 µl Hepes buffer (without 
substrates), twice. After this, the supernatant was finally removed and the Eppendorf 
tubes were dried using an ear-bud. The pellet was dissolved in 500 µL 1N NaOH in 
the waterbath at 60C for ~15-30 minutes. 
To render a concentration of 0.5 N NaOH, 500 µl dH2O was added to the pellet. These 
samples were used for Lowry protein determination (refer to Chapter 2, Section 6) and 
counting of the radio-activity accumulation using a scintillation counter.  
For the 2DG uptake measurement in the scintillation counter, 100 µl of the dissolved 
sample in 0.5 N NaOH was added to 3 ml scintillation fluid (in duplicate). A blank was 
prepared with only scintillation fluid and another vial was prepared with scintillation 
fluid and 25 µl of the radiolabelled 2DG mixture. This was included to determine the 
specific activity of the 1100 pmol (picomol) 2DG in 25 uL. The vials were left to stand 
in a dark room overnight. This was done to minimize chemiluminescence production 
after adding the alkaline solution to the scintillation fluid. The radioactivity was counted 
in a Beckman® scintillation counter as disintegrations per minute (DPM). From the 
Lowry assay, the total protein values (mg/mL) were calculated and used with the DPM 
values to calculate glucose uptake in pmol 2DG/mg protein/30 mins. The Phloretin 
samples’ average (expressed as pmol 2DG/mg protein/30 mins) were subtracted from 
every sample to correct for background 2DG uptake. 
6. Lowry Protein Determination 
The Lowry protein determination procedure is designed to determine protein 
concentrations of 0.01 mg/mL to 1.0 mg/mL (Lowry, et al., 1951). This procedure uses 
the Folin reaction. Initially, the proteins are pre-treated with copper ions in an alkali 
solution. These proteins reduce the phosmolybdic-phosphotungstic acid in the Folin 
Ciocalteus reagent, causing a blue colour to appear (Schagger, et al., 1994). The 
protein levels are then calculated from the amount of reduced Folin-Ciocalteu reagent 
in the solution. The reading absorbance is at 759 nm and a standard curve of selected 
known Bovine Serum Albumin (BSA) concentrations were used to calculate the protein 
concentrations in each sample.  
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The BSA standards were prepared from a BSA solution in H2O with a known 
concentration. The OD was determined spectrophotometrically at 280 nm, using the 
molar extinction coefficient of BSA (1.51) to calculate the exact concentration of the 
stock standard. This stock was then used to prepare the working standards in 0.5 N 
NaOH, as indicated in Table 2.1. 
Table 2.1 BSA Standards 
Standard 1 1 ml undiluted BSA in 200 ml 0.5 N 
NaOH 
Standard 2  2 ml undiluted BSA in 200 ml 0.5 N 
NaOH 
Standard 3 2 ml undiluted BSA in 100 ml 0.5 N 
NaOH 
Stock solutions included 2% Na-K-Tartrate in dH2O, 1% CuSO4.5H2O in dH2O, 2% 
Na2CO3 in dH2O, Folin-Ciocalteu (kept at 4 °C) and BSA standard solutions. The Na-
K-Tartrate-CuSO4 solution was made up of 98 ml 2% Na2CO3, 1 ml 1% CuSO4.5H2O 
and 1 ml 2% Na-K-Tartrate. For the Folin Ciocult dilution (1:3), 4 ml Folin-Ciocalteu 
was mixed with 8 ml dH2O to make up 12 ml. 
For the blank, 50 µl of 0.5 N NaOH was pipetted into a Lucham tube. 50 µl of each of 
the three BSA standards (assayed in triplicate) was pipetted into their designated 
Lucham tubes. For the samples, 50 µl of each were pipetted into their designated 
tubes. The samples were assayed in duplicate.  
After preparation, 1 ml Na-K-Tartrate-CuSO4 was added to each tube at time intervals 
of 10 seconds. Every tube was vortexed after addition. Ten minutes after the first 
addition of Na-K-Tartrate-CuSO4, 100 µl of the Folin-Ciocalteu dilution was added to 
each tube, also with time intervals of 10 seconds between additions. The tubes were 
also vortexed after addition. When done, the tubes were left on the bench for 30 
minutes to allow full colour development before reading the OD values on the 
spectrophotometer at 750 nm. The blank was set with the 0.5 N NaOH sample.  
The standard curve was set up in an Excel sheet by plotting the OD values on the Y-
axis and the standard protein concentrations (mg/ml) on the X-axis. This standard 
curve was used to determine the total protein amount (mg/ml) of every sample. 
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7. Mitochondrial Isolation 
Polarographic measurement of mitochondrial respiration was used to determine the 
oxidative phosphorylation potential of the hearts. This was carried out by measuring 
the oxygen tension using the Hansatech Clark-type oxygen electrode (Hansatech 
Instruments).  
 
Reagents included 0.18 M KCl, 0.01 M Ethylenediaminetetraacetic acid (EDTA), lysis 
buffer and 10 % Trichloroacetic acid (TCA).  
 
Procedure: 
The heart ventricles were longitudinally cut after sacrifice. Each half was minced 
separately into small pieces in Sorvall tubes containing ice cold KE buffer (0.18 M KCl 
and 0.01 M EDTA, pH 7.4) and rinsed to remove all traces of blood. In two bursts, the 
hearts were homogenised on ice with the Heidolph silent crusher M homgenizer for 4 
seconds at 12000 rpm. The homogenates were centrifuged (Sorvall SS34 rotor) for 10 
min at 4 °C at 2500 rpm to pellet the nuclei and larger remaining debris. The 
supernatant was decanted and centrifuged for another 10 min at 12500 rpms at 4 °C 
to sediment the mitochondria into a pellet. After this step, two separate Sorvall tubes 
with pellets were available. The supernatant was gently removed from both pellets. 
The one pellet was carefully removed and suspended in 0.26 ml KE buffer for oxidative 
phosphorylation determination (Hansatech Clark-type oxygen electrode) (referred to 
as Suspension 1). Using a Glass-Teflon homogenizer (Teflon® pestle PYREX® 
Potter-Elvehjem tissue grinders), the pellet was gently homogenized. The other pellet 
was gently suspended, homogenized (Teflon® pestle PYREX® Potter-Elvehjem 
tissue grinders) and stored away in 200 µl standard lysis buffer at -80 °C (refer to ‘8.1 
Lysate Preparation’) for Western Blot analysis (‘8. Western Blots’) (referred to as 
Suspension 2).  
 
Of Suspension 1, 50 μl was precipitated in 1 mL 10% TCA for the Lowry assay (‘6. 
Lowry Protein Determination’). For the oxygraph, 100 μl of the mitochondrial 
suspension was used and the rest was stored away at -80 °C for determination of the 
citrate synthase activity.  
 
 
Stellenbosch University  https://scholar.sun.ac.za
67 
 
7.1. Mitochondrial Oxidative Phosphorylation  
 
Reagents included 2 substrate media; glutamate (with malate) and palmitoyl-L-
carnitine (with malate). The glutamate (carbohydrate) medium consisted of 2 ml 1.25 
M sucrose, 1 ml 100 mM Tris-HCl (pH 7.4 with 2 M Tris), 1 ml 85 mM KH2PO4, 1 ml 50 
mM glutamate (pH 7.4 with 2 M Tris), 1 ml 20 mM malate (pH 7.4 with 2 M Tris) and 
dH2O. The palmitoyl-L-carnitine (fatty acid) medium consisted of all the ingredients for 
glutamate medium, but instead of glutamate, 1 ml 45 mM palmitoyl-L-carnitine was 
added. The pH was again adjusted to 7.4 before dH2O was added up to 10 ml. The 
media were kept at room temperature.  
Other reagents included 50% KCl, Na₂S₂O₄ (Merck Pty Ltd) and adenosine-5’-
diphosphate monopotassium salt hydrate (ADP) (Sigma-Aldrich). ADP was prepared 
by dissolving 0.02 g in 5 ml dH2O and the final concentration was determined with an 
Ultra Violet (UV) spectrophotometer at 259 nm (ADP molar extinction coefficient: 
15,4).  
7.1.1. Oxygraph setup: 
 
One drop of 50% KCl (an electrolyte) was applied to the cathode and 3 drops on the 
anode beneath the dome. A paper spacer (Rizla) was first placed over the cathode 
and dome, and then an oxygen permeable membrane over the paper spacer. The 
paper spacer and membrane were secured with an O-ring using an applicator shaft. 
The electrode disk was sealed into the oxygen electrode chamber with an outer O-ring 
(refer to Figure 2.4 and Figure 2.5 for a visual representation of the oxygraph 
instrument used in this study (Hansatech Instruments, 2017)). 
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Figure 2.4 The Oxygraph System (Hansatech Instruments) (adapted from Hansatech Instruments (2017)). 
 
 
 
 
 
 
 
Figure 2.5 The S1 electrode from the Oxygraph System (Hansatech Instruments) (adapted from Hansatech 
Instruments (2017)). 
 
The system was calibrated before every experiment by adding 650 μl of the respective 
incubation medium (glutamate or palmitoyl-L-carnitine) and a small magnetic stirrer to 
the oxygraph chamber. The temperature was set to 25 °C and the speed of the 
magnetic stirrer to 100. The oxygraph was calibrated in the liquid phase. After the 
plateau of ambient oxygen saturation of the medium was reached, a few grains of 
Na₂S₂O₄ was added to the chamber to remove all oxygen within the chamber (zero 
oxygen levels). Once the plateau was reached again, the settings of 100% and 0% 
oxygen were stored and the chamber rinsed thoroughly with dH2O before replacing 
with fresh 650 μl of incubation medium for the experiment.  
 
Procedure: 
The chamber was filled with 650 μl of the respective incubation medium. 100 μl of the 
mitochondria suspension in KE buffer (Suspension 1) was added to the chamber. The 
Inner O-ring 
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system was the closed and allowed to record for several seconds (this was state 2, 
where respiration of mitochondria took place in the presence of the substrate alone). 
After a few seconds, 50 μl of ADP was added to the chamber using a Hamilton syringe. 
This represented state 3, where mitochondria can convert the ADP to ATP. As soon 
as a curve started to form (this was where the mitochondria returned to their normal 
respiration state 4 after the mitochondria converted all ADP to ATP), it was allowed to 
run for about 60 seconds before 50 μl of 10x ADP concentration (± 3500 nM) was 
added to the chamber. This enabled the mitochondria to convert as much ADP to ATP 
as possible, until all the oxygen in the chamber was consumed. As soon as the oxygen 
levels reached zero, the recording was stopped and the mitochondria were subjected 
to anoxia for 20 minutes. After the 20 minutes, a Pasteur pipet was used to re-
oxygenate the medium to ~50% of the initial concentration. Measurement of the re- 
oxygenation state 3 respiration was thus performed.  
 
Figure 2.6 An illustration of the mitochondrial registration generated by the oxygraph.  The labels represent the 
three states mitochondrial respiration. State 2 is the respiration of mitochondria in the presence of the substrate 
alone, where State 3 represents the mitochondrial respiration in the presence of ADP (oxidative phosphorylation). 
State 4 represents the mitochondrial respiration after all ADP was converted to ATP. Re-oxygenation (State 3) 
represents the mitochondrial respiration after the mitochondria were subjected to 10x concentrated ADP and 20 
minutes hypoxia. 
Several parameters were obtained or calculated from the graph generated by the 
oxygraph (Table 2.2). Along with these parameters, the protein determination from the 
Lowry Assay were used to determine the mitochondrial function. Standardizing the 
measured parameters to protein content allows for comparison between samples.  
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Table 2.2 Mitochondrial Respiration Parameters 
Parameter Definition/Calculation 
ADP/O (coupling efficiency of the 
mitochondria) 
Ratio of ATP production to total oxygen uptake 
during State 3: nmoles ATP ÷ nAtom of oxygen 
consumed 
QO2 (State 2) 
Number of atoms oxygen used in the presence of 
the substrate alone / mg mitochondria protein / 
min 
QO2 (State 3) 
Number of atoms oxygen used in the presence of 
ADP / mg mitochondria protein / min 
QO2 (State 4) 
Number of atoms oxygen used in the absence of 
ADP / mg mitochondria protein / min 
Respiration Control Index (RCI) QO2 (S3) ÷ QO2 (S4) 
Oxidative Phosphorylation rate (Sate 3) 
QO2 (S3) x ADP/O (nmoles ATP produced / mg 
mitochondria protein / min) 
Percentage recovery after re-oxygenation 
% recovery after 20 mins hypoxia and re-
oxygenation (measured against QO2 (State 3)) 
 
8. Western Blots  
8.1. Lysate Preparation 
A standard lysis buffer was prepared in a 50-ml tube using 10X concentrated stock 
solutions as follows: 3 ml 200 mM Tris-HCl/10 mM EGTA, 300 µl 100 mM EDTA, 4.5 
ml 1 M NaCl. 3 ml 10 mM Na3VO4 (prepared weekly with 0.018g Na3VO4 in 10 ml 
dH2O), 3 ml 10 % Triton X-100. The following was added: 0.006 g β-glycerophosphate, 
0.03 g tetra-Na-pyrophosphate, 30 µl Leupeptin, 30 µl Aprotinin (final concentration 
10 g/ml each) and 90 µl 100 mM PMSF. The solution was then filled up with dH2O to 
a total volume of 30 ml. 
8.1.1. Lysate preparation from whole heart tissue: 
Lysates were prepared from freeze clamped ventricles. A small piece of the freeze 
clamped heart was broken off and submerged in the lysis buffer in the lysate 
preparation tube. The Heidolph Silent Crusher M homogenizer was used to 
homogenise the sample at 20 rpm for 4 seconds. The aggregate of the homogeniser 
was rinsed with dH2O between samples. Once all samples were homogenised, each 
sample was homogenised again.  
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The lysate was allowed to stand for 15 - 30 minutes on ice before the sample was 
transferred to Eppendorf tubes which were centrifuged for 20 minutes at 15000 rpm in 
the Sigma 1-14K Refrigerated Microfuge. The supernatant of each sample was then 
removed and transferred into a new Eppendorf tube. Samples were constantly kept 
on ice. Protein determination was done by the method of Bradford (kindly refer to ‘8.1.3 
Bradford Protein Determination’) (Bradford, 1976). 
8.1.2. Lysate preparation from the mitochondrial suspension in 200 µl standard 
lysis buffer: 
The samples were taken from storage and thawed on ice. Four to five Zirconium Oxide 
Beads was then added to the thawed samples for homogenisation. The samples, 
along with the beads, were then placed in a Bullet Blender® (Next Advanced Inc., 
USA) at 4 °C for 3 minutes at a speed of 5. After homogenisation, the samples were 
allowed to stand on ice for 15 minutes for full lysis. After this, the homogenates were 
centrifuged (Sigma 1-14K Refrigerated Microfuge) at 4 °C for 20 minutes at 15000 
rpms. The Bradford method was also used for protein determination of these samples 
(kindly refer to ‘8.1.3 Bradford Protein Determination’) (Bradford, 1976). 
8.1.3. Bradford Protein Determination: 
Bradford solution (0.6 mM Coomasie Brilliant Blue G-250in 95 % ethanol and 50 % 
(v/v) phosphoric acid) was diluted 1:5 and filtered through a double layer of Whatman 
filter paper. For the standard curve, a BSA stock solution (5 mg/ml dH2O) was used 
and diluted in a 1:4 ratio (100 μl BSA stock in 400 μl dH2O). For the standard curve, 
the diluted BSA was further diluted in duplicate in the following series (Table 2.3): 
Table 2.3 Bradford Standards 
Diluted BSA dH2O 
0 µl 100 µl 
5 µl 95 µl 
10 µl 90 µl 
20 µl 80 µl 
40 µl 60 µl 
60 µl 40 µl 
80 µl 20 µl 
For the 1:10 dilution of the lysate samples, 50 µl of it was added to 450 µl dH2O in an 
Eppendorf and vortexed. Of this dilution, 5 µl was added to 95 µl dH2O in the respective 
reaction tube. The samples were all assayed in duplicate.  
Stellenbosch University  https://scholar.sun.ac.za
72 
 
To each tube, 900 µl of the filtered Bradford reagent was added and vortexed. After 
the tubes were left to stand for 20 minutes, the optical density (OD) was read on the 
spectrophotometer at 595 nm (Spectronic® 20 Genesys™ Spectrophotometer, 
Thermo Fisher Scientific Inc., RSA). The 0 µl BSA standard was used as the blank. 
The standard ODs were then used to draw up a standard curve and calculate the 
protein concentrations in each sample. These calculations were done using an Excel 
sheet. The samples were diluted with lysis buffer to contain equal amounts of protein 
per volume unit after which a 3x Laemmli sample buffer was added in a 1:2 (v/v) ratio 
to the sample (Laemmli, 1970).  The 3x Laemmli buffer consisted of 0.125 M Tris-HCl 
(pH 6.8), 4 % SDS, 20 % glycerol, 10 % β-mercaptoethanol and 0.0004 % 
bromophenol blue. Dilutions were usually made to yield in a protein concentration of 
50 ug/15 uL volume to load on the SDS PAGE gel. Samples were boiled for 5 minutes 
and then stored in -80 °C. 
8.2. Protein Separation 
8.2.1. Precast Gel Preparation 
For protein separation, 26-well Criterion™ TGX (Tris-Glycine,eXtended) Stain-Free™ 
Precast Gels (Bio-Rad Laboratories Inc., USA) with a gradient of 4-15 % were used. 
Gels were placed in a Criterion™ Cell system (Bio-Rad Laboratories Inc., USA). The 
system was filled with running buffer until the maximum level. The samples were then 
loaded into the wells with a Hamilton syringe. For the proteins under 100 kDa, 
PageRuler™Prestained Protein Ladder (Thermo Fisher Scientific Inc., RSA) was 
used. For proteins larger than 100 kDa, HiMark™ Pre-Stained High Molecular Weight 
Protein Standard was used. After the protein ladder, samples were added to the next 
lanes of the gel. For the insulin signalling proteins (GLUT4, Akt/PKB, AMPK, ERK and 
ATM), autophagy proteins (BNIP3, Beclin-1, LC3-II) and stress-responsive protein 
(Sesn2), 15 µl of the sample (containing 50 µg of protein) was added to the respective 
wells. These samples were added in the following sequence: control samples (C); 
controls injected with insulin before sacrifice (C I); controls treated with Afriplex GRT 
Extract (CT); controls treated with Afriplex GRT Extract and injected with insulin before 
sacrifice (CT I); high fat diet rats (HFD); HFD rats injected with insulin before sacrifice 
(HFD I); HFD rats treated with Afriplex GRT Extract (HFDT) and, lastly, HFD rats 
treated with Afriplex GRT Extract and injected with insulin before sacrifice (HFDT I).  
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For the mitophagy proteins (p62, PINK1, Parkin), 12 µl of the sample (containing 30 
µg of protein) was added to the respective wells. The samples were loaded as follows: 
C, HFD, CT, HFDT, metformin (Met). Note that the sequences will be displayed along 
with the blots in ‘Chapter 3: Results.’   
Gels were run for 10 minutes at 100 V and 200 mA, followed by 50 minutes at 200 V 
and 200 mA.  After the proteins were separated, the gels were activated in the 
ChemiDoc™ MP System (Bio-Rad Laboratories Inc., USA) and the image stored. 
8.3. Protein Transfer 
After the proteins have been separated and the gels activated, the proteins were 
transferred to polyvinylidene fluoride (PVDF) membranes with wet transfer using the 
Criterion™ Blotter (Bio-Rad Laboratories Inc., USA). The proteins were allowed to 
transfer for 35 minutes at 200 V and 200 mA. The membranes were then visualized 
on the Bio-Rad ChemiDoc™ MP System to establish transfer and document the 
amount of proteins transferred. After visualizing the membranes, they were blocked 
on a shaker (lab rotor V1.00) with a 5 % fat free milk TBS-Tween solution (containing 
Tris-buffered saline (TBS) and 0.1 % Tween 20) for 2 hours to ensure blocking of non-
specific binding sites. After blocking, the membranes were washed with TBS-Tween 
solution for 30 minutes (3 x 10 minutes at a time, replacing with fresh TBS-Tween 
solution every wash). After washing, the membranes were probed overnight (at 4 °C 
on the lab rotor V1.00) with their respective primary antibody, diluted 1:1000. The 
following table is a summary of the primary antibodies blotted for in this study and the 
conditions utilized to enable optimal visualization of the band of interest (Table 2.4). 
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Table 2.4 Antibody Summary (Criterion™ Stain-Free Pre-Cast gels were used for all 
blots) 
Protein Molecular 
Size (kDa) 
Primary 
Antibody 
(AB) 
Secondary 
Antibody (AB) 
Exposure Method 
GLUT4 45 - 54 7,5 µl/5 ml 
primary 
SignalBoost™ 
1,25 µl/2.5 ml 
TBS-Tween/2.5 
ml 2.5 % milk 
(anti-mouse 2° 
AB) 
ChemiDoc™ MP 
System 
Akt/PKB 60 7,5 µl/7,5 ml 
TBS-Tween 
1,25 µl/5 ml 
TBS-Tween 
ChemiDoc™ MP 
System 
tAMPK + 
pAMPK 
62 7,5 µl/7,5 ml 
TBS-Tween 
1,25 µl/5 ml 
TBS-Tween 
ChemiDoc™ MP 
System 
tERK + 
pERK 
42 + 44 7,5 µl/7,5 ml 
TBS-Tween 
1,25 µl/5 ml 
TBS-Tween 
ChemiDoc™ MP 
System 
tATM + 
pATM 
370 7,5 µl/5 ml 
primary 
SignalBoost™ 
1,25 µl/5 ml 
TBS-Tween 
Signalboost™ 
ChemiDoc™ MP 
System 
Sesn2 54 – 56  7,5 µl/7,5 ml 
TBS-Tween 
1,25 µl/5 ml 
TBS-Tween 
ChemiDoc™ MP 
System 
p62 62 7,5 µl/7,5 ml 
TBS-Tween 
1,25 µl/5 ml 
TBS-Tween 
ChemiDoc™ MP 
System 
PINK1 50 + 60 7,5 µl/7,5 ml 
TBS-Tween 
1,25 µl/5 ml 
TBS-Tween 
ChemiDoc™ MP 
System 
Parkin 52 7,5 µl/3.75 ml 
TBS-
Tween/3.75 5 
% milk 
1,25 µl/2.5 ml 
TBS-Tween.  
ChemiDoc™ MP 
System 
LC3 14 + 16 7,5 µl/7,5 ml 
TBS-Tween 
1,25 µl/5 ml 
TBS-Tween 
ChemiDoc™ MP 
System 
Beclin-1 60 7,5 µl/7,5 ml 
TBS-Tween 
1,25 µl/5 ml 
TBS-Tween 
ChemiDoc™ MP 
System 
BNIP3 22 – 28 
50 – 55  
7,5 µl/7,5 ml 
TBS-Tween 
1,25 µl/5 ml 
TBS-Tween 
ChemiDoc™ MP 
System 
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8.4. Immunodetection of Protein using Secondary Antibody 
After the membranes were probed overnight with primary antibody, they were washed 
with TBS-Tween (3 x 10 minutes with fresh TBS-Tween every wash) for 30 minutes. 
Hereafter, all the membranes (except GLUT4) were incubated for an hour at room 
temperature in diluted secondary anti-rabbit immunoglobulin G, HRP-conjugated 
secondary antibody (Cell Signaling Technology, Inc). GLUT4 was incubated in anti-
mouse immunoglobulin G, HRP-conjugated secondary antibody (Cell Signaling 
Technology, Inc). After the one-hour incubation, the membranes were washed again 
(3 x 10 minutes with fresh TBS-Tween every wash) for 30 minutes. 
The membranes were visualized by incubating them in BioRad Clarity™ Enhanced 
Chemiluminescence (ECL) substrate for 5 minutes and then exposing in the Bio-Rad 
ChemiDoc™ MP System.  
8.5. Visualization and Normalization on Bio-Rad ChemiDoc MP System 
The exposure times varied for the different antibodies. Exposure times were set to run 
with intervals of seconds prior to exposing in the Bio-Rad ChemiDoc™ MP System. 
The system also shows when any band is overexposed. The images were saved and 
quantified for analysis of the blots.  
The best image of the exposed membrane without any band overexposed, was 
normalised to the density of the protein bands against the total protein per lane 
transferred to the respective PVDF membrane image saved previously (see ‘8.3 
Protein Transfer’). This system negates the use of loading controls. All blots were 
analyzed using the BioRad ChemiDoc™ ImageLab 5.0 series software. 
9. Statistical Analysis 
For statistical analysis of all the data, GraphPad Prism 5 was used. The values were 
expressed as Mean ± Standard Error of the Mean (SEM). For analysis between protein 
markers with one variable (arbitrary densitometry units), One-way Analysis of Variance 
(ANOVA) was used followed by a Bonferroni post-hoc test. Between groups with two 
factors/variables (such as arbitrary densitometry units of tERK and pERK at 42 kDa 
and 44 kDa), a 2-way ANOVA was used to determine the differences. For OGTT 
analysis, a 2-way ANOVA with repeated measures was used for significant 
differences. A p-value of less than 0.05 was considered significant. 
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CHAPTER 3: Results 
 
1. Biometric Data 
 
1.1. Body Weights 
 
Figure 3.1 A t-test of the bodyweights, at week 10, of the control groups versus that of the HFD groups (*p<0.05; 
**p<0.001; ***p<0.0001). 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2 A 1-way ANOVA of the bodyweights, at week 16, of the control groups (with and without Afriplex GRT 
Extract) versus that of the HFD groups (with and without Afriplex GRT Extract) (*p<0.05; **p<0.001; 
***p<0.0001). 
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Body weights of the HFD groups were significantly increased by week 10, indicating 
that the HFD caused obesity (p = 0.0055) (Figure 3.1). At week 16, the HFD groups 
still had significantly higher body weights than that of the control groups (p = 0.0011) 
(Figure 3.2). The Afriplex GRT Extract resulted in lower body weight in the HFD groups 
indicating lower body weight gain over this period (p = 0.0011) (Figure 3.2). 
1.2. Food and Water Intake 
 
 
 
 
 
 
 
 
 
 
Figure 3.3 2-way ANOVAs of the food and water intake of the control groups (with and without Afriplex GRT 
Extract) versus that of the HFD groups (with and without Afriplex GRT Extract) over a period of 16 weeks 
(*p<0.05; **p<0.001; ***p<0.0001; # p<0.05; ## p<0.001). 
A 2-way ANOVA indicated that the HFD animals had significantly more food intake 
than the control animals over the 16-week period (p < 0.0001) (Figure 3.3). In 
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another 2-way ANOVA, the water intake was less in the HFD animals than that of the 
control animals (p < 0.0001), especially at weeks 2 (p < 0.05), 11 (p < 0.05) and 12 
(p < 0.001)). Whereas the Afriplex GRT Extract significantly increased water intake in 
the control animals (p < 0.0001) (Figure 3.3), especially at weeks 3 (p < 0.05), 4 (p < 
0.01) and 5 (p < 0.05). 
1.3. Liver Weight 
 
Figure 3.4 A 2-way ANOVA of the liver weights, after 16 weeks, of the control groups (with and without Afriplex 
GRT Extract) versus that of the HFD groups (with and without Afriplex GRT Extract) (*p<0.05; **p<0.001; 
***p<0.0001). 
The HFD groups displayed significantly higher liver weight than the controls (p < 
0.0001). The Afriplex GRT Extract attenuated this increase in the liver weights in the 
HFD groups (p < 0.05). A 2-way ANOVA indicated that the effect of the diet was overall 
very significant (p < 0.0001). 
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1.4. Intraperitoneal (IP) Fat Weight 
 
Figure 3.5 A 2-way ANOVA of the intraperitoneal fat weights, after 16 weeks, of the control groups (with and 
without Afriplex GRT Extract) versus that of the HFD groups (with and without Afriplex GRT Extract) (*p<0.05; 
**p<0.001; ***p<0.0001). 
The HFD groups displayed significantly higher IP fat weight than the controls (Figure 
3.5) (p < 0.0001). The Afriplex GRT Extract resulted in lower IP fat gain in the HFD 
groups (p < 0.05). No effect was seen on the control groups. A 2-way ANOVA indicated 
that the effect of the diet was overall very significant (p < 0.0001). 
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1.5. Oral Glucose Tolerance Tests 
 
Figure 3.6 A 2-way ANOVA of the OGTT results, at week 10, of the control groups versus that of the 
HFD groups (*p<0.05; **p<0.001; ***p<0.0001). 
 
Figure 3.7 A 2-way ANOVA of the OGTT results, at 16 weeks, of the control groups (with and without Afriplex 
GRT Extract) versus that of the HFD groups (with and without Afriplex GRT Extract) versus HFD groups with 
metformin (*p<0.05; **p<0.001; ***p<0.0001). 
At weeks 10 and 15, animals were fasted overnight to investigate their glucose 
tolerance. To do this, an OGTT was performed (refer to Chapter 2, ‘3. Oral Glucose 
Tolerance Test and Glucose Measurement’). 
At week 10, there was significantly increased blood glucose levels in the HFD group 
compared to the control group. A 2-way ANOVA indicated that the effect of the diet 
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was very significant (p < 0.0001) (Figure 3.6). This was expected, because a high fat 
diet is known to impair oral glucose tolerance and cause a higher OGTT curve. At 
week 16 (Figure 3.7), the HFD group’s glucose levels were slightly higher than that of 
the controls, not significantly though. A 2-way ANOVA indicated that the Afriplex GRT 
Extract significantly decreased the glucose levels in the control groups (p = 0.0022), 
especially at minutes 25, 30, 45 and 120 (p < 0.05).  
There were no significant differences seen between the HFD groups and metformin 
treated HFD groups.  
1.6. Basal Glucose Levels 
 
Figure 3.8 A t-test of the basal glucose level, at week 10, of the control groups versus that of the HFD groups 
(*p<0.05; **p<0.001; ***p<0.0001). 
 
Figure 3.9 A 2-way ANOVA of the basal glucose level, at week 15, of the control groups (with and without 
Afriplex GRT Extract) versus that of the HFD groups (with and without Afriplex GRT Extract) (*p<0.05; **p<0.001; 
***p<0.0001). 
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At week 10 (Figure 3.8), the controls showed a lower, though not significant, basal 
glucose level than that of the HFD groups. At week 16 (Figure 3.9), there was a 
significantly higher basal glucose level in the HFD group treated with Afriplex GRT 
Extract than that of the non-treated HFD groups (p < 0.01).  
1.7. Urine Volume 
 
Figure 3.10 A 2-way ANOVA of the urine volumes at week 15 of the control groups (with and without Afriplex 
GRT Extract) versus that of the HFD groups (with and without Afriplex GRT Extract) (*p<0.05; **p<0.001; 
***p<0.0001).  
The urine volume of the HFD groups were significantly lower than that of the controls 
(p = 0.0410). The same effect was seen on the groups treated with Afriplex GRT Extract 
(p = 0.0016). The Afriplex GRT Extract did not have significant effect on any of the 
groups, however a 2-way ANOVA indicated that the overall effect of the diet was 
significant (p = 0.0003). 
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1.8. ELISA Assays 
1.8.1. Leptin 
 
 
 
 
 
 
Figure 3.11 A 2-way ANOVA of the leptin levels of the control groups (with and without Afriplex GRT Extract) 
versus that of the HFD groups (with and without Afriplex GRT Extract) (*p<0.05; **p<0.001; ***p<0.0001). 
The leptin levels were significantly increased in the HFD groups compared to the 
controls (Figure 3.11) (p < 0.5). The Afriplex GRT Extract group presented with 
significantly lower leptin levels in the HFD fed animals, while having no effect in the 
controls (p < 0.05). A 2-way ANOVA indicated that the overall effect of the diet was 
significant (p = 0.0062). 
1.8.2. Adiponectin 
 
Figure 3.12 A 2-way ANOVA of the adiponectin levels of the control groups (with and without Afriplex GRT 
Extract) versus that of the HFD groups (with and without Afriplex GRT Extract) (*p<0.05; **p<0.001; 
***p<0.0001). 
The Afriplex GRT Extract had no significant effect on the adiponectin levels in either 
of the groups. The diet did, however, have an overall significant effect on the 
adiponectin levels (p = 0.0137). 
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1.8.3. Insulin 
 
 
 
 
 
 
 
 
Figure 3.13 A 2-way ANOVA of the insulin levels of the control groups (with and without Afriplex GRT Extract) 
versus that of the HFD groups (with and without Afriplex GRT Extract) (*p<0.05; **p<0.001; ***p<0.0001). 
There were no significant differences seen in the insulin levels between the different 
groups. 
1.9. HOMA IR index 
 
Figure 3.14 A 2-way ANOVA of the HOMA IR Index values between the control groups (with and without Afriplex 
GRT Extract) versus that of the HFD groups (with and without Afriplex GRT Extract) (*p<0.05; **p<0.001; 
***p<0.0001). 
A 2-way ANOVA indicated that the Afriplex GRT Extract and metformin had a very 
significant effect overall (p = 0.006). The low n-value is due to the limited fasting serum 
and fasting insulin values that were available. There was thus borderline significance 
seen, where Afriplex GRT Extract improved insulin resistance in the control animals 
(p = 0.07), and the metformin improved insulin resistance in HFD animals (p = 0.06). 
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2. 2DG Uptake Levels induced by Insulin 
 
Figure 3.15 A 2-way ANOVA of the 2DG Uptake Levels in cardiomyocytes at an Insulin Concentration of 100 nM 
between the control groups (with and without Afriplex GRT Extract) versus that of the HFD groups (with and 
without Afriplex GRT Extract) (*p<0.05; **p<0.001; ***p<0.0001). 
2DG uptake levels in cardiomyocytes prepared from the control and HFD animals were 
measured in response to treatment with 100 nM insulin stimulation. No significant 
differences were observed (n = 5 - 6 per group).   
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3.  The effect of the HFD and Afriplex GRT™ Extract on mitochondrial 
energetics. 
 
The mitochondria were prepared immediately after excision of the hearts from the 
chest cavity of the animal. 
3.1. ADP/O Ratio 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.16 A 2-way ANOVA of the ADP/O Ratio of mitochondria in glutamate plus malate or palmitoyl-
L-carnitine plus malate substrate media (*p<0.05; **p<0.001; ***p<0.0001). 
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The mitochondria from the Afriplex GRT Extract treated HFD animals had a 
significantly higher ADP/O ratio (in the palmitoyl-L-carnitine media) than that of the 
Afriplex GRT Extract control groups (p < 0.05). The Afriplex GRT Extract also 
increased the ADP/O ratio in the mitochondria of the HFD groups (p < 0.05). There 
were no significant differences between the controls and Afriplex GRT Extract treated 
controls. 
3.2. QO2 (States 2, 3 and 4) 
 
 
 
 
 
 
 
Figure 3.17 A 2-way ANOVA of the QO2 (State 2) Respiration of mitochondria in glutamate plus malate 
or palmitoyl-L-carnitine plus malate substrate media (*p<0.05; **p<0.001; ***p<0.0001). 
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Figure 3.18 A 2-way ANOVA of the QO2 (State 3) Respiration of mitochondria in glutamate plus malate 
or palmitoyl-L-carnitine plus malate substrate media (*p<0.05; **p<0.001; ***p<0.0001). 
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Figure 3.19 A 2-way ANOVA of the QO2 (State 4) Respiration of mitochondria in glutamate plus malate 
or palmitoyl-L-carnitine plus malate substrate media (*p<0.05; **p<0.001; ***p<0.0001). 
There was significantly increased state 2 respiration in the non-treated HFD animals 
compared to the metformin treated HFD animals (in both glutamate and palmitoyl-L-
carnitine media) (Figure 3.17) (p < 0.05). In addition, in the palmitoyl-L-carnitine media, 
the Afriplex GRT Extract treated HFD groups also had a higher state 2 respiration than 
that of the metformin treated HFD animals (p < 0.05). There was an increased state 4 
respiration in the metformin treated HFD groups compared to that of non-treated HFD 
groups (in the palmitoyl-L-carnitine media) (Figure 3.19) (p < 0.01). In both states 3 
(Figure 3.18) and 4, a 2-way ANOVA indicated that the media had a significant effect 
(in state 3, p = 0.0007; in state 4, p = 0.0328). In the palmitoyl-L-carnitine media, the 
state 3 and state 4 respiration rates were higher compared to the mitochondria in the 
glutamate media. 
Stellenbosch University  https://scholar.sun.ac.za
90 
 
3.3. RCI Values 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.20 A 2-way ANOVA of the Respiratory Control Index of mitochondria in glutamate plus malate 
or palmitoyl-L-carnitine plus malate substrate media (*p<0.05; **p<0.001; ***p<0.0001). 
The Afriplex GRT Extract significantly increased the RCI values in the control groups 
(in the palmitoyl-L-carnitine media) (p < 0.01). In addition, the Afriplex GRT Extract 
treated HFD groups had lower RCI rates than that of the Afriplex GRT Extract treated 
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control groups (p < 0.05). The treatment had an overall significant effect on the RCI 
value (p < 0.0001). 
3.4. Oxidative Phosphorylation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.21 A 2-way ANOVA of the Oxidative phosphorylation rate of mitochondria (State 3) in 
glutamate plus malate or palmitoyl-L-carnitine plus malate substrate media (*p<0.05; **p<0.001; 
***p<0.0001). 
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In the glutamate media, the Afriplex GRT Extract improved the oxidative 
phosphorylation rate in the control groups (p < 0.05). In the palmitoyl-L-carnitine 
media, metformin increased oxidative phosphorylation rate in the HFD groups (p < 
0.05).  
3.5. Percentage recovery in state 3 respiration after re-oxygenation of mitochondria 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.22 A 2-way ANOVA of the percentage recovery after re-oxygenation in glutamate plus 
malate or palmitoyl-L-carnitine plus malate substrate media (*p<0.05; **p<0.001; ***p<0.0001). 
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In a 2-way ANOVA, the overall effect of the media was significant (p < 0.0001) (Figure 
3.22). In the Afriplex GRT Extract treated HFD groups, recovery was significantly 
improved in the glutamate media compared to the palmitoyl-L-carnitine media (p < 
0.001). In the metformin treated HFD groups, there was also a significantly improved 
recovery in the glutamate media than in the palmitoyl-L-carnitine media (p < 0.05). No 
significant differences were seen otherwise.  
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4. Western Blot Data 
Note: The .JPEG images of every blot can be found on the CD-ROM attached. See 
Appendix A for the methods by which the calculations of the Western blots were 
performed.  
4.1. Insulin Signalling Proteins 
The tissue in this section was prepared from hearts that were immediately freeze-
clamped after being removed from the animals from cohort 1. The lysates were 
prepared from the cytosolic fraction, thus allowing us to observe the effects seen on 
baseline levels. The animals were not fasted before sacrifice.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.23 A 1-way ANOVA of the GLUT4 expression between control groups (with and without 
Afriplex GRT Extract), control groups (with and without insulin injection), HFD groups (with and 
without Afriplex GRT Extract) and HFD groups (with and without insulin injection) (*p<0.05; **p<0.001; 
***p<0.0001). 
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The HFD groups presented with significantly lower cytosolic GLUT4 levels in the 
cytosolic compartment than the controls and the same effect was seen in control 
groups and HFD groups injected with insulin before sacrifice (p < 0.0001) (Figure 
3.23). Afriplex GRT Extract treatment also significantly decreased cytosolic GLUT4 
levels in the cytosolic compartment in the controls and this was also seen in those 
injected with insulin. Afriplex GRT Extract had no effect on the GLUT4 levels in the 
hearts of the HFD animals. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.24 A 1-way ANOVA of the total and phosphorylated PKB expression between control groups 
(with and without Afriplex GRT Extract), control groups (with and without insulin injection), HFD 
groups (with and without Afriplex GRT Extract) and HFD groups (with and without insulin injection) 
(*p<0.05; **p<0.001; ***p<0.0001). 
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Figure 3.25 A 2-way ANOVA of the ratio of phosphorylated vs total levels of PKB expression between 
control groups (with and without Afriplex GRT Extract), control groups (with and without insulin 
injection), HFD groups (with and without Afriplex GRT Extract) and HFD groups (with and without 
insulin injection) (*p<0.05; **p<0.001; ***p<0.0001).   
The HFD groups had significantly lower total PKB levels than the controls (p < 0.001) 
(Figure 3.24). Afriplex GRT Extract also significantly decreased total PKB expression 
in the controls (p < 0.05). No significant differences were found between the 
phosphorylated PKB levels of the groups. There were also no significant differences 
between the ratio of phosphorylated PKB versus total PKB in the groups (Figure 3.25), 
but insulin treatment seemed to have increased phosphorylated PKB expression in all 
the groups. It is very interesting that the HFD hearts reacted on insulin treatment 
despite the low total PKB levels. 
Please note: In the blot from Figure 3.24, the gel was not placed straight in the 
ChemiDoc in the Gel Activation step. This explains why the bands seem to increase 
in size across the blot.  
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Figure 3.26 A 1-way ANOVA of the total and phosphorylated AMPK expression between control 
groups (with and without Afriplex GRT Extract), control groups (with and without insulin injection), 
HFD groups (with and without Afriplex GRT Extract) and HFD groups (with and without insulin 
injection) (*p<0.05; **p<0.001; ***p<0.0001). 
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Figure 3.27 A 1-way ANOVA of the ratio of phosphorylated vs total levels of AMPK expression 
between control groups (with and without Afriplex GRT Extract), control groups (with and without 
insulin injection), HFD groups (with and without Afriplex GRT Extract) and HFD groups (with and 
without insulin injection) (*p<0.05; **p<0.001; ***p<0.0001). 
The HFD groups had significantly lower total AMPK levels than the controls (p < 
0.0001) and the same effect was seen in the controls groups and HFD groups injected 
with insulin before sacrifice (p < 0.05) (Figure 3.26). Afriplex GRT Extract also 
significantly decreased total AMPK expression in the controls (with and without the 
insulin injection before sacrifice). No significant differences were found between the 
phosphorylated AMPK levels of the groups. There were also no significant differences 
between the ratio of phosphorylated AMPK versus total AMPK in the groups (Figure 
3.27). 
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Figure 3.28 A 1-way ANOVA of the total and phosphorylated ATM expression between control 
groups (with and without Afriplex GRT Extract), control groups (with and without insulin injection), 
HFD groups (with and without Afriplex GRT Extract) and HFD groups (with and without insulin 
injection) (*p<0.05; **p<0.001; ***p<0.0001). 
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Figure 3.29 A 1-way ANOVA of the ratio of phosphorylated vs total levels of ATM expression 
between control groups (with and without Afriplex GRT Extract), control groups (with and without 
insulin injection), HFD groups (with and without Afriplex GRT Extract) and HFD groups (with and 
without insulin injection) (*p<0.05; **p<0.001; ***p<0.0001). 
The HFD significantly decreased baseline phosphorylated ATM (p < 0.05) (Figure 
3.28). In addition, Afriplex GRT Extract significantly decreased phosphorylated ATM 
expression in the control groups (p < 0.05). No significant differences were found 
otherwise. 
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Figure 3.30 A 2-way ANOVA of the total and phosphorylated ERK (at 42 kDa and 44 kDa) expression 
between control groups (with and without Afriplex GRT Extract), control groups (with and without 
insulin injection), HFD groups (with and without Afriplex GRT Extract) and HFD groups (with and 
without insulin injection) (*p<0.05; **p<0.001; ***p<0.0001). 
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Figure 3.31 A 2-way ANOVA of the ratio of phosphorylated vs total levels of ERK (at 42 kDa and 44 
kDa) expression between control groups (with and without Afriplex GRT Extract), control groups (with 
and without insulin injection), HFD groups (with and without Afriplex GRT Extract) and HFD groups 
(with and without insulin injection) (*p<0.05; **p<0.001; ***p<0.0001). 
The HFD groups had significantly lower phosphorylated ERK levels than the controls 
(p < 0.05) (Figure 3.30). Afriplex GRT Extract also significantly decreased 
phosphorylated ERK expression in the controls, as well as the ratio of phosphorylated 
ERK to total ERK (p < 0.05) (Figure 3.31). No significant differences were found 
between the total ERK levels of the groups.  
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4.2. Stress Responsive Proteins 
 
 
Figure 3.32 A 1-way ANOVA of the Sesn2 expression between control groups (with and without 
Afriplex GRT Extract), control groups (with and without insulin injection), HFD groups (with and 
without Afriplex GRT Extract) and HFD groups (with and without insulin injection) (*p<0.05; **p<0.001; 
***p<0.0001). 
Sesn2 levels were significantly decreased in the HFD groups (p < 0.05). The Afriplex 
GRT Extract also significantly decreased Sesn2 expression in the controls (p < 0.05). 
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4.3. Proteins associated with autophagy, measured in the cytosolic compartment of 
the cell 
The tissue in this section was prepared from hearts that were immediately freeze-
clamped after being removed from the animals from cohort 1. The lysates were 
prepared from the cytosolic fraction, thus allowing us to observe the effects seen on 
baseline levels. The animals were not fasted before sacrifice.  
 
 
Figure 3.33 A 1-way ANOVA of the Beclin-1 expression between control groups (with and without 
Afriplex GRT Extract), control groups (with and without insulin injection), HFD groups (with and 
without Afriplex GRT Extract) and HFD groups (with and without insulin injection) (*p<0.05; **p<0.001; 
***p<0.0001). 
Cytosolic Beclin-1 expression was significantly lower in the controls treated with 
Afriplex GRT Extract than those not treated. A 2-way ANOVA indicated that the HFD 
(p = 0.0346) and the Afriplex GRT Extract (p = 0.0032) decreased Beclin-1 expression. 
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Figure 3.34 A 1-way ANOVA of the BNIP3 (at 22 – 28 kDa and 50 – 55 kDa) expression between 
control groups (with and without Afriplex GRT Extract), control groups (with and without insulin 
injection), HFD groups (with and without Afriplex GRT Extract) and HFD groups (with and without 
insulin injection) (*p<0.05; **p<0.001; ***p<0.0001). 
According to a 2-way ANOVA, the HFD resulted in lower levels of BNIP3 (p = 0.0019). 
In addition, the 22 – 28 kDa BNIP3 expression was lowered in the controls treated with 
Afriplex GRT Extract and injected with insulin compared to that of the controls only 
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treated with Afriplex GRT Extract (p = 0.0124). Futhermore, a 1-way ANOVA indicated 
that the 50-55 kDa homodimers of BNIP3 was lower in the hearts of the control animals 
treated with Afriplex GRT Extract (p < 0.05). Animals on the HFD, treated with Afriplex 
GRT Extract then injected with insulin, had significantly higher BNIP3 homodimer (50 
– 55 kDa) levels than the Afriplex GRT Extract treated control groups injected with 
insulin (p < 0.001).  
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Figure 3.35 A 1-way ANOVA of the LC3-I and LC3-II expression between control groups (with and 
without Afriplex GRT Extract), control groups (with and without insulin injection), HFD groups (with 
and without Afriplex GRT Extract) and HFD groups (with and without insulin injection) (*p<0.05; 
**p<0.001; ***p<0.0001). 
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Figure 3.36 A 1-way ANOVA of the ratio of LC3-II vs LC3-I expression between control groups (with 
and without Afriplex GRT Extract), control groups (with and without insulin injection), HFD groups 
(with and without Afriplex GRT Extract) and HFD groups (with and without insulin injection) (*p<0.05; 
**p<0.001; ***p<0.0001). 
There was an increase in LC3-II expression in Afriplex GRT Extract treated HFD 
groups, compared to the non-treated HFD group (Figure 3.35) (p < 0.001). The LC3-
II to LC3-I ratio of the Afriplex GRT Extract treated HFD groups was significantly higher 
than that of normal HFD groups (p < 0.001).  
Please note: the blot in Figure 3.35 seems as if the bands are decreasing in size 
across the blot. This can be explained by the fact that, when placing the gel on to the 
transfer paper before the transfer step, the gel was placed askew. 
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4.4. Mitophagy Proteins 
The lysates used in this section was prepared from hearts from cohort 2 that were 
prepared immediately after removal from the chest cavity.  
 
 
 
 
 
 
 
 
Figure 3.37 A 1-way ANOVA of the PINK1 expression of between control groups (with and without 
Afriplex GRT Extract), HFD groups (with and without Afriplex GRT Extract) and HFD treated with 
metformin (*p<0.05; **p<0.001; ***p<0.0001). 
No significant differences in mitochondrial PINK1 expression were found between 
either of the groups (Figure 3.37). 
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Figure 3.38 A 2-way ANOVA of the Parkin expression of between control groups (with and without 
Afriplex GRT Extract), HFD groups (with and without Afriplex GRT Extract) and HFD treated with 
metformin (*p<0.05; **p<0.001; ***p<0.0001). 
No significant differences were found between the groups (Figure 3.38). 
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Figure 3.39 A 2-way ANOVA of the p62 expression of between control groups (with and without 
Afriplex GRT Extract), HFD groups (with and without Afriplex GRT Extract) and HFD treated with 
metformin (*p<0.05; **p<0.001; ***p<0.0001). 
The Afriplex GRT Extract also decreased p62 levels in the control and HFD groups (p 
< 0.001) (Figure 3.39). Levels of mitochondrial p62 were significantly decreased in the 
Afriplex GRT Extract treated HFD groups compared to that of Afriplex GRT Extract 
treated control groups (p < 0.05). Expression of p62 was also decreased in HFD 
groups treated with metformin (positive control) compared to non-treated HFD groups 
(p < 0.0001). 
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CHAPTER 4: Discussion and Conclusion 
 
1. Body Weight, IP Fat Weight, Liver Weight and Urine Volume 
Generally, increased consumption of fats, cholesterol, sugar and carbohydrates are 
associated with an increase in bodyweight. This increase is attributed to the imbalance 
that originates when energy intake is more than energy outflow (Spiegelman & Flier, 
2001; The Heart and Stroke Foundation South Africa, 2016). As previously mentioned, 
this imbalance is associated with development of insulin resistance. 
The high fat diet (HFD) used in our study has been previously tested and established 
in our laboratory (Huisamen, et al., 2013). This HFD is aimed to induce obesity and 
insulin resistance in the animals. The biometric parameters of the animals were 
characterized, before experimentation, to ensure that the animals fed with the HFD 
developed both insulin resistance and obesity. This was done by performing OGTTs 
on the animals at week 10, to ensure insulin resistance in the HFD animals. The body 
weights were also monitored weekly and compared to the controls. 
The diet fed to the HFD groups significantly increased the bodyweight gain in 
comparison to control fed animals, demonstrating the success of the diet regime to 
induce obesity in the animals (Figure 3.1 and 3.2). Along with the bodyweights, 
increased liver weights and IP fat gain was also seen in the HFD groups, again 
showing that the diet regime resulted in central obesity as well as having effects on 
the liver (Figure 3.4 and 3.5) (Hariri & Thibault, 2010; Gao, et al., 2015). 
Ingestion of Afriplex GRT Extract, for a period of 6 weeks, resulted in significantly 
lowered weight gain as well as lesser IP fat weight gain by the HFD groups (Figure 3.2 
and Figure 3.5). In addition, the Afriplex GRT Extract counteracted the increase in the 
liver weights in the HFD groups demonstrating that the product changed the metabolic 
profile of the animals resulting in a healthier profile with diminished central obesity.  
Afriplex GRT Extract contains a fair amount of quercetin (0.5 %) and, in previous 
studies, quercetin has been shown to cause weight-loss and to have anti-obesity 
properties (Kuppusamy & Das, 1992; Ahn, et al., 2008; Rivera, et al., 2008). Ahn, et 
al. (2008) states that quercetin improves obesity through the AMPK and MAPK 
signalling pathways and Hoon, et al. (2013) have shown that quercetin suppresses 
adipogenesis. The quercetin in the Afriplex GRT Extract could account for the lowered 
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weight gain and overall obesity improvement in the treated animals (Figure 3.2, 3.4 
and 3.5). 
The food intake of the HFD animals were significantly more than that of the control 
animals throughout the 16-week period, explaining the higher bodyweight seen in 
these animals (Figure 3.3). However, the HFD groups also ingested significantly less 
water than the control groups, especially from week 11. This could be because the 
normal rat-chow diet (of the control animals) was simply less moist than that of the 
HFD (which contained 200 ml water in the diet composition).  
In addition, the Afriplex GRT Extract treated control animals ingested significantly 
more water than the non-treated controls, especially from weeks 3 to 5 of the treatment 
period, indicating that Afriplex GRT Extract caused increased thirst (Figure 3.3). Thirst 
can be either physiological or a subjective desire to drink fluids. Animals or humans 
drink fluid to either maintain body fluid homeostasis or as a result of social factors (an 
example could be competitive behaviour between the animals, causing them to fight 
for the water) (McKinley & Johnson, 2004). Thus, this study’s results could indicate 
that Afriplex GRT Extract somehow influences the body’s fluid content, causing the 
animals to have an increased thirst and urinate more frequently (almost in a way that 
caffeine has diuretic properties).  
Urine volume was measured at week 15 after the animals were subjected to a 24-hour 
period in a metabolic cage. The HFD animals presented with a significantly lower urine 
volume than the control animals indicating increased water retention (Figure 3.10). 
The Afriplex GRT Extract had no significant effect on the urine volume of the HFD 
animals, but a strong tendency to increased urine volume can be seen in Afriplex GRT 
Extract treated control animals compared to non-treated controls. It has been said that 
rooibos is able to reduce fluid retention by its diuretic properties (Bredenkamp, 2006; 
Balance Me Beautiful, 2017). This could also be the explanation for the effect on urine 
volume in Afriplex GRT Extract treated controls.  
Water retention can also be an explanation for the increased bodyweights in HFD 
animals. Extreme thirst or hunger and water retention are symptoms of insulin 
resistance (Zhou, et al., 2014; Roland & Marcin, 2017). The latter suggests that the 
low urine volume in the HFD animals could confirm insulin resistance, but it does not 
fit the observation that HFD animals drank less water than the control animals. The 
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HFD animals might have, however, simply drank less water because their diet was 
moister than the normal control diet. The low water intake could be the reason for the 
lower urine volume, thus it cannot be confirmed that the HFD animals had water 
retention. Further studies are necessary to elaborate on this.  
The ADH (antidiuretic hormone) regulates water balance in the body and an increase 
in fluid loss results in decreased blood pressure (Rice & Luo, 2017). The low urine 
output in the HFD animals could also indicate that the HFD animals might have 
exhibited high blood pressure, confirming insulin resistance in these animals (Vallance 
& Norman, 2001; Hoshiyama, et al., 2003). Aldosterone- and angiotensin levels are 
two hormones that maintain blood pressure and could thus have been measured to 
confirm if the HFD animals exhibited high blood pressure. 
2. Glucose Levels, Insulin Levels and HOMA IR Index 
2.1. OGTT Data and Basal Glucose Levels 
An increased fasting basal glucose level can be an indication of insulin resistance 
(Cefalu, 2001), but at week 10 of the HFD period, this was not seen (Figure 3.8). 
However, the results obtained from the OGTT assays showed that animals on the HFD 
presented with significantly higher plasma glucose levels after ingestion of a glucose 
load at week 10 (Figure 3.6). This confirms that the animals on the HFD were insulin 
resistant and unable to effectively utilize the glucose load. This was expected, seeing 
as an increased glucose level indicates insulin resistance. Insulin resistant humans 
have higher plasma glucose levels than normal. Ingestion of Afriplex GRT Extract 
significantly increased the basal glucose levels after week 15 in the HFD groups and 
did not improve the OGTT generated curves (Figure 3.7 and 3.9), showing that Afriplex 
GRT Extract did not improve whole body insulin resistance in the HFD animals. 
On the other hand, the OGTT data demonstrated that ingestion of Afriplex GRT Extract 
improved the ability of the animals on a normal control diet to handle a glucose load 
by week 15 (Figure 3.7). This may be because Afriplex GRT Extract was able to 
improve the peripheral glucose utilization of these animals but not in the HFD animals. 
Afriplex GRT Extract did not increase insulin secretion by the pancreatic β-cells, 
indicated by the fasting insulin levels measured in the animals.  
The results obtained in our study, using a high fat diet-induced obesity and insulin 
resistant model, contrast with the data reported by Kamakura, et al. (2015), who 
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demonstrated that insulin resistance was improved in obese diabetic mice using a 
different green rooibos extract, and Kawano, et al. (2009), who demonstrated a 
hypoglycaemic effect on db/db mice treated with aspalathin. 
2.2. Insulin levels and HOMA IR Index 
Validating the OGTT results, a 2-way ANOVA of the HOMA-IR indicated that the 
Afriplex GRT Extract improved insulin resistance in the control animals (Figure 3.14). 
More specifically, the Afriplex GRT Extract had a borderline significant effect on the 
control animals, where the HOMA-IR was improved by this product. Metformin also 
had a borderline significant effect on the HFD animals, where insulin resistance was 
improved. The term ‘borderline significance’ is used because of the low n-value that 
was due to the limited fasting serum and fasting insulin values that were available.  
3. Leptin and Adiponectin Levels 
In the HFD animals the significantly increased leptin levels were expected because of 
the central obesity in the animals (Figure 3.11) (Li & Wu, 2012). The increased leptin 
levels in the HFD animals confirm once again that obesity was induced via the HFD 
regime as leptin levels are proportional to fat mass (Maffei, et al., 1995; Trayhurn & 
Bing, 2006).  
Leptin is a hunger inhibiting hormone and ghrelin an appetite-increasing hormone 
(Brennan & Mantzoros, 2006). Ghrelin levels are increased when the stomach is 
empty, thus increasing appetite (Klok, et al., 2007). Leptin, on the other hand, is 
secreted to inhibit appetite when the stomach satiated. In obesity, T2D and insulin 
resistance there is increased leptin levels because of the increased fat mass. Along 
with the increased leptin levels, leptin resistance develops that cause obese patients 
to fail to control their hunger (Considine, et al., 1996).  
The Afriplex GRT Extract did, however, significantly decrease the leptin levels in the 
HFD groups, probably because of the loss of IP fat (Figure 3.11). No significant 
differences were seen with Afriplex GRT Extract and the adiponectin levels, but the 
diet had a significant effect overall, according to a 2-way ANOVA (Figure 3.12). This 
was not expected. Adiponectin is produced by adipocytes and inversely related to fat 
mass, in contrast to leptin (Maffei, et al., 1995; Hu, et al., 1996). Adiponectin improves 
insulin sensitivity by AMPK activation (Yamauchi, et al., 2002). Low adiponectin levels 
are associated with obesity and is a known risk factor for cardiovascular disease 
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(Sattar, et al., 2006; Goyal, et al., 2014). The high adiponectin levels in the HFD is 
interesting and should be further explored especially in view of the obesity paradox 
(Carnethon, et al., 2012).   
4. 2DG Uptake 
The 100 nM insulin concentration was not sufficient to elicit a glucose response in the 
cardiomyocytes (Figure 3.15). This lack of effect was also seen in a study by Smit, et 
al. (2017), where aspalathin had no effect on the 2DG uptake of heart cells from obese 
and insulin resistant rats, compared to the marked stimulation observed in 
cardiomyocytes from young, control rats. They argue that aspalathin is dependent on 
the PI3K signalling pathway in order to have any effect (Smit, et al., 2017). This leads 
us to the speculation that the animals from this study might have been too old and that 
they were already insulin resistant by the time of sacrifice. Comparison to a young, 
control rat would have been beneficial to provide confirmation on the latter. 
5. Mitochondrial Respiration 
5.1. Mitochondrial Function 
Mitochondria play a pivotal role in cell physiology and pathology (Bournat & Brown, 
2010). Because of its widespread role in fat- and glucose metabolism, it is important 
to investigate the functionality of mitochondria to potentially provide answers for the 
effects seen in this study.  
Certain parameters of mitochondrial function were determined using an oxygraph. As 
these analyses were performed on mitochondria isolated from fresh hearts, using 
differential centrifugation, the changes observed must be of such a nature that they 
are retained through the isolation procedure.     
The HFD did not have any significant effect on the mitochondrial function with regards 
to the mitochondrial respiration studies. 
State 2 respiration of mitochondria is recorded with no ADP present in the incubation 
medium and reflects the oxygen consumed by the mitochondria under these 
conditions. Metformin increased the state 2 respiration in cardiac myocyte 
mitochondria from HFD animals in both glutamate and a fatty acid medium, palmitoyl-
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L-carnitine (Figure 3.17). According to Owen, et al. (2000) and Zhou, et al. (2001), this 
is the mechanism whereby metformin activates AMPK.  
A 2-way ANOVA indicated that the mitochondrial state 3 respiration was overall higher 
when their cardiac myocyte mitochondria were incubated in the palmitoyl-L-carnitine 
media (Figure 3.18). This was expected, since Cole, et al. (2011) also demonstrate 
that state 3 respiration rates were increased in a palmitoyl-L-carnitine media and 
unchanged in glutamate and pyruvate substrates. In state 4, the mitochondria from 
HFD hearts treated with metformin presented with an increased respiration rate in 
comparison to the non-treated HFD animals, but only in the fatty acid medium (Figure 
3.19). This higher respiration rate means that the metformin might have caused 
uncoupled mitochondria or an oxygen leak, because metformin is known to inhibit 
complex I in the ETC (Owen, et al., 2000).  
Ingestion of Afriplex GRT Extract significantly improved the ADP/O ratio in the HFD 
groups (Figure 3.16) and the RCI values in the control groups in the palmitoyl-L-
carnitine media (Figure 3.20). The increased ADP/O ratio shows that Afriplex GRT 
Extract improved coupling efficiency and mitochondrial oxygen utilization in the HFD 
animals (Brand & Nicholls, 2011). The increased RCI value in the Afriplex GRT Extract 
treated control animals indicates that Afriplex GRT Extract ingestion also improved the 
coupling function of the mitochondria in the control animals. These mitochondria now 
displayed a higher capacity for substrate oxidation and formation of ATP. 
The oxidative phosphorylation rate may be the best indication of mitochondrial function 
in these studies, since the calculation includes both ADP/O ratio and state 3 
respiration. Afriplex GRT Extract ingestion improved the oxidative phosphorylation 
rate in the control groups but not in the HFD animals when incubated in a carbohydrate 
or a fatty acid medium (Figure 3.21).  This may indicate that one of the ETC complex 
proteins that allows the flow of electrons through the ETC, may be compromised in the 
HFD animals.  Further studies on the individual proteins may shed light on this.  
Metformin was able to improve the oxidative phosphorylation rate of mitochondria from 
the HFD animals when incubated in the palmitoyl-L-carnitine media.  As it has been 
shown that metformin inhibits complex I of the ETC chain thereby activating AMPK 
(Owen, et al., 2000), this could mean that the mitochondria were able to have an 
improved import of fatty acids through the CPT-1 complex in the presence of a fatty 
Stellenbosch University  https://scholar.sun.ac.za
118 
 
acid substrate. CPT-1 is indirectly activated by AMPK through the inhibition of acetyl 
CoA carboxylase, thereby lifting the inhibitory effects of malonyl-CoA on CPT-1 
(Stanley, et al., 2005). Furthermore, it has been demonstrated that this activation of 
AMPK can reverse the inhibitory effects of metformin on complex I and accelerate β-
oxidation (González-Barroso, et al., 2012).  
The ability of the isolated mitochondria to withstand an anoxic period followed by re-
oxygenation was tested (Figure 3.22). The results showed that in all groups incubation 
of mitochondria in the fatty acid medium significantly reduced their ability to withstand 
anoxia and then regain state 3 respiration (Figure 3.22). This is an indication of 
mitochondrial dysfunction in the presence of fatty acids as substrate medium 
(Weinberg, et al., 2000).  In addition, no significant differences were found between 
the groups in the percentage recovery after exposure to hypoxia followed by re-
oxygenation. These results suggest that the contractile recovery after ischaemia 
during reperfusion was better in the glutamate medium than with palmitoyl-L-carnitine 
medium, and previous studies have demonstrated that the contractile recovery after 
ichaemia of the heart is improved in glucose substrates rather than fatty acids 
substrates (Kjekshus & Mjos, 1972; Burkhoff, et al., 1991; Korvald, et al., 2000). 
5.2. Mitophagy Proteins  
Please note that these Western blot analyses were done on the lysates prepared from 
the isolated myocardial mitochondria. Mitochondrial lysates were prepared 
immediately after excision of the heart from the chest cavity, thus the mitochondria 
were in normal conditions and should not be expected to exhibit changes in mitophagy. 
No significant differences were found in the PINK1 and Parkin levels between either 
of the groups (Figure 3.37 and 3.38). A possible explanation for this could be that, 
because the mitochondria were isolated immediately after excision of the hearts, they 
(the mitochondria) were under normal conditions where one would not expect 
upregulation of mitophagy.  
The Afriplex GRT Extract did, however, significantly decrease mitochondrial p62 levels 
in the control and HFD groups, indicating that the Afriplex GRT Extract treatment could 
potentially have compromised autophagosome formation in the mitophagy process 
and therefore decreased mitophagy (Figure 3.39). Expression of p62 was also 
decreased because of the metformin treatment. This correlates with the fact that, 
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among other mechanisms, metformin activates autophagy by downregulating p62 
levels (Komatsu, et al., 2007; Nazim, et al., 2016). Interestingly, low p62 levels has 
also been recorded in type 2 diabetes, indicating increased autophagy (Kobayashi, et 
al., 2012). 
In this study, autophagy flux was not determined by using substances that will inhibit 
any step on the process. This could have been done by using chloroquine to block the 
autophagosome to lysosome flux (shortcoming) (Redmann, et al., 2017). The p62 
expression data from this study was simply a ‘snapshot’ and what we see are the p62 
proteins in the cytosolic pool. We could thus not see p62 accumulation. No conclusion 
can really be drawn from these results, but the increased LC3-II levels and decreased 
p62 levels in the Afriplex GRT Extract treated HFD groups (versus not treated with 
Afriplex GRT Extract) suggest that p62 was already associated with the 
autophagosome membrane and taken out of the cytosolic pool to activate mitophagy 
(Figure 3.35).  
The increased LC3-II levels show that Afriplex GRT Extract increased mitophagy and 
autophagy in the HFD animals, but this was not substantiated by the other markers of 
mitophagy; namely Beclin-1, PINK1, Parkin or p62 levels of the mitochondria from 
HFD (treated and non-treated) animals. This leads us to speculate that there is a 
different pathway that resulted in the increased autophagy and mitophagy seen in the 
Afriplex GRT Extract treated HFD animals. Since the ULK1 pathway could have 
regulated these effects, ULK1 expression and phosphorylation could have been 
investigated to potentially answer these questions (Wu, et al., 2014). 
6. Effects on the Insulin Signalling Pathway Proteins, Sestrin2, autophagy 
proteins and mitophagy proteins. 
Please note that these Western blots were done with the lysates prepared from the 
freeze-clamped hearts. 
6.1. Insulin Signalling Pathway Proteins  
Indicating diet-induced insulin resistance, the HFD groups all had lower GLUT4 
(Figure 3.23), total PKB (Figure 3.24), total AMPK (Figure 3.26), phosphorylated ATM 
(Figure 3.28) and phosphorylated ERK expression (Figure 3.30). This correlates with 
what was seen in previous publications (Mueckler, 2001; Brozinick Jr, et al., 2003; 
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Rotter, et al., 2003; Chakraborty, et al., 2010) (refer to Figure 4.1 below to see a 
schematic summarizing the effects seen of the HFD, used in this study, on the insulin 
pathway). Furthermore, lower GLUT4 levels in the HFD animals confirm that the diet 
regime induced obesity, as it has previously been shown that GLUT4 expression is 
suppressed in obese rats (Garvey, et al., 1991; Kahn & Pedersen, 1993). There were 
no differences seen between the HFD animals and the insulin injected HFD animals 
and this could be because the animals were already too old and insulin resistant.  
The Afriplex GRT Extract, on the other hand, significantly decreased GLUT4 (Figure 
3.23), total PKB (Figure 3.24), total AMPK (Figure 3.26), phosphorylated ATM (Figure 
3.28) and phosphorylated ERK levels (Figure 3.30) in the control groups (refer to 
Figure 4.2 below to see a schematic summarizing the effects seen of the Afriplex GRT 
Extract on the insulin pathway). This indicated that Afriplex GRT Extract might have 
detrimental effects on the insulin signalling pathway and further investigation needs to 
be done. This data is contradicting to the biometrical data and OGTT results which 
suggested that Afriplex GRT Extract improved whole-body insulin resistance in control 
animals.  
Bearing in mind that these blots represent protein levels in the cytosolic compartment, 
the significantly lowered GLUT4 expression in the Afriplex GRT Extract treated 
controls could indicate that the Afriplex GRT Extract might have been able to stimulate 
GLUT4 translocation out of the cytosol and to the membrane for glucose uptake. 
Fractionation of the cytosolic and membrane compartments in future may confirm that 
the GLUT4 did, in fact, translocate to the membrane and induce glucose uptake. 
On the other hand, decreased glucose uptake in Afriplex GRT Extract treated controls 
could indicate that the Afriplex GRT Extract ‘forced’ the animals to utilize the fatty acids 
rather than glucose as energy source. PGC1α and PPARγ levels could have been 
measured to potentially explain or confirm the latter, because of their pivotal roles in 
fatty acid and glucose metabolism (Liang & Ward, 2006; Puigserver & Spiegelman, 
2003). Phosphorylation of PDK4 levels could also have been investigated, because it 
inhibits the PDH complex and can thus be used to see if the HFD had any effect 
(PGC1α and PDK4 expression would have been upregulated).  
When glucose is ingested, CPT-1 is downregulated and PDH upregulated to allow for 
glucose metabolism to form acetyl-CoA that will enter the citric acid cycle. Overload 
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glucose suppresses CPT-1 by signal transduction. Glucose metabolism causes 
decreased PGC1α and PPARγ. The opposite happens when fatty acids are ingested, 
causing CPT-1 to be upregulated and PDH downregulated to allow β-oxidation of the 
fatty acids, forming the acetyl-CoA. Fatty acid overload can lead to excess citrate that 
inhibits the PDH complex by activation of transcription factors (PGC1α and PPARγ). 
CD36 activates PDK4 and suppresses GLUT4. These are just a few of the many 
factors that control the uptake of either glucose or fatty acids into the mitochondria to 
utilize as energy substrate. 
PKB is a central mediator in insulin signalling. The lowered total PKB expression 
indicates that both the HFD and Afriplex GRT Extract compromised the insulin 
signalling of the animals (Figure 3.24) (Whiteman, et al., 2002). However, injection of 
the animals with insulin before sacrifice resulted in enhanced phosphorylation of PKB 
indicating that insulin can still exert an effect on the stimulation of the protein. This was 
especially noticeable in the phospho/total ratio observed.  
Total AMPK expression was decreased in the control animals treated with Afriplex 
GRT Extract (Figure 3.26). The decreased phosphorylated AMPK levels and 
increased phosphorylated PKB levels in the groups injected with insulin correspond 
with literature and was expected. Insulin induces AMPK’s direct phosphorylation by 
Akt/PKB, thus inhibiting AMPK (Hawley, et al., 2014; Jeon, 2016). Since AMPK can 
activate AS160 and increase GLUT4 expression, the decreased AMPK levels in 
Afriplex GRT Extract treated controls could explain the decreased GLUT4 levels 
(Jeon, 2016). 
The phosphorylated ERK levels were significantly decreased in the control animals 
treated with the Afriplex GRT Extract, leading us to speculate that the Afriplex GRT 
Extract could potentially have negatively altered nuclear transcription and cellular 
function (Figure 3.30) (Adcock & Caramori, 2009).  
Below are two diagrams that summarize the effects resulting from the HFD and from 
the effects of Afriplex GRT Extract treatment on control animals. Afriplex GRT Extract 
had no significant effect on the HFD animals, therefore there is no figure for the HFD 
animals in comparison to Afriplex GRT Extract treated HFD animals. 
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Figure 4.1 A schematic summary of the effects of the HFD on the PI3K-dependent pathway. 
 
Figure 4.2 A schematic summary of the effects of Afriplex GRT Extract on the PI3K-dependent 
pathway in control animals. 
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6.2. Stress-responsive Protein, Sesn2 
It has been proven, by previous studies, that Sesn2 levels are downregulated in 
obesity (Nourbakhsh, et al., 2017). Similarly, Sesn2 levels were significantly 
decreased in the HFD groups in comparison to the control groups, corroborating the 
previous findings (Figure 3.32).  
The Afriplex GRT Extract decreased the Sesn2 levels in the control animals. The low 
Sesn2 levels could indicate that the Afriplex GRT Extract either (i) reduced oxidative 
stress (confirming the anti-oxidant capability of the aspalathin-rich product), or (ii) 
simply impaired the ability of the animals to handle oxidative stress and protect the 
heart. 
(i) Sesn2 expression is induced by oxidative stress, hypoxia of DNA damage (Lee, et 
al., 2013; Rhee & Bae, 2015). This statement leads to the conclusion that a decreased 
Sesn2 level indicates decreased oxidative stress. This would agree with the proven 
fact that rooibos has anti-oxidant properties (Schulz, et al., 2003; Koza, 2013), as well 
as the capability to ameliorate oxidative stress (Dludla, et al., 2017). Dludla, et al. 
(2014) argues that PPAG can prevent oxidative stress and apoptosis. Quercetin and 
rutin are also appealing flavonols in rooibos that have anti-obesity properties 
(Kuppusamy & Das, 1992; Ahn, et al., 2008; Rivera, et al., 2008).  
(ii) On the contrary it is known that, through AMPK activation, Sesn2 is able to protect 
the muscle and heart (Budanov, et al., 2010). Sesn2 activates AMPK, thus inhibiting 
mTORc1 and consequently preventing autophagy. Increased Sesn2 levels are 
conventionally seen in oxidative stress since it is a stress-inducible protein that is 
known to inhibit ROS (Pasha, et al., 2017). The low expression of Sesn2 in hearts 
from the obese animals could therefore indicate that they have a compromised ability 
to react against stress.  
Further research should be done to establish which of these possibilities could be the 
answer. 
6.3. Autophagy Proteins  
Increased Beclin-1 expression is associated with increased autophagy. Beclin-1 can 
associate with Bcl-2, which is an anti-apoptotic protein. This association inhibits 
autophagy (Marquez & Xu, 2012). The Beclin-1 and Bcl-2 complex plays a significant 
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role in the switch between autophagy and apoptosis. Afriplex GRT Extract significantly 
decreased Beclin-1 expression in the control groups (Figure 3.33), indicating that Bcl-
2 was not able to effectively associate with Beclin-1 to decrease autophagy (Liang, et 
al., 1998). Hence, this could mean that Afriplex GRT Extract potentially decreased 
autophagy in the normal control animals.  
The Afriplex GRT Extract treated controls injected with insulin had higher BNIP3 (22 
kDa – 28 kDa) levels than that of the Afriplex GRT Extract treated controls not injected 
with insulin (Figure 3.34). A decrease in BNIP3 indicates decreased autophagy. 
Afriplex GRT Extract treated HFD animals (injected with insulin) had increased BNIP3 
homodimer (50 – 55 kDa) expression than that of the Afriplex GRT Extract treated 
controls (also injected with insulin). Not much can be concluded from these results, 
but the reduced BNIP3 homodimer levels in the Afriplex GRT Extract controls indicate 
that the Afriplex GRT Extract upregulated the drive from autophagy to apoptosis (Kubli, 
et al., 2008). The BNIP3 homodimer also associates with Bcl-2, pulling Bcl-2 away 
from the mitochondria and dissociating Bcl-2 from Bax. This leaves Bax, which has 
pro-apoptotic potential, to induce apoptosis (Walls, et al., 2009; Marquez & Xu, 2012). 
Further research should investigate Bax and Bcl-2 levels. 
Along with Beclin-1, BNIP3 and p62 expression, LC3-II expression must also be 
determined to confirm whether autophagy was actually inhibited or activated. Afriplex 
GRT Extract increased LC3-II and LC3-II to LC3-I ratio of expression in the HFD 
groups, thus increasing mitophagy (Figure 3.35 and 3.36). In the glutamate media, the 
oxidative phosphorylation rate was significantly increased in the Afriplex GRT Extract 
treated controls. The increased LC3-II levels indicate increased mitophagy, thus 
increased mitophagic removal of depolarized mitochondria. This could explain the 
improved oxidative phosphorylation rate, mitochondrial function and coupling 
efficiency seen in Afriplex GRT Extract treated groups.  
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7. Conclusion 
We can conclude that the high fat diet induced insulin-resistance, as these animals 
exhibited increased leptin levels, body weight, IP fat weight gain and liver weight gain.  
According to protein expression, Afriplex GRT Extract did not improve the insulin 
resistance in the HFD groups; and had a negative effect on insulin pathway mediating 
proteins in the control groups. On the contrary, Afriplex GRT Extract significantly 
increased basal serum glucose levels and the overall metabolic profile as indicated in 
the HFD groups (compared to non-treated HFD animals), which is in contrast to the 
worsened insulin resistance reflected by the protein expression levels, such as 
GLUT4, total PKB, total AMPK, phosphorylated ATM and phosphorylated ERK.  
Afriplex GRT Extract improved coupling efficiency, mitochondrial function and 
oxidative phosphorylation. Most of the improvements were seen in the control animals 
and not the HFD animals. This could be because aspalathin only influences control 
animals and not insulin resistant animals. Smit, et al. (2017) stated that aspalathin 
increased glucose uptake in cardio-myocytes of young, control rats; but could not 
increase glucose uptake in cells from rats on a high-caloric diet (Smit, et al., 2017). 
The high fat diet had no effect on mitochondrial oxidative phosphorylation capacity. 
The most significant changes with regards to mitophagy proteins, were observed in 
the expression of p62 in mitochondria from hearts of HFD animals. The reduced p62 
in Afriplex GRT Extract treated groups could not fully provide an answer since these 
results only display a ‘snapshot’ of the p62 levels in the cytosol. We suggest that the 
lower p62 levels indicate that these p62 proteins had already associated to the 
autophagosome and increased depolarized mitochondria removal. This explains the 
improved oxidative phosphorylation seen in the mitochondrial respiration data, 
primarily in controls.  
The decreased Sesn2 levels bring this product and its anti-oxidant capacity in to 
question. As mentioned earlier, Afriplex GRT Extract has a high aspalathin and PPAG 
content that allows Afriplex GRT Extract to display anti-oxidant effects (Dludla, et al. 
(2017). This validates our speculation that the lowered Sesn2 expression seen in 
Afriplex GRT Extract treated animals indicate that this product has strong anti-oxidant 
potential and ultimately improved oxidative stress. 
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Afriplex GRT Extract seemed to have decreased autophagy in controls according to 
the Beclin-1 levels, having no effect in cardiomyocytes from the HFD hearts. However, 
the extract upregulated apoptosis, according to BNIP3 homodimer formation, in the 
HFD hearts. It has been shown that BNIP3 homodimers have the ability to associate 
directly with LC3 to induce mitophagy without the linkage formed by the association 
with p62. BNIP3 may also result in the depolarization of the membrane potential of 
mitochondria, thereby driving mitophagy.  Afriplex GRT Extract did increase LC3-II 
levels in the HFD group, confirming upregulated mitophagy. The increased mitophagy 
in the treated HFD groups might therefore have been driven and regulated by a 
different pathway, e.g. the ULK mediated pathway. 
We can conclude that Afriplex GRT Extract improved overall mitochondrial function 
and the obesity profile, but conversely had a negative effect on the insulin signalling 
pathway intermediates. There were also no detrimental effects observed with the 
dosage of Afriplex GRT Extract used. 
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CHAPTER 5: Limitations and Future Research 
 
• The small n-value from the first cohort of rats that were used in Western Blots 
was a big limitation. 
• Another limitation would be that we did not send a sample of our high fat diet 
away for diet composition analyses. 
• Future research could look in to the p62 accumulation by blocking the 
autophagosome to autophagolysosome flux by using chloroquine. 
Furthermore, the apoptotic proteins BCl2 and Bax should be analysed. 
• ULK1 expression determination might have answered and confirmed the 
increased autophagy and mitophagy seen in Afriplex GRT Extract treated 
animals (with regards to the LC3-II levels). 
• It would be interesting to analyse the ETC complex proteins in both their 
expression levels as well as their activity.  This can be done using specific 
antibodies to determine expression levels as well as different inhibitors of the 
complex I to complex V proteins to determine their individual contribution to 
ATP production. 
• In addition, the actual ATP that was produced by state 3 respiration may be 
determined by isolating the residual ADP and the ATP formed to determine the 
levels by HPLC methods.  
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CHAPTER 6: Appendices 
 
Appendix A – The Methods by which the calculations of the Western blots were 
performed.  
Gel (used for GLUT4 expression): 
 
Membrane (used for GLUT4 expression): 
 
Blot (used for GLUT4 expression): 
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BioRad ChemiDoc™ ImageLab 5.0 series software used to analyse blots:
 
(BioRad, 2017) 
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Appendix B – Certificate of Analysis of Afriplex GRT Extract 
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Appendix C – Turnitin Report 
Please note that the whole thesis was submitted, excluding the Appendices and 
References. 
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